Document:

Collaboration and License Agreement

 EXHIBIT 10.1 
  
 COLLABORATION AND LICENSE AGREEMENT 
  
 THIS COLLABORATION AND
LICENSE AGREEMENT (the “Agreement”) is made and entered into as of September 3, 2003 (the “Effective Date”), by and between POZEN INC., a
Delaware corporation (“POZEN”), with a business address of 1414 Raleigh Road, Suite 400, Chapel Hill, NC 27517, and XCEL PHARMACEUTICALS, INC., a Delaware corporation
(“Xcel”), located at 6363 Greenwich Drive, Suite 100, San Diego, CA 92122. POZEN and Xcel are sometimes referred to in this Agreement individually as a “Party” and collectively as “Parties.”

  
 RECITALS 
  
 A. Xcel is a specialty pharmaceutical company focused on the treatment
of disorders of the central nervous system and possesses substantial expertise in the marketing of pharmaceutical products for the treatment of migraine. 
  
 B. POZEN is a pharmaceutical development company currently specializing in the development of products for migraine therapy. 
  
 C. Xcel desires to obtain, and POZEN is willing to grant, the
exclusive right to market, promote, sell and distribute POZEN’s MT 300TM product within the United States of America and its territories in accordance with this Agreement. 
  
 AGREEMENT 
  
 In consideration of the mutual covenants contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the Parties agree as follows: 
  
 1. DEFINITIONS

  
 The capitalized terms used herein will have the meanings
given to them in this Section 1 and throughout this Agreement. Unless the context indicates otherwise, the singular will include the plural and the plural will include the singular. 
  
 1.1 “Affiliate” means a corporation or other business entity which, directly or indirectly, through
one or more intermediaries, controls, is controlled by or is under common control with a Party. For purposes of this definition only, “control” and, with corresponding meanings, the terms “controlled by” and “under common
control with,” means (a) the possession, directly or indirectly, of the power to direct the management or policies of a legal 
  
 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS AND BRACKETS ([***]). A COMPLETE COPY OF THIS
AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 entity, whether through the ownership of voting securities or by contract relating to voting rights or corporate
governance, or (b) the ownership, directly or indirectly, of more than 50% of the voting securities or other ownership interest of a legal entity; provided, however, that if local law restricts foreign ownership, control will be established
by direct or indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests. 
  
 1.2 “ANDA” means an abbreviated NDA filed pursuant to 21 C.F.R. §§ 314.92 et seq. (2003), or any equivalent filing as
may be available at the time. 
  
 1.3
“Autoinjector” means the automatic injection device for multiple uses selected by the Parties in accordance with Section 3.2.1. 
  
 1.4 “Autoinjector Presentation” means the Initial Licensed Product in the Autoinjector. 
  
 1.5 “CMC” has the meaning as set forth in Section
2.1. 
  
 1.6 “Combination Product” means
any formulation of dihydroergotamine in any dosage strength in combination with one or more additional pharmaceutically active ingredients administered by [***] or [***], and specifically without limitation excluding any formulation administered by
any [***]. 
  
 1.7 “Commercial Launch”
means nationwide launch of commercial sale, promotion and distribution of a Licensed Product in the Territory following Marketing Approval for such Licensed Product. 
  
 1.8 “Commercialization” means (a) pre-launch market development activities conducted with a product
in anticipation of Marketing Approval, and (b) marketing, promotion, use, advertising, selling, having sold, distributing or importing a product after Marketing Approval has been obtained. The term “Commercialize” has a correlative
meaning. 
  
 1.9 “Commercially Reasonable
Efforts” mean, as to either Party relative to any Licensed Product, those efforts and resources normally used by such Party for a product owned by it which has a similar market potential and is at a similar stage in its product life cycle
as the Licensed Product at issue; provided, however, that such efforts and resources will be no less than those typically applied by a pharmaceutical company of similar size as such Party as of the Effective Date (or any larger size that such
Party may have at such later time) for a product owned by such company which has a similar market potential and is at a similar stage in its product life cycle as the Licensed Product at issue. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 1.10 “Confidential Information” has the meaning as set forth in Section 13.1.

  
 1.11 “Control” means, with respect to
any Patent, Know-How, Improvement or other intellectual property right, the possession of the ability to grant a license or a sublicense to such Patent, Know-How, Improvement or right as provided for in this Agreement without violating the terms of
any agreement with any Third Party. 
  
 1.12
“Controlled Affiliates” with respect to a Party, mean the Affiliates of such Party which are controlled by such Party (with “controlled by” having the meaning set forth in the definition of “Affiliate”
above). 
  
 1.13 “Development Costs” mean
(a) the direct costs and expenses and (b) the indirect costs and expenses associated with the operation of any laboratory or manufacturing facilities, in each instance (i) incurred by a Party in carrying out research and development activities
agreed to by the Parties and conducted by or on behalf of a Party as contemplated pursuant to this Agreement and (ii) calculated in accordance with generally accepted accounting principles consistently applied and in accordance with such
Party’s cost accounting systems. Development Costs include all reasonable out-of-pocket costs, such as materials, consultants, and other outside services, attributable to the performance of such activities. Employees of any Party at issue will
be charged [***] $[***] (which will be increased once annually on the anniversary of the Effective Date based on any increases of the consumer price index (United States Department of Labor U.S. City Average for All Items, or any successor index)
following the Effective Date). 
  
 1.14
“Development Fees” mean a Party’s [***] percent [***]%[***]. 
  
 1.15 “Development Study” has the meaning as set forth in Section 3.3.1. 
  
 1.16 “DHE” has the meaning as set forth in Section 4.1.1. 
  
 1.17 “DHE-45” means the injectable formulation of dihydroergotamine described in U.S. NDA #05929 (as
supplemented or amended from time to time). 
  
 1.18
“Dispute Resolution” means the process for resolving Disputes as outlined in Section 16. 
  
 1.19 “Dispute” has the meaning as set forth in Section 16.1. 
  
 1.20 “Excepted Communications” mean information regarding Licensed Products set forth in detail
aids, promotional pieces and sales force reprints of information already in the public domain. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 1.21 “FDA” means the United States Food and Drug Administration, or any successor
agency thereof. 
  
 1.22 “FD&C Act”
means the United States Federal Food, Drug and Cosmetics Act, as amended from time to time. 
  
 1.23 “Field” means the treatment of human diseases or conditions by means of a prescription pharmaceutical product. 
  
 1.24 “First Commercial Sale Date” means the date of the first commercial sale of a Licensed
Product by Xcel to a Third Party in the Territory following receipt of Marketing Approval for such Licensed Product in the Territory. 
  
 1.25 “Foreign Licensed Product” means any Royalty Product which (a) is developed or manufactured inside or outside the Territory
for Commercialization outside the Territory or is Commercialized outside the Territory and (b) would, if developed, manufactured or Commercialized inside the Territory, infringe one or more Valid Claims under the POZEN Patents; provided,
however, that in all events: (i) the Initial Licensed Product and the Autoinjector Presentation are deemed to be Foreign Licensed Products; and (ii) DHE-45 is deemed not to be a Foreign Licensed Product. 
  
 1.26 “Generic Equivalent” means, as to any Licensed Product
which is commercially sold by Xcel, a Third Party’s generic version of such Licensed Product which (a) is approved by the FDA under an ANDA which refers to such Licensed Product as the Reference-Listed Drug and (b) contains all and only the
same pharmaceutically active ingredients as such Licensed Product. 
  
 1.27 “Generic Erosion” means achievement of aggregate gross dollar sales by all Generic Equivalents of at least [***] percent ([***]%) [***] aggregate gross dollar sales [***] commercially sold by
Xcel, calculated on a calendar quarterly basis pursuant to the provisions of Section 8.5. 
  
 1.28 “Improvement” means any invention, discovery or Know-How, whether or not patentable, relating to any Royalty Product and
made, conceived or reduced to practice after the Effective Date and during the Term, but excluding any such invention, discovery or Know-How to the extent incorporated into any Valid Claim within an Xcel Patent or a POZEN Patent. 
  
 1.29 “IND” means an Investigational New Drug
Application filed with the FDA in conformance with applicable laws and regulations. 
  
 1.30 “Initial Licensed Product” means that certain injectable formulation of dihydroergotamine designated by POZEN as MT 300 for which POZEN has filed the POZEN NDA. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 1.31 “Know-How” means non-public information, results and data of any type
whatsoever, in any tangible or intangible form whatsoever, including databases, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, medicinal chemistry,
biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and manufacturing process and development information, results and data. 
  
 1.32 “Knowledge of POZEN” means the collective
knowledge or recollection, as of the Effective Date and as to any facts or circumstances that relate to the subject matter of any representation or warranty at issue, of (a) each officer of POZEN and (b) the employees of POZEN with operational
responsibility (while performing their duties and job responsibilities) for the activities of POZEN which relate to such subject matter, in each instance with respect to such employees assuming the completion of a reasonable level of inquiry by each
such person. 
  
 1.33 “LEK” means LEK
Pharmaceutical and Chemical Company, D.D., a corporation organized under the laws of Slovenia with its principal offices located at Verovskova 57, 1526 Ljubljana, Slovenia. 
  
 1.34 “LEK Agreement” means that certain Manufacturing Supply Agreement by and among POZEN, LEK, and
LEK Pharmaceuticals, Inc., a Delaware corporation with its principal offices located at 115 North Third St., Suite 301, Wilmington, NC 28401, executed on October 15, 2001. 
  
 1.35 “Licensed Product” means any Royalty Product which cannot be developed, manufactured or
Commercialized without infringing one or more Valid Claims under the POZEN Patents; provided, however, that in all events: (i) the Initial Licensed Product and the Autoinjector Presentation are deemed to be Licensed Products; and (ii) DHE-45
is deemed not to be a Licensed Product. 
  
 1.36
“Licensed Technology” means the POZEN Patents, POZEN Know-How and POZEN Improvements. 
  
 1.37 “Manufacturing Liaison Costs” mean (a) the direct costs and expenses and (b) the indirect costs and expenses associated with
the operation of any laboratory or manufacturing facilities, in each instance (i) incurred by POZEN pursuant to Section 4.4 of this Agreement in carrying out reasonably necessary manufacturing liaison activities and (ii) calculated in accordance
with generally accepted accounting principles consistently applied and in accordance 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 with POZEN’s cost accounting systems. Manufacturing Liaison Costs include, without limitation, all reasonable
out-of-pocket costs, such as materials, consultants, and other outside services, attributable to performance of such activities. Employees of POZEN will be charged [***] $[***] (subject to increase in respect of adjustments to the consumer price
index (United States Department of Labor U.S. City Average for All Items, or any successor index) following the Effective Date). 
  
 1.38 “Manufacturing Liaison Fee” means POZEN’s [***] percent ([***]%). 
  
 1.39 “Marketing Approval” means the final approval
received from the FDA for a product in the United States, immediately following which such product may be commercially sold in the United States. 
  
 1.40 “Marketing Plan” has the meaning as set forth in Section 5.2.1. 
  
 1.41 “NDA” means a new drug application submitted to the FDA to obtain FDA approval for the
marketing of a pharmaceutical product in the United States. 
  
 1.42 “Net Sales” mean the amount of gross sales of product to Third Parties [***], less the following deductions: 
  
 (a) Quantity, trade, cash and other discounts actually allowed or given by Xcel; 
  
 (b) Discounts, replacements, credits, refunds and allowances actually allowed or given by Xcel for product returns or
rejections or indigent patient and similar programs; 
  
 (c)
Rebates, chargebacks and price adjustments actually allowed or given by Xcel to customers; 
  
 (d) Actual write-offs of uncollectible amounts receivable by Xcel; provided, however, that if any such amount is in fact subsequently received by Xcel, such received amount will be included in the
calculation of Net Sales; 
  
 (e) Import, export, excise,
sales or use taxes, value added taxes, and other taxes, tariffs or duties levied, absorbed or directly imposed and properly allocable to product sales (in any event excluding taxes on the income of Xcel); and 
  
 (f) Freight, postage, shipping, insurance, and packaging costs and
other outbound transportation charges to the extent included in the invoiced amount; 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 provided, however, that: 
  
 (x) Net Sales will be determined, without limitation, with reference to the amount or fair market value of all
consideration received by Xcel for sale of a product, whether such consideration is in cash, payment in kind, exchange or other form; provided that if: (i) a product is sold together with other goods, with or without a separate price for such
product, (ii) the consideration exchanged for a product includes any non-cash consideration, or (iii) a product is transferred in any other manner other than as an invoiced sale, then the Net Sales applicable to the quantity of such product included
in any such transaction will be deemed to be the average Net Sales for such quantity of such product for all transactions of such product (other than those described in the preceding clauses (i)-(iii), inclusive) made in the Territory (1) during the
last full calendar quarter prior to such transaction, or (2) if there were no Net Sales during the prior calendar quarter, during the current calendar quarter; 
  

(y) Products transferred free of charge in connection with the performance of clinical trials, testing, quality control or other development
work, or as professional samples will not be included in the calculation of Net Sales; and 
  
 (z) Amounts relevant to the determination of Net Sales, and the timing of sales, will be [***]. 
  
 1.43 “Patent” means patents, applications for patents, provisional applications for patents, and any patents issuing therefrom
(including any divisions, continuations, continued prosecution applications and continuations-in-part thereof), reexamination certificates, reissue patents, patent extensions, and patent term restorations. 
  
 1.44 “POZEN Improvements” mean any and all
Improvements owned or Controlled by POZEN that are (a) Technologically Necessary for the development, manufacture or Commercialization of any Licensed Product, or (b) necessary for the development or manufacture of the Initial Licensed Product, or
(c) developed in the course of performing this Agreement solely by POZEN or its Affiliates or Third Party contractors, or jointly by POZEN and Xcel or its or their Affiliates or Third Party contractors, and useful for the development, manufacture or
Commercialization of any Royalty Product. 
  
 1.45
“POZEN Know-How” means any and all Know-How owned or Controlled by POZEN as of the Effective Date that is (a) Technologically Necessary for the development, manufacture or Commercialization of any Licensed Product, or (b)
necessary for the development, manufacture or Commercialization of the Initial Licensed Product, or (c) useful for the development, manufacture or Commercialization of any Royalty Product and is disclosed to Xcel during the Term. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 1.46 “POZEN NDA” means NDA #[***] (as supplemented or amended from time to time)
or any NDA filed as a replacement for such NDA. 
  
 1.47
“POZEN Patents” mean any and all Patents owned or Controlled by POZEN during the Term with Valid Claims that would be infringed, in the absence of a license, by the development or Commercialization of any Royalty Product in the
Territory, or by the manufacture of any Royalty Product anywhere in the world. In any event, POZEN Patents include the following: 
  
 (a) those certain patents and patent applications identified on Exhibit D attached hereto; 
  
 (b) any patents that are or may be granted from any of the patents or
patent applications referred to in this definition, including any extensions, continuations, continuations-in-part, divisionals, reissues, reexaminations, renewals, additions, registrations and confirmations thereof; and 
  
 (c) any patents or patent applications claiming priority of any of the
patents or patent applications referred to in this definition. 
  
 1.48 “POZEN Trademarks” mean any trademarks or trade names used or registered by POZEN to identify itself in the Territory. 
  
 1.49 “Product Trademarks” mean any trademarks, trade dress, logos, slogans, and designs, whether or not registered in the
Territory, used to identify or promote any Licensed Product in the Territory, but excluding any Xcel Trademarks or POZEN Trademarks. 
  
 1.50 “Promotional Materials” mean all sales representative training materials and all written, printed, graphic, electronic, audio
or video matter, including but not limited to journal advertisements, sales visual aids, leave-behind items, formulary binders, reprints, direct mail, direct-to-consumer advertising, internet postings, media broadcast advertisements, and sales
reminder aids (for example, note pads, pens and other such items) intended for use or used by Xcel in connection with the promotion of any Licensed Product. 
  
 1.51 “PTO” means the United States Patent and Trademark Office. 
  
 1.52 “Reciprocating Licensee” has the meaning set forth in Section 7.4. 
  
 1.53 “Reference-Listed Drug” means a listed drug
identified by the FDA as a drug product upon which an applicant may rely in seeking approval of an ANDA (or any equivalent process as may be available at the time). 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 1.54 “Regulatory Approval” means any approvals and any master files,
establishment licenses, registrations or authorizations of any national or local regulatory agency, department, bureau or other governmental entity, necessary for the manufacture, use, storage, importation, export, transport, distribution or sale of
any Licensed Product in the Field in the Territory. 
  
 1.55
“Royalty Product” means any formulation of dihydroergotamine in any dosage strength as the single pharmaceutically active ingredient administered by [***] injection [***] injection [***] including DHE-45, the Initial Licensed
Product and the Autoinjector Presentation, and specifically without limitation excluding any formulation administered by [***]. 
  
 1.56 “Royalty Term” means the duration of Xcel’s obligation to pay royalties under Section 8.3 as set forth in Section 8.3.2.

  
 1.57 “SNDA” means a supplemental NDA
filed pursuant to 21 C.F.R. § 314.70 (2003), or any equivalent filing as may be available at the time. 
  
 1.58 “Technologically Necessary” means, with respect to any Improvement or Know-How relative to a Licensed Product, that either
(a) such Licensed Product could not be developed, manufactured or Commercialized without the use of such Improvement or Know-How or (b) the use or development of alternative technology to achieve the effect of such Improvement or Know-How would
encounter significant hurdles that could be overcome, if at all, only with a significant or unreasonable investment of time, resources or effort. 
  
 1.59 “Term” has the meaning as set forth in Section 14.1. 
  
 1.60 “Territory” means the United States of America and its territories (including Puerto Rico).

  
 1.61 “Third Party” means any
individual or entity other than POZEN, Xcel and their respective Affiliates. 
  
 1.62 “Third Party Payments” mean [***] that are paid by Xcel to any Third Party solely to acquire rights to intellectual property rights that would be infringed or misappropriated in the
absence of a license (a) by the development or Commercialization of the Initial Licensed Product or the Autoinjector Presentation in the Territory, or (b) by the manufacture of the Initial Licensed Product or the Autoinjector Presentation in any
country inside or outside the Territory where any such product is being manufactured (“Blocking IP”). With respect to the Autoinjector Presentation, Blocking IP will not include any intellectual property rights held by 

 

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 the developer or manufacturer of the Autoinjector to the extent pertaining solely to the Autoinjector. In the event that
any payments are made to a Third Party that is not only granting a license to any Blocking IP, but also providing services or supplying product or materials to Xcel or a Third Party manufacturing the Initial Licensed Product or the Autoinjector
Presentation, then the Parties will in good faith determine the applicable amount of such payments made with respect to the acquisition of rights to Blocking IP, and only such amount will be deemed a Third Party Payment. 
  
 1.63 “Valid Claim” means (a) any claim of an issued
and unexpired Patent that has not been held unenforceable or invalid by a court or other governmental agency of competent jurisdiction in a decision that is not appealed or cannot be appealed, and that has not been disclaimed or admitted to be
invalid or unenforceable through reissue, reexamination, disclaimer or otherwise, and (b) a pending claim in a bona fide, pending patent application so long as such patent claim is prosecuted with customary diligence. Notwithstanding the foregoing
clause (b), in the event that a pending claim in a pending patent application does not issue as a valid and enforceable claim in an issued patent within [***] after the earliest date from which such claim was initially applied for, such a pending
claim will not be a Valid Claim, unless and until such pending claim subsequently issues as a valid and enforceable claim in an issued patent, in which case such claim will be reinstated and be deemed to be a Valid Claim, subject to the other
provisions of this definition, as of the date of issuance of such patent. 
  
 1.64 “Xcel Improvements” mean any and all Improvements owned or Controlled by Xcel that are (a) Technologically Necessary for the development, manufacture or Commercialization of any Licensed
Product, or (b) necessary for the development or manufacture of the Initial Licensed Product, or (c) developed in the course of performing this Agreement solely by Xcel or its Affiliates or Third Party contractors, or jointly by Xcel and POZEN or
its or their Affiliates or Third Party contractors, and useful for the development, manufacture or Commercialization of any Royalty Product. 
  
 1.65 “Xcel Know-How” means any and all Know-How owned or Controlled by Xcel as of the Effective Date that is (a) Technologically
Necessary for the development, manufacture or Commercialization of any Licensed Product, or (b) necessary for the development, manufacture or Commercialization of the Initial Licensed Product, or (c) useful for the development, manufacture or
Commercialization of any Royalty Product and is disclosed to POZEN during the Term. 
  
 1.66 “Xcel Patents” mean any and all Patents owned or Controlled by Xcel during the Term with Valid Claims that would be infringed, in the absence of a license, by the development, manufacture
or Commercialization of any Royalty Product. In any event, Xcel Patents include the following: 
  
 (a) those certain patents and patent applications identified on Exhibit E attached hereto; 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 (b) any patents that are or may be granted from any of the patents or patent applications referred
to in this definition, including any extensions, continuations, continuations-in-part, divisionals, reissues, reexaminations, renewals, additions, registrations and confirmations thereof; and 
  
 (c) any patents or patent applications claiming priority of any of the
patents or patent applications referred to in this definition. 
  
 1.67 “Xcel Post-Approval Study” means any Xcel-sponsored study funded through a grant to one or more investigators [***] and conducted with a Licensed Product following Marketing Approval for such Licensed Product.

  
 1.68 “Xcel Technology” means the Xcel
Patents, Xcel Know-How and Xcel Improvements. 
  
 1.69
“Xcel Trademarks” mean any trademarks or trade names used or registered by Xcel to identify itself in the Territory. 
  
 2. COLLABORATION GOVERNANCE 
  
 2.1 Formation and Composition of the Collaboration Management Committee. The Parties will manage the Commercialization and further development of
any Licensed Products through a collaboration management committee (the “CMC”). Prior to the first meeting of the CMC, each Party will designate two (2) of its employees as its members on the CMC (although each Party may bring
additional employees to any meeting of the CMC). An alternate member designated by a Party may serve temporarily in the absence of a permanent member. Each Party may replace any of its permanent members of the CMC by providing written notice thereof
to the other Party. Each Party will bear its own costs of participation in the CMC. 
  
 2.2 Functions and Powers of the CMC. The CMC will perform the following functions, and such other functions assigned to it in this Agreement: (a) provide input regarding the preparation and filing of Regulatory
Approvals and other material matters pertaining to regulatory affairs relating to any Licensed Product; (b) serve as a forum for communication between the Parties for the activities performed pursuant to each Marketing Plan; (c) review and approve
all Study Plans and monitor progress of any Development Studies; and (d) address and attempt to resolve conflicts or disputes that may arise during the course of performing this Agreement with respect to the function and tasks of the CMC.

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 2.3 Limitations of CMC Powers. The CMC will have only such powers as are specifically delegated to
it in this Agreement, and will have no power to amend this Agreement or waive a Party’s rights or obligations under this Agreement. 
  
 2.4 CMC Actions. No business will be transacted at any meeting of the CMC unless at least one member from each Party is present. Each Party will
have one vote (i.e., if more than one member attends any meeting of the CMC on behalf of a Party, both members of such Party may collectively exercise only one vote), and actions by the CMC will be taken only with the approval of each Party.
If the CMC is unable to obtain the approval of both Parties on any matter within 15 days of the first vote at which no unanimous decision was reached on such matter, then either Party may refer such matter to the Chief Executive Officers of the
Parties for resolution. If a matter is so referred, then such Chief Executive Officers will meet within 15 days of referral to discuss such matter in good faith. If such discussions do not result in a mutually acceptable resolution within 10 days of
such meeting, then the Chief Executive Officer of Xcel will make the final decision, except that unanimous agreement of the Chief Executive Officers is required with respect to (a) matters relating to any activities to be performed pursuant to
Section 3.1 and 3.2 or (b) the design and performance of any Study Plans if POZEN reasonably objects thereto on the grounds that the outcome of the related Development Study could materially and adversely affect the Commercialization of the Licensed
Product. Notwithstanding this Section 2.4, either Party may initiate dispute resolution procedures pursuant to Section 16 if the subject of such dispute is alleged to constitute a breach of contract by the other Party. 
  
 2.5 CMC Meetings. The CMC will hold meetings at such times and places
as will be determined by the Parties, but in no event will such meetings be held in person less frequently than as follows: (a) [***] during the [***] following the Effective Date; (b) [***] during the [***] following the Effective Date; (c) [***]
during [***] following the Effective Date; and (d) thereafter, [***] upon the request of either Party; provided, however, that any meeting of the CMC which is solely for the purpose of addressing matters referenced in Section 2.2(d) will not
count for purposes of determining whether the provisions of this sentence have been satisfied. The first meeting of the CMC will take place within 90 days after the Effective Date. In addition to the meetings specified above, if any material matters
exist and are pending review or approval by the CMC as contemplated by this Agreement, then either Party may call a meeting of the CMC on at least 30 days’ written notice to the other Party. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 3. REGULATORY MATTERS; DEVELOPMENT 
  
 3.1 Initial Licensed Product. 
  
 3.1.1 POZEN has filed the POZEN NDA in its own name and at its own expense. Subject to the provisions of Section 3.4,
prior to approval of the POZEN NDA, POZEN will be solely responsible for any and all communications with the FDA relating to the Initial Licensed Product or the POZEN NDA. 
  
 3.1.2 Upon approval by the FDA of the POZEN NDA, POZEN will transfer such approved NDA to Xcel. Following such
transfer, Xcel will maintain such NDA during the Term at Xcel’s expense and will (a) obtain and maintain such other Regulatory Approvals as are necessary for the Commercialization of the Initial Licensed Product in the Territory, and (b)
exercise Commercially Reasonable Efforts to cause any manufacturers of the Initial Licensed Product (or any components thereof, as applicable) to obtain and maintain such other Regulatory Approvals as are necessary for the manufacture at their
respective facilities of the Initial Licensed Product (or any components thereof, as applicable) for commercial sale in the Territory. 
  
 3.1.3 POZEN will retain the IND filed by POZEN for the Initial Licensed Product until POZEN has either (a) [***] the SNDA for the Autoinjector
Presentation (the “Autoinjector SNDA”) for submission to the FDA pursuant to Section 3.2 and such SNDA is approved by the FDA, or (b) [***] the Autoinjector SNDA and Xcel has [***] the Autoinjector SNDA, which ever occurs first. At
such time, POZEN will transfer such IND to Xcel, subject to POZEN’s retained right to have Xcel make filings to such IND on behalf of POZEN, at POZEN’s request and expense, for purposes of further development of Licensed Products by POZEN
for use outside the Territory. 
  
 3.1.4 If the FDA
requires or suggests that additional data or information be submitted by POZEN as a condition to approving the POZEN NDA, POZEN will inform Xcel thereof without delay. Subject to Section 3.1.5 below, [***] will conduct such studies (including any
post-approval studies required by the FDA as a condition to approval of the POZEN NDA) as are necessary to satisfy the requests of the FDA, at [***] expense.  
  
 3.1.5 Abandonment of POZEN NDA. 
  
 (a) If POZEN determines that the studies necessary for generating any additional data or information that are
required by the FDA for the approval of the POZEN NDA, or that are deemed necessary by POZEN to address issues or respond to questions raised by the FDA, would jeopardize the commercial viability of the Initial Licensed Product or exceed the
financial resources available at POZEN for the Initial Licensed Product, POZEN will inform Xcel thereof without delay. If the Parties are unable to come to a mutually acceptable resolution 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 of the matter within 30 days, POZEN may elect by written notice to Xcel to withdraw the POZEN NDA and abandon the
preparation of an NDA for the Initial Licensed Product; provided, however, that in such event Xcel will be given a reasonable opportunity (before such withdrawal or abandonment) to assume control of efforts to seek approval of the POZEN NDA
at Xcel’s cost (subject to Section 3.1.6 below). If Xcel elects to assume such control, POZEN will (i) exercise its Commercially Reasonable Efforts (at Xcel’s expense) to assist Xcel with respect to seeking approval of the POZEN NDA, and
(ii) transfer the POZEN NDA to Xcel promptly after receipt of such approval. Xcel will provide POZEN with written notice of its election within 90 days after receiving written notice of POZEN’s intent to withdraw the POZEN NDA and abandon the
preparation of an NDA for the Initial Licensed Product. 
  
 (b) If (i) Xcel does not assume control of efforts to seek approval of the POZEN NDA as provided in subsection (a) above, or (ii) Xcel assumes such control but terminates its efforts at anytime by written notice to POZEN, or (iii)
Xcel assumes such control but does not undertake or pursue any material development activities during a period of more than [***] (provided that such [***] period will be extended by the period of any delays in such development activities caused by
circumstances outside of Xcel’s reasonable control, but in no event will such extension exceed [***]), this Agreement will terminate upon receipt of the notice by POZEN . 
  
 3.1.6 If, pursuant to Section 3.1.5, POZEN elects to withdraw the POZEN NDA and abandon the preparation of an NDA for
the Initial Licensed Product and Xcel assumes control of efforts to seek approval of the POZEN NDA and obtains such approval, then, subject to the terms set forth in Section 8.4, Xcel may [***] in connection with seeking approval of the POZEN NDA,
subject to a limit of [***] $ [***] against [***] with respect to the Initial Licensed Product pursuant to Sections 8.2 or 8.3; provided, however, that Xcel may [***] that result from development activities agreed upon by the Parties, with
the agreement on the part of POZEN not to be unreasonably withheld. 
  
 3.2 Autoinjector. 
  
 3.2.1 Within 90 days
after the Effective Date, POZEN will prepare the development plan for the Autoinjector Presentation (the “Autoinjector Development Plan”) and will submit such plan for review and approval by the CMC at the next meeting. The outline
of the Autoinjector Development Plan with the target timeline for the submission of the Autoinjector SNDA is attached as Exhibit B. 
  
 3.2.2 POZEN will (a) conduct all development activities relating to the Autoinjector and the Autoinjector Presentation pursuant to the Autoinjector
Development Plan at POZEN’s expense; provided that POZEN will not be required [***] $ [***] with respect to the 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 performance of the Autoinjector Development Plan; (b) prepare the Autoinjector SNDA at its own expense, deliver to Xcel
such SNDA for filing by Xcel with the FDA and [***]; and (c) subject to the provisions of Section 3.4, be solely responsible for any and all communications with the FDA relating to the Autoinjector Presentation prior to the filing of the
Autoinjector SNDA by Xcel pursuant to Section 3.2.3. 
  
 3.2.3
Xcel will (a) file the Autoinjector SNDA with the FDA, (b) inform POZEN of any material developments with respect to the Autoinjector Presentation and the Autoinjector SNDA, including any requirements or suggestions by the FDA regarding the
submission of data or information as a condition to approving the Autoinjector SNDA; and (c) be the primary point of contact with the FDA relating to the Autoinjector Presentation and the Autoinjector SNDA. Upon approval by the FDA of the
Autoinjector SNDA, Xcel will maintain the Autoinjector SNDA during the Term at Xcel’s expense and will (x) obtain and maintain such other Regulatory Approvals as are necessary for the Commercialization of the Autoinjector Presentation in the
Territory, and (y) exercise Commercially Reasonable Efforts to cause any manufacturers of the Autoinjector Presentation (or any components thereof, as applicable) to obtain and maintain such other Regulatory Approvals as are necessary for the
manufacture at their respective facilities of the Autoinjector Presentation (or any components thereof, as applicable) for commercial sale in the Territory. 
  
 3.2.4 If, before or following the initial filing of the Autoinjector SNDA, the FDA requires or suggests or the Parties agree that data or
information be submitted as a condition to approving the Autoinjector SNDA in addition to the data or information that is generated in the performance of the Autoinjector Development Plan, the CMC will discuss how to address such FDA requirements
and suggestions and modify the Autoinjector Development Plan as appropriate. Subject to Section 3.2.5 below, POZEN will perform the modified Autoinjector Development Plan at POZEN’s expense. 
  
 3.2.5 If POZEN determines that (a) the performance of the Autoinjector
Development Plan would require [***] $ [***] in Development Costs, or (b) the studies necessary for generating any additional data or information that are required by the FDA for the approval of the Autoinjector SNDA, or that are deemed necessary by
POZEN or Xcel to address issues or respond to questions raised by the FDA, would jeopardize the commercial viability of the Autoinjector Presentation or exceed [***]$[***] in Development Costs, POZEN will inform Xcel thereof without delay. If the
Parties are unable to come to a mutually acceptable resolution of the matter within 30 days, POZEN may elect to abandon the performance of the Autoinjector Development Plan or the preparation of the Autoinjector SNDA; provided, however, that
in such event Xcel will be given a reasonable opportunity (before such abandonment) to assume control of efforts to seek approval of the Autoinjector SNDA at its cost (subject to Section 3.2.6 below). If Xcel elects to assume such control, POZEN
will exercise its Commercially Reasonable Efforts to assist Xcel (at Xcel’s expense) with respect to seeking approval of the Autoinjector SNDA; provided, however, that Xcel may suspend or terminate its efforts at anytime. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 3.2.6 If, pursuant to Section 3.2.5, POZEN elects to abandon the development of the Autoinjector
Presentation or the preparation of the Autoinjector SNDA and Xcel assumes control of efforts to seek approval of the Autoinjector SNDA and obtains such approval, then, subject to the terms set forth in Section 8.4, Xcel may [***] in connection with
the development of the Autoinjector Presentation or seeking approval of the Autoinjector SNDA, subject to a [***] $ [***] plus [***] $ [***] in Development Costs anticipated in Section 3.2.5 which has not been [***] prior to its abandonment of the
development of the Autoinjector Presentation or the preparation of the Autoinjector SNDA, [***] pursuant to Sections 8.2 or 8.3; provided, however, that Xcel may [***] result from development activities agreed upon by the Parties, with the
agreement on the part of POZEN not to be unreasonably withheld. 
  
 3.3 Other Licensed Products. 
  
 3.3.1
Xcel will have the right, but not the obligation, to perform development studies with Licensed Products beyond the activities contemplated by Sections 3.1 and 3.2 (each such study, a “Development Study”), including: (a)
development of Licensed Products in injectable formulations and dosage strengths other than those of the Initial Licensed Product; and (b) development of Licensed Products for indications other than the indication for which POZEN has filed the POZEN
NDA. Any Development Study [***], including study designs or protocols for such Development Study, will be subject to review and approval by the CMC. 
  
 3.3.2 Xcel will give POZEN written notice of any Xcel Post-Approval Study that is not contemplated by a Marketing Plan previously reviewed by POZEN
prior to initiating such Xcel Post-Approval Study, and POZEN will have the right to review and [***] such Xcel Post-Approval Study. 
  
 3.3.3 If Xcel desires that a Development Study [***] be conducted, then Xcel will notify POZEN of such desire and will accompany such notice with a
description of the objectives for the Development Study. Promptly thereafter, the Parties will prepare a development plan and budget for such Development Study for review and approval by the CMC (each such plan a “Study Plan”). If
POZEN desires to perform such Study Plan, (a) it will notify Xcel in writing prior to the meeting at which the Study Plan is submitted to the CMC for review and approval and (b) the Parties will negotiate an agreement with customary terms and
conditions for the conduct of the Study Plan, including that Xcel will reimburse POZEN monthly on a net 30 days from invoice date payment basis for POZEN’s Development Fees incurred in connection with such Study Plan. During such time as POZEN
holds the IND for the Initial Licensed Product, POZEN agrees to make, on Xcel’s behalf, any required filings to such IND as may be required for performance of any Study Plan. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 3.3.4 Xcel will, at its own expense, file any NDAs or other regulatory filings for Licensed
Products developed in a Development Study under the terms of this Agreement, and upon approval thereof will (a) obtain and maintain such other Regulatory Approvals as are necessary for the Commercialization of the applicable Licensed Product in the
Territory, and (b) exercise Commercially Reasonable Efforts to cause any manufacturers of such Licensed Product (or any components thereof, as applicable) to obtain and maintain such other Regulatory Approvals as are necessary for the manufacture at
their respective facilities of such Licensed Product (or any components thereof, as applicable) for commercial sale in the Territory. 
  
 3.3.5 POZEN will provide Xcel with [***] updates on the clinical development programs conducted by or on behalf of POZEN [***] for Foreign Licensed
Products (to the extent known to POZEN), where such activities [***] the development, manufacture or Commercialization of any Licensed Product in the Field in the Territory. 
  
 3.4 FDA Correspondence. 
  
 3.4.1 To the extent either Party receives any material written or oral communications relating to any Licensed Product from the FDA, such Party
will promptly inform the other Party thereof (including by providing a copy of any such written communication or a written account of any such oral communication), but in no event later than five business days after receipt of such communication.
The Party that is responsible for communicating with the FDA in connection with the development, registration or Commercialization of any Licensed Product at issue under the terms of this Agreement (i.e., the Party holding the NDA—the
“Communicating Party”) will use reasonable efforts to solicit the other Party’s advice and review of the nature and text of any written communications received from or to be sent to the FDA in reasonably sufficient time prior
to responding or dispatching such communications to the FDA, and the Communicating Party will consider in good faith the other Party’s reasonable comments related thereto. 
  
 3.4.2 Each Party will promptly notify the other Party, and provide such other Party with a copy, of any material
correspondence or other reports or complaints submitted to or received by the first Party from the FDA or any Third Party claiming that any Promotional Materials are inconsistent with any Licensed Product labeling or are otherwise in violation of
applicable law or regulation. 
  
 3.4.3 Each Party will
provide the other Party with a copy of any material documents or reports filed with the FDA during the Term with respect to any Licensed Product. 
  
 3.4.4 Prior to the transfer of the POZEN NDA to Xcel from POZEN pursuant to 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Section 3.1.2, (a) Xcel will be provided with the opportunity to have an observer in attendance at any in-person meetings
or pre-scheduled telephone calls with the FDA with respect to any Licensed Product and (b) the Parties will agree on any change to the labeling for the Initial Licensed Product (as compared with the draft label included in the POZEN NDA as of the
Effective Date). If the Parties are unable to agree on a label change, either Party will have the right to refer such disagreement (the “Label Dispute”) by written notice to the CEO of Xcel and the CEO of POZEN for resolution. If the CEOs
of the Parties are unable to reach unanimous agreement on how to resolve the Label Dispute [***] after such matter has been referred to the CEOs, the CEO of POZEN will make the final decision regarding any change to the label of the Initial Licensed
Product. Xcel will have the right to terminate this Agreement by written notice to POZEN [***] after such decision by the CEO of POZEN. [***] of such termination, POZEN will pay to Xcel the withdrawal fee set forth in Exhibit A attached hereto.

  
 3.5 Adverse Events Reporting. 
  
 3.5.1 For purposes of this Section 3.5: (a) the definition “drug
safety reports” shall comply with the requirements set forth by the FDA in the Code of Federal Regulations, Title 21 CFR 312.32 (“IND Safety Reports”); and (b) all information provided to Xcel pursuant to this Section 3.5 will
be provided in a complete and accurate manner. 
  
 3.5.2
During such time as Xcel holds the POZEN NDA and POZEN holds the IND for the Initial Licensed Product or is performing work under an IND for any Licensed Product or Foreign Licensed Product, POZEN will submit to Xcel all drug safety reports for
Licensed Products or Foreign Licensed Products brought to the attention of POZEN (whether inside or outside the Territory) as well as any material events and matters concerning or affecting the safety of Licensed Products or Foreign Licensed
Products. POZEN will forward copies of all such drug safety reports to Xcel within seven days of receipt thereof by POZEN. 
  
 3.6 Compliance with Laws. 
  
 3.6.1 Xcel will comply with all laws, regulations, and ordinances (including any laws, regulations, and ordinances prohibiting the promotion of
Royalty Products prior to Marketing Approval) applicable to the performance by Xcel of this Agreement (including, as applicable, the development, manufacture and Commercialization of Royalty Products by Xcel in the Territory). 
  
 3.6.2 POZEN will comply with all laws, regulations, and ordinances
applicable to the performance by POZEN of this Agreement. 
  
 3.7 Records. Each Party will keep complete, accurate and authentic accounts, notes, data and records (in good scientific manner and as required by applicable regulatory rules and regulations) of all activities performed by or for it
pursuant to this Agreement. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 4. MANUFACTURE AND SUPPLY 
  
 4.1 Manufacturing and Supply Agreement for DHE. 
  
 4.1.1 Promptly following the Effective Date, Xcel will exercise good faith efforts to enter into an agreement with
[***]. POZEN will exercise good faith efforts to assist Xcel in its discussions and negotiations with [***] with respect to such agreement. Xcel will keep POZEN informed of the progress of Xcel’s negotiations with [***] and, as applicable,
provide POZEN with a near-final draft of such agreement and a copy of such agreement as executed. 
  
 4.1.2 Xcel hereby covenants and agrees that, [***]. 
  
 4.2 Manufacturing and Supply Agreement for [***]. 
  
 4.2.1 Promptly following the Effective Date, Xcel will exercise good faith efforts to enter into an agreement with [***]. POZEN will exercise good
faith efforts to assist Xcel in its discussions and negotiations with [***] with respect to such agreement. Xcel will keep POZEN informed of the progress of Xcel’s negotiations with [***] and, as applicable, provide POZEN with a near-final
draft of such agreement and a copy of such agreement as executed. 
  
 4.2.2 The Parties acknowledge that POZEN and [***] have executed an agreement pursuant to which [***] is scaling up the manufacturing process for bulk packaged Initial Licensed Product to [***]. POZEN will exercise its Commercially
Reasonable Efforts so that, as soon as reasonably possible following the Effective Date, [***] produces a demonstration batch of bulk packaged Initial Licensed Product from such [***] process which meets or exceeds all of the release specifications
set forth in the POZEN NDA (the “Demonstration Batch”). [***] will be responsible for all costs incurred for producing batches of bulk packaged Initial Licensed Product until the Demonstration Batch is determined to meet or exceed all of
the release specifications set forth in the POZEN NDA. Thereafter, [***] the costs incurred for producing batches of bulk packaged Initial Licensed Product from such [***] process until [***] batches are produced which each meet or exceed all of the
release specifications set forth in the POZEN NDA approved by the FDA (such [***] batches referred to as the “Validation Batches”), and each of the Parties will exercise its Commercially Reasonable Efforts to cause such production to occur
as soon as reasonably possible [***] to manufacture bulk packaged Initial Licensed Product. Notwithstanding the preceding sentence, (a) either Party will have the right to request the manufacture of bulk packaged Initial Licensed Product [***] to
manufacture bulk packaged Initial Licensed Product, provided that [***] will bear all 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 costs reasonably incurred by either Party in connection with such manufacture, and (b) [***] will pay or reimburse [***]
the costs reasonably incurred in connection with the manufacture of the Validation Batches. 
  
 4.3 Quality Agreement for [***]. Promptly following the Effective Date, Xcel will exercise good faith efforts to enter into a quality agreement with [***]. POZEN will exercise good faith efforts to assist Xcel
in its discussions and negotiations with [***] with respect to such agreement. Xcel will keep POZEN informed of the progress of Xcel’s negotiations with [***] and, as applicable, provide POZEN with a near-final draft of such agreement and a
copy of such agreement as executed. 
  
 4.4 Supply through
POZEN. 
  
 4.4.1 If Xcel is unable to execute an
agreement with [***], the Parties will negotiate in good faith regarding an agreement under which POZEN would secure the supply to Xcel of [***]. The payments to be made by Xcel to POZEN pursuant to subsection (a) and (b) above will be made
no later than 10 days in advance of the due date of any payments required to be made by POZEN to [***]. 
  
 4.4.2 If Xcel is unable to execute an agreement with [***], the Parties will use good faith efforts to secure the supply of [***].

  
 5. COMMERCIALIZATION 
  
 5.1 Principles of Commercialization. 
  
 5.1.1 Xcel will be responsible for the Commercialization of Licensed
Products in the Field in the Territory during the Term, and will use Commercially Reasonable Efforts to perform the activities and apply the resources set forth in each Marketing Plan (defined below) [***]. Except with respect to the costs of the
development and regulatory activities to be performed by POZEN or that may be off-set by Xcel as provided in Sections 3.1 or 3.2, Xcel will bear all expenses incurred in connection with the preparation and execution of each Marketing Plan.

  
 5.1.2 Promptly after the Effective Date, the
appropriate representatives of each Party will meet to discuss matters pertaining to the manufacture, marketing and promotion of the Initial Licensed Product, including plans for sales force deployment, and the transfer of manufacturing
responsibilities from POZEN to Xcel. Promptly after the Effective Date, the Parties will establish a plan, to be performed at Xcel’s expense, governing the communication of scientific and technical information regarding the Initial Licensed
Product prior to approval of the POZEN NDA, including any such information to be included in papers, posters, conference 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 presentations, focus group activities, conferences and meetings with doctors, and Xcel will adhere to such plan in its
communications with Third Parties prior to approval of the POZEN NDA; provided, however, that the following activities will not be subject to such plan or the restrictions of this sentence: advisory board meetings, market research activities
and the development of marketing campaigns or sales and marketing materials for use after approval of the POZEN NDA (as well as any activities reasonably related to such activities). 
  
 5.2 Marketing Plan. 
  
 5.2.1 Xcel will prepare a marketing plan for the Licensed Products for 2004 (the “Marketing Plan”) and provide a copy of the
Marketing Plan to POZEN for comment [***]. POZEN will provide its comments to the Marketing Plan to Xcel [***], and Xcel will finalize the Marketing Plan [***]. The outline of the initial Marketing Plan for the Initial Licensed
Products is attached hereto as Exhibit C. 
  
 5.2.2
Xcel will update the Marketing Plan at least once every year, and will submit each updated Marketing Plan to POZEN for review and comment in accordance with Xcel’s corporate planning cycle and with sufficient lead time for POZEN to have a
reasonable opportunity to review and comment on such updated Marketing Plan. 
  
 5.2.3 Each Marketing Plan will include, for the calendar year covered, Xcel’s then-current plans as to: (i) medical education (including a communication plan), market development, marketing, pricing,
advertising, and sales, supply and distribution strategies; (ii) targeted populations and distribution channels for promotional efforts and other resources to be devoted to such efforts; (iii) number and positioning of details to be performed for
Licensed Products; (iv) positioning of Licensed Products in the market; (v) market and sales forecasts for Licensed Products; (vi) [***]; (vii) the overall plan for the development of Licensed Products (if any), including any Xcel Post-Approval
Studies (if any); and (viii) general strategy and operating guidelines for Commercialization of Licensed Products. 
  
 5.3 Co-Promotion. 
  
 5.3.1 POZEN may co-promote any Licensed Product in the Territory in the event that: 
  
 (a) the Parties mutually agree (i) that such co-promotion would benefit the promotion of such Licensed Product and
(ii) to terms for a co-promotion agreement; or 
  
 (b)
POZEN reasonably demonstrates that greater sales efforts are required to realize the market potential of such Licensed Product and POZEN [***] associated with its co-promotion efforts (with Xcel agreeing that it will not [***]). 
  
 5.3.2 If Section 5.3.1(b) above is applicable, then, for a period of
60 days 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 thereafter, the Parties will negotiate in good faith a co-promotion agreement governing the co-promotion of the
applicable Licensed Product by POZEN in the Territory (with the intent that such agreement will contain terms and conditions customary for a co-promotion agreement in the pharmaceutical industry, as well as providing for a co-promotion role for
POZEN in the marketing and promotion of the applicable Licensed Product commensurate with [***] and in accordance with the Marketing Plan then in effect, although Xcel will set the sales price, [***], and book all sales revenue). If the Parties are
unable to agree on all terms of such a co-promotion agreement with respect to the applicable Licensed Product prior to expiration of such 60-day period, then either Party may invoke and proceed in accordance with the dispute resolution procedure set
forth in Exhibit F attached hereto. 
  
 5.3.3 If
Xcel desires to enter into a co-promotion arrangement for a Licensed Product with a Third Party, subject to the terms set forth in Section 5.3.4 below, then Xcel will notify POZEN of such desire and will accompany such notice with a description of
the intended role for such Third Party (including a description of related requirements such as the number and territory of sales representatives and the number, frequency and positioning of details). If POZEN desires to perform such co-promotion
arrangement, it will notify Xcel in writing within 30 days after receipt of the corresponding notice from Xcel. In the event that POZEN is able to provide the resources that Xcel is seeking for the performance of the requirements identified by Xcel,
promptly thereafter the Parties will negotiate, for a period of 60 days, a co-promotion agreement governing the co-promotion of the applicable Licensed Product by POZEN in the Territory (with the intent that such agreement will provide for a
co-promotion role for POZEN in the marketing and promotion of the applicable Licensed Product corresponding to the role for any Third Party described by Xcel in its notice to POZEN (and in accordance with the Marketing Plan then in effect), although
Xcel will set the sales price, [***], and book all sales revenue). If the Parties are not able to agree upon such a co-promotion agreement within such 60-day period, then Xcel may seek to have a Third Party perform the co-promotion arrangement;
provided, however, that Xcel may not offer to any such Third Party terms which are, in the aggregate, more beneficial to such Third Party than the last offer made by Xcel to POZEN during the above-referenced 60-day negotiating period without
providing POZEN with a period of at least 10 days to accept any improved terms which Xcel intends to offer to any Third Party. 
  
 5.3.4 Notwithstanding anything in this Agreement to the contrary, (a) Xcel may enter into a co-promotion arrangement with a Third Party for
Licensed Products only if such arrangement: [***], and (b) subject to the limitations set forth in subsection (a) above, Xcel is not required to first offer co-promotion rights to POZEN pursuant to Section 5.3.3 with respect to a proposed
co-promotion arrangement with a Third Party pursuant to which [***]. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 5.4 Branding; Trademarks; Trade Dress; Logos. 
  
 5.4.1 Following the Effective Date, the Parties will work together to
select a Product Trademark for the Initial Licensed Product. In the event that the Parties have not agreed upon such a Product Trademark by October 30, 2003, then [***] may select a Product Trademark for the Initial Licensed Product, subject to the
approval of [***]. Xcel will thereafter use such Product Trademark in the Commercialization of the Initial Licensed Product. 
  
 5.4.2 Prior to Marketing Approval for any Licensed Product other than the Initial Licensed Product, the Parties will work together to determine a
Product Trademark for such Licensed Product. In the event that the Parties have not agreed upon such a Product Trademark within 60 days of Xcel’s delivery to POZEN of notice that a Product Trademark is required for such Licensed Product in
order for Xcel properly to commence pre-launch market development activities in anticipation of Marketing Approval for such Licensed Product, then [***] may select a Product Trademark for the Licensed Product, subject to the approval of [***]. Xcel
will thereafter use such Product Trademark in the Commercialization of such Licensed Product. 
  
 5.4.3 At the request of POZEN, Xcel will, to the extent permitted by law (including applicable FDA regulations), include any POZEN Trademark designated by POZEN (the “Designated POZEN
Trademark”) on any joint press releases and seminar and conference posters and presentations regarding any Licensed Product. Prior to any such use, Xcel will provide POZEN with an opportunity to review and comment upon the planned use of
the Designated POZEN Trademark. In addition, any such use of the Designated POZEN Trademark will comply with the provisions of Section 5.4.5. 
  
 5.4.4 POZEN will be the sole owner of the Product Trademarks. In consideration for the licenses granted by POZEN to Xcel for Product Trademarks
under this Agreement, Xcel will pay to POZEN a royalty of [***]% [***] for the duration of the use of any such Product Trademarks by Xcel [***]. 
  
 5.4.5 In connection with the use of any Product Trademarks or any Designated POZEN Trademark, Xcel will (a) place the appropriate trademark symbol,
such as TM or ®, adjacent to any Product Trademark
or Designated POZEN Trademark and (b) not use such Product Trademark or Designated POZEN Trademark as an adjective or in the plural or possessive form. Xcel recognizes and agrees that such steps are necessary to protect and enhance the value and
goodwill of the Product Trademarks or any Designated POZEN Trademark. POZEN will have the right to review any Product Promotional Materials and any labels or packaging materials prepared by or for Xcel that bear any Product Trademarks or any
Designated POZEN Trademark in order to confirm that such trademarks are being used in all material respects in accordance with the terms of this Section 5.4.5. Upon written notice of non-compliance from POZEN to Xcel, Xcel will modify the applicable
Product Promotional Materials, labels, or packaging materials to make them comply with the terms of this Section 5.4.5. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 5.4.6 POZEN reserves all rights in the Product Trademarks and the POZEN Trademarks not expressly
granted to Xcel in this Agreement. Xcel acknowledges POZEN’s exclusive right, title and interest in and to the Product Trademarks and POZEN Trademarks and acknowledges that nothing herein will be construed to accord to Xcel any rights in such
trademarks except as expressly provided herein. Xcel further acknowledges that its use of the Product Trademarks and POZEN Trademarks will not create in Xcel any right, title or interest in such trademarks, and that all use of such trademarks and
the goodwill generated thereby will inure solely to the benefit of POZEN. Upon any termination of this Agreement, Xcel hereby agrees not to [***]. 
  
 5.4.7 Except as expressly permitted herein, POZEN will not use, or knowingly permit any Third Party to use, any Product Trademarks except in
connection with the development, manufacture and Commercialization outside of the Territory of Foreign Licensed Products, and will impose on all direct or indirect licensees of Foreign Licensed Products using the Product Trademarks obligations
similar to those imposed on Xcel pursuant to Section 5.4.5. 
  
 6. DILIGENCE

  
 6.1 General Diligence Obligations. Xcel will,
during the Term, exercise Commercially Reasonable Efforts to Commercialize the Licensed Products in the Field in the Territory following receipt of Marketing Approval. 
  
 6.2 Minimum Launch Diligence Obligations. Without limiting the diligence obligations of Section 6.1 above, Xcel will
conduct the Commercial Launch of each Licensed Product in the Territory as soon as reasonably possible after receipt of Marketing Approval for such Licensed Product, but in no event later than [***]. Without limiting the diligence obligations of
Section 6.1 above, Xcel will conduct the Commercial Launch of the Initial Licensed Product in the Territory before conducting the Commercial Launch of any other Licensed Product in the Territory. 
  
 6.3 Minimum Commercialization Diligence Obligations. Without
limiting the diligence obligations of Section 6.1 above, during the [***] following the First Commercial Sale Date for the Initial Licensed Product, Xcel will: [***]. 
  
 6.4 Lack of Diligence. Any material failure by Xcel to fulfill a diligence obligation set forth in this Section 6
will be deemed a material breach of this Agreement. Xcel’s fulfillment of the diligence obligations set forth in Sections 6.2 and 6.3 will be taken into account when determining whether Xcel has fulfilled its obligations set forth in Section
6.1, but will not be considered conclusive proof that such obligations have also been fulfilled. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 7. LICENSES AND OTHER RIGHTS 
  
 7.1 Grants to Xcel. Subject to the terms and conditions set forth in this Agreement, POZEN hereby grants to Xcel:

  
 7.1.1 An exclusive license (even as to POZEN) under
the Licensed Technology to Commercialize Royalty Products in the Field in the Territory; 
  
 7.1.2 Except as provided in Section 4.1.2, a worldwide, non-exclusive license under the Licensed Technology to make or have made Royalty Products for Commercialization in the Field in the Territory; 

 
 7.1.3 A non-exclusive license under the Licensed Technology to
develop Royalty Products in the Territory; 
  
 7.1.4 An
exclusive license (even as to POZEN) to use the Product Trademarks in connection with the Commercialization of Licensed Products in the Territory; and 
  
 7.1.5 A non-exclusive license to use Designated POZEN Trademarks pursuant to Section 5.4.3. 
  
 7.2 Sublicenses by Xcel. Except for any co-promotion arrangements
entered into by Xcel with any Third Parties in accordance with Section 5.3, the licenses granted in Sections 7.1.1, 7.1.4 and 7.1.5 are not sublicensable by Xcel. The licenses granted to Xcel in Section 7.1 in connection with any co-promotion
arrangement entered into in accordance with Section 5.3, and the licenses granted to Xcel in Section in 7.1.2 and 7.1.3, are sublicensable by Xcel. Xcel will impose on any sublicensee of Xcel’s rights such obligations as may be necessary for
(a) Xcel to be able to perform its obligations under this Agreement and (b) the required performance of such sublicensee to be in compliance with the requirements of this Agreement. 
  
 7.3 Grants to POZEN. Subject to the terms and conditions set forth in this Agreement, Xcel hereby grants to POZEN:

  
 7.3.1 An exclusive license (even as to Xcel) under the
Xcel Technology, but solely to Commercialize in the Field outside the Territory any Foreign Licensed Products; 
  
 7.3.2 A non-exclusive, worldwide license under the Xcel Technology, but solely to develop, make or have made for Commercialization in the Field
outside the Territory any Foreign Licensed Products; and 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 7.3.3 The non-exclusive right to use and reference the filed or approved POZEN NDA and the
Autoinjector SNDA (and, if applicable, the NDA for any Licensed Product other than the Initial Licensed Product) and any data and information contained in such filed or approved POZEN NDA or Autoinjector SNDA (or, if applicable, such other NDA) for
(a) the development, registration and Commercialization of products other than Royalty Products inside the Territory, (b) the development of Foreign Licensed Products inside or outside the Territory, and (c) the registration and Commercialization of
Foreign Licensed Products outside the Territory. 
  
 7.4
Sublicenses by POZEN. The licenses and rights granted in Section 7.3 are sublicensable by POZEN without the prior written consent of Xcel, but only if the following conditions are met: (a) any sublicensee is, with respect to any territory at
issue, concurrently receiving from POZEN a license under one or more Patents Controlled by POZEN to Commercialize Foreign Licensed Products in the Field in such territory; (b) such license is granted with the same scope of exclusivity and under the
same termination and expiration terms as the sublicenses granted under the licenses and rights granted in Section 7.3; (c) such sublicensee is licensing to POZEN [***] owned or Controlled by such sublicensee that are [***] for the development,
manufacture, having manufactured or Commercialization of any Licensed Products in the Field in the Territory, which license to POZEN is to be sublicensable (and deemed sublicensed) to Xcel in accordance with the terms of the licenses granted in
Section 7.1; and (d) Xcel receives prior written notice of any such sublicense. Any sublicensee in an arrangement meeting the requirements of the foregoing clauses (a), (b), (c) and (d) is herein referred to as a “Reciprocating
Licensee.” Notwithstanding the foregoing, POZEN will have the right to sublicense to any of its licensees its right of use and reference of the filed or approved POZEN NDA and the Autoinjector SNDA and any data and information contained in
such filed or approved POZEN NDA or Autoinjector SNDA for (a) the development, registration and Commercialization of products other than Royalty Products inside the Territory, (b) the development of Foreign Licensed Products inside and outside the
Territory and (c) the registration and Commercialization of Foreign Licensed Products outside the Territory. 
  
 7.5 Negative Covenants. 
  
 7.5.1 Xcel covenants and agrees that it will not (a) use or practice the Licensed Technology or the Product Trademarks, except as expressly
permitted by this Agreement, (b) use or practice the Licensed Technology for the purposes of developing, distributing or Commercializing any Licensed Product for non-prescription sale, (c) apply for any Regulatory Approval that would allow the
over-the-counter sale of any Licensed Product, (d) sell any Licensed Product to patients without a prescription therefore, (e) sell, or knowingly permit any Third Party to sell, any Licensed Product for export, distribution, resale or use outside
the Territory or (f) [***]. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 7.5.2 POZEN covenants and agrees that it will not (a) use or practice the Xcel Technology, except
as expressly permitted by this Agreement, (b) sell, or knowingly permit any Third Party to sell, any Royalty Product for import, distribution, resale or use in the Territory, (c) conduct any Commercialization, or knowingly permit any Third Party to
conduct any Commercialization, of any Royalty Product in the Territory, (d) [***] or, (e) except for Third Parties which are obligated to POZEN to maintain confidentiality of the same in accordance with arrangements which are at least as protective
as the provisions set forth in Section 13 or as expressly contemplated by this Agreement, disclose any Licensed Technology, or any Confidential Information of POZEN relating to any Licensed Technology, to any Third Party. 
  
 7.5.3 If either Party desires to develop a Combination Product, it
will notify the other Party thereof in writing, and the Parties will discuss and negotiate the terms pursuant to which such Combination Product should be developed. If the Parties are unable to reach agreement on whether or under what terms to
develop such Combination Product, [***] will have the right to Commercialize such Combination Product in the Territory during the Term, [***] with or through a Third Party by license, sale or other transfer of product assets or otherwise.

  
 7.5.4 If either Party desires to develop a Licensed
Product that would require the filing of a new NDA (i.e., in addition to the POZEN NDA), it will notify the other Party thereof in writing, and the Parties will discuss and negotiate the terms pursuant to which such Licensed Product should be
developed. If the Parties are unable to reach agreement on whether or under what terms to develop such Licensed Product, [***] will have the right to Commercialize such Licensed Product in the Territory during the Term, [***] or with or through a
Third Party by license, sale or other transfer of product assets or otherwise. 
  
 7.5.5 Except for the rights specifically granted in this Agreement, each Party expressly reserves (a) all rights owned or controlled by it, including as to all products and intellectual property rights, and (b)
the right to utilize, and to allow Third Parties to utilize, such products and intellectual property rights in any manner not inconsistent with the terms of this Agreement. 
  
 7.6 Upstream Licensors of Future Technology. 
  
 7.6.1 With respect to any intellectual property rights included in any POZEN Improvement or POZEN Patent acquired by
or licensed to POZEN from a Third Party after the Effective Date and practiced by Xcel in the development, manufacture or Commercialization of 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 any Royalty Product other than the Initial Licensed Product as envisaged as of the Effective Date, such intellectual
property rights will not be included in the licenses granted under Section 7.1 unless Xcel agrees to pay to POZEN any amounts that may become due to any such Third Party licensor as a result of the practice of such intellectual property rights by
Xcel pursuant to the licenses granted under Section 7.1, with such payment to be made no later than 10 days prior to the date POZEN’s payment is due to such Third Party licensor. POZEN will provide written notice to Xcel describing any payment
obligations associated with the practice of any such intellectual property rights at the time POZEN discloses such intellectual property rights or related information or technology to Xcel. 
  
 7.6.2 With respect to any intellectual property rights included in any
Xcel Improvement or Xcel Patent acquired by or licensed to Xcel from a Third Party after the Effective Date and practiced by POZEN or any Reciprocating Licensee in the development, manufacture or Commercialization of any Licensed Product or Foreign
Licensed Product other than the Initial Licensed Product as envisaged as of the Effective Date, such intellectual property rights will not be included in the licenses granted under Section 7.3 unless POZEN agrees to pay to Xcel any amounts that may
become due to any such Third Party licensor as a result of the practice of such intellectual property rights by POZEN or any such Reciprocating Licensee pursuant to the licenses granted under Section 7.3, with such payment to be made no later than
10 days prior to the date Xcel’s payment is due to such Third Party licensor. Xcel will provide written notice to POZEN describing any payment obligations associated with the practice of any such intellectual property rights at the time Xcel
discloses such intellectual property rights or related information or technology to POZEN. 
  
 8. COMPENSATION 
  
 8.1
License Fees. Xcel will pay to POZEN a non-refundable, non-creditable license fee of US$2,000,000 on the Effective Date. 
  
 8.2 Milestones. Subject to the terms and conditions of this Agreement, Xcel will make the following non-refundable, non-creditable payments to
POZEN in the amounts set forth below within 15 days of the occurrence of the related event: 
  

			
	 Milestone Event

	  	Milestone
Payment

	 [***]
	  	[***]$[***]
	 [***]
	  	[***]$[***]
	 [***]
	  	[***]$[***]

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 8.3 Royalties. 
  
 8.3.1 Royalty Rate. Subject to the terms and conditions of this Agreement, Xcel will pay to POZEN a royalty, based on
aggregate Net Sales of Royalty Products in the Territory for each calendar year during the Royalty Term, as follows: 
  
 [***]%[***]$[***]; 
  
 [***]%[***]$[***]$[***]; and 
  
 [***]%[***]$[***]; 
 [***]%[***]%[***]%[***]%[***]. 
  
 8.3.2 Royalty
Term. Royalties due under this Section 8.3 will be payable with respect to all Royalty Products for the period (the “Royalty Term”) commencing on the First Commercial Sale Date of the first Licensed Product and ending on the
later of “X” or “Y” where “X” is the day that is 12 years following such First Commercial Sale Date and “Y” is the earlier of (a) the day that is the expiration date of the last-to-expire issued Patent within
the Licensed Technology containing a Valid Claim covering any Licensed Product in the Territory or (b) the last day of the fourth consecutive calendar quarter in which Generic Erosion persists and which fourth quarter ends on or after the day that
is 12 years following the First Commercial Sale Date of the first Licensed Product. 
  
 8.4 Offsets. 
  
 8.4.1
Subject to the terms of this Section 8.4, Xcel may offset up to [***]% of any Third Party Payments against any of the payments required to be made by Xcel in Section 8.2, or any of the payments made by Xcel in Section 8.3 based on Net Sales of
the Initial Licensed Product, the Autoinjector Presentation or DHE-45. 
  
 8.4.2 Notwithstanding any provision herein to the contrary, the amount of any offsets taken by Xcel pursuant to Sections 3.1.6, 3.2.6, and 8.4.1, in the aggregate, will be subject to a maximum, as to any specific payment, of [***]
([***]%) of the amount payable by Xcel under this Agreement prior to application of the offset(s), [***]. 
  
 8.4.3 Notwithstanding any provision herein to the contrary, Xcel will not be entitled to take any offset pursuant to Sections 3.1.6, 3.2.6, or
8.4.1 from royalties due for Net Sales of a Licensed Product during such time as the royalty rate for such Licensed Product is reduced pursuant to the proviso in Section 8.3.1, [***]. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 8.5 Reduction Due to Generic Erosion. Generic Erosion for Licensed Products will be calculated on
a calendar quarterly basis. Gross sales information for Licensed Products and Generic Equivalents will be determined by using reference data published by IMS Health, Scott-Levin or another industry-accepted source used by Xcel at the time that such
determination is made. The reduced royalty set forth in the proviso in Section 8.3.1 will apply and be limited to each calendar quarter in which Generic Erosion exists, as documented by Xcel pursuant to this Section 8.5. Xcel will notify POZEN in
writing promptly upon its determination that Generic Erosion has occurred with respect to a calendar quarter and will provide with such notice such information and documentation as is reasonably necessary for POZEN to confirm the accuracy of such
determination. 
  
 8.6 Payments and Reports. Payments
required to be made by Xcel in Section 8.3 will be made on a calendar quarter basis (calculated as the amount owed for the then current calendar year through the end of such quarter less any amounts previously paid in respect of such year), with
such payments to be (a) made within [***] after the end of the applicable calendar quarter and (b) accompanied by a written report setting forth in reasonable detail the calculation of the amount of the payment made; provided, however, that
(i) within [***] of the end of each calendar quarter, Xcel will provide POZEN with a report stating the number of units of each Royalty Product sold by Xcel during the relevant payment period, the amount of gross sales, any deductions taken in the
calculation of Net Sales, and the royalty payable pursuant to Section 8.3 in respect of such quarter, and (ii) if any information bearing on the amount of any royalty payment pursuant to Section 8.3 [***] becomes known following the making of any
such payment (or the delivery of any related report), adjustments will be made in subsequent payments (i.e., to “true-up” the aggregate amount of royalty payments made) and the reports made with respect to such subsequent payments
will indicate the basis and amount of any such adjustments. 
  
 8.7 Payment Method; Currency. Xcel will make all payments under this Agreement in United States dollars by wire transfer in immediately available funds to an account designated by POZEN. Any payments or portions thereof due hereunder
that are not paid on the date such payments are due under this Agreement will bear interest at a per annum rate equal to the lesser of (a) the prime rate as published in The Wall Street Journal, Eastern Edition, on the first day of each calendar
quarter in which such payments are overdue, [***] percentage [***], and (b) the maximum rate permitted by law, calculated on the number of days such payment is delinquent. 
  
 8.8 Taxes. Xcel will have the right to withhold taxes in the event that authorities in the Territory require the
withholding of taxes on amounts paid hereunder to POZEN. Such taxes 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 will be deducted by Xcel from such payment and will be paid by Xcel to the proper taxing authority on behalf of POZEN.
Xcel will promptly secure and send to POZEN proof evidencing payment of such taxes withheld and paid by Xcel for the benefit of POZEN. Xcel will assist POZEN in claiming exemption from such deductions or withholdings under any applicable tax treaty
by providing such documentation as may be reasonably required by POZEN to claim such exemption. 
  
 8.9 Audit Rights; Adjustments. 
  
 8.9.1 Each Party (the “Audited Party”) will permit an independent certified public accountant designated by the other Party (the
“Auditing Party”) and reasonably acceptable to the Audited Party (the “Auditor”) to have access to the Audited Party’s records and books, insofar as the same relate to any of the payments to be made under the
provisions of this Agreement, for the sole purpose of determining the accuracy of the amounts reported and actually paid or otherwise payable under the terms of this Agreement (the “Audit”); provided, however, that (i) any Audit
will cover a period not to exceed three years immediately preceding such Audit, (ii) each period may be the subject of only one Audit, (iii) the Auditor will agree to (x) execute and be bound by a confidentiality agreement in customary form and (y)
reveal only the results of the Audit (the “Auditor’s Results”) to the Auditing Party (and not, for example, the information reviewed with respect thereto), (iv) the Auditing Party will bear all costs and expenses in connection
with any Audit, (v) any Audit will be performed during a mutually determined period upon at least 30 calendar days’ prior written notice during regular business hours, and (vi) Audits will not be requested by any one Party to occur more than
once in each calendar year during the Term and once following expiration or termination of this Agreement. 
  
 8.9.2 Where the Audit relates to royalty payments made by Xcel under Section 8.3: (a) if the Auditor’s Results determine that any royalty
payment(s) at issue have been overstated, then POZEN will repay to the Xcel the amount of any resulting overpayment within 30 days after receipt of the Auditor’s Results, after deducting the reasonable costs and expenses incurred by POZEN in
connection with the Audit; and (b) if the Auditor’s Results determine that any royalty payment(s) at issue have been understated, then (i) Xcel will pay to POZEN the amount of any resulting underpayment within 30 days after receipt of the
Auditor’s Results together with interest on any underpayment from the date originally due, calculated at a per annum rate equal to the prime rate as published in The Wall Street Journal, Eastern Edition, on the first day of each calendar
quarter in which such underpayment occurs, [***] percentage [***], and, (ii) where the underpayment of any royalty payment(s) at issue is greater than [***]% of the amount of such royalty payment(s) actually due under the terms of this Agreement,
then Xcel will reimburse POZEN for the reasonable costs and expenses incurred by POZEN in connection with the Audit. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 8.9.3 Where the Audit relates to payments made by Xcel to POZEN other than royalty payments under
Section 8.3 (e.g., payments for Development Fees pursuant to a Study Plan as contemplated by Section 3.3.3 or payments for Manufacturing Liaison Fees as contemplated by Section 4.4): (a) if the Auditor’s Results determine that any payment(s) at
issue have been overstated, then (i) POZEN will repay to Xcel the amount of any resulting overpayment within 30 days after receipt of the Auditor’s Results together with interest on any overpayment from the date originally due, calculated at a
per annum rate equal to the prime rate as published in The Wall Street Journal, Eastern Edition, on the first day of each calendar quarter in which such overpayment occurs, [***] percentage [***], and, (ii) where the overpayment of any payment(s) at
issue is greater than [***]% of the amount of such payment(s) actually due under the terms of this Agreement, then POZEN will reimburse Xcel for the reasonable costs and expenses incurred by Xcel in connection with the Audit; and (b) if the
Auditor’s Results determine that any underpayment has occurred, then Xcel will pay to POZEN the amount of any resulting underpayment within 30 days after receipt of the Auditor’s Results, after deducting the reasonable costs and expenses
incurred by Xcel in connection with the Audit. 
  
 8.9.4 In
connection with any audits of POZEN’s books and records conducted on behalf of [***] or its Affiliates pursuant to the [***], POZEN will have the right to make available to [***] and its Affiliates any Auditor’s Results with respect to
Xcel’s books and records insofar as the same address matters affecting [***] under the [***].  
  
 9. INTELLECTUAL PROPERTY 
  
 9.1 Ownership. All right, title and interest in and to the Licensed Technology, POZEN Trademarks, and Product Trademarks will remain exclusively with POZEN, subject only to the licenses granted to Xcel under this Agreement. All
right, title and interest in and to the Xcel Technology will remain exclusively with Xcel, subject only to the licenses granted to POZEN under this Agreement. 
  

9.2 Patent and Trademark Filing, Prosecution and Maintenance. 
  
 9.2.1 As between the Parties, POZEN will have the first right, using counsel of its choice, to prepare, file,
prosecute, maintain and obtain extensions of all POZEN Patents and Product Trademarks in the Territory, subject to any obligations POZEN may have to Third Parties with respect to POZEN Patents that are licensed by such Third Party to POZEN. If POZEN
undertakes any such activities, then (a) POZEN will bear the costs relating to such activities, (b) POZEN will consider in good faith the interests of Xcel in so doing and (c) POZEN will use Commercially Reasonable Efforts to obtain the strongest
commercially reasonable patent or trademark protection (under the circumstances and, as to patent protection, for applications of each POZEN Patent for Royalty Products). POZEN will use reasonable 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 efforts to solicit Xcel’s advice and review of the nature and text of POZEN Patents, applications for Product
Trademarks and material prosecution matters related thereto in reasonably sufficient time prior to filing thereof or action thereon, and POZEN will consider in good faith Xcel’s reasonable comments related thereto. 
  
 9.2.2 If POZEN, prior or subsequent to filing any POZEN Patent owned
by POZEN or any application for a Product Trademark, elects not to file, prosecute or maintain such POZEN Patent or such application for a Product Trademark, then POZEN will give Xcel written notice thereof within a reasonable period prior to
allowing such POZEN Patent or such application to lapse or become abandoned or unenforceable, and Xcel will thereafter have the right, at its expense, to assume title and ownership to, and to prepare, file, prosecute and maintain, such POZEN Patent
or such application for a Product Trademark. 
  
 9.2.3 As
between the Parties, Xcel will have the first right, using counsel of its choice, to prepare, file, prosecute, maintain and obtain extensions of all Xcel Patents, subject to any obligations Xcel may have to Third Parties with respect to Xcel Patents
that are licensed by such Third Party to Xcel. If Xcel undertakes any such activities, then (i) Xcel will bear the costs relating to such activities, (ii) Xcel will consider in good faith, to the extent that any such Xcel Patent relates to any
Licensed Product, the interests of POZEN in so doing and (iii) Xcel will use Commercially Reasonable Efforts to obtain the strongest commercially reasonable patent or trademark protection (under the circumstances and, as to patent protection to the
extent that any such Xcel Patent relates to any Licensed Product, for applications of such Xcel Patent for Licensed Products). To the extent that any such Xcel Patent relates to any Licensed Product, Xcel will use reasonable efforts to solicit
POZEN’s advice and review of the nature and text of such Xcel Patent and material prosecution matters related thereto in reasonably sufficient time prior to filing thereof or action thereon, and Xcel will consider in good faith POZEN’s
reasonable comments related thereto. 
  
 9.2.4 If Xcel,
prior or subsequent to filing any Xcel Patent owned by Xcel, elects not to file, prosecute or maintain such Xcel Patent, then Xcel will give POZEN written notice thereof within a reasonable period prior to allowing such Xcel Patent to lapse or
become abandoned or unenforceable, and POZEN will thereafter have the right, at its expense, to assume title and ownership to, and to prepare, file, prosecute and maintain, such Xcel Patent. 
  
 9.3 Improvements. 
  
 9.3.1 All Improvements made jointly by employees of POZEN and Xcel
(or their Affiliates or Third Party contractors), and all joint Know-How, will be owned jointly by the Parties and each Party will retain full ownership under any Patents resulting therefrom, with full ownership rights in any field and, subject to
the licenses granted in Section 7, the right to 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 sublicense without the consent of the other Party, without obligation to account to the other Party. The laws of the
United States with respect to joint ownership of inventions will apply in all jurisdictions giving force and effect to this Agreement. 
  
 9.3.2 POZEN will disclose any POZEN Improvements to Xcel, and Xcel will disclose any Xcel Improvements to POZEN, in each case promptly after the
relevant Party recognizes that any Improvement falls within the definitions set forth in Section 1.44 or 1.64, respectively. Further, each Party will disclose to the other Party all Improvements made jointly by the disclosing Party and the other
Party, or its or their Affiliates or Third Party contractors. The disclosing Party will provide such information in reasonable detail, sufficient to permit an understanding of the nature of the Improvements by a practitioner reasonably skilled in
the relevant technical or scientific area. 
  
 9.3.3 Upon
disclosure of a jointly owned Improvement, the Parties will discuss, in good faith, the most appropriate course of action for the protection of such Improvement. Unless the Parties agree that one Party will assume responsibility for filing and
prosecution of any Patents with respect to such Improvement, the Parties will retain joint patent counsel for such activities (and will share the costs relating thereto equally). 
  
 9.4 Enforcement Rights. 
  
 9.4.1 Notification of Infringement. If either Party learns of any misappropriation or any infringement or threatened infringement of the Licensed
Technology, the Xcel Technology or the Product Trademarks in the Field and in the Territory (the “Product Rights”), such Party will promptly notify the other Party and will provide such other Party with all available evidence of
such misappropriation or infringement. 
  
 9.4.2 Enforcement of
Patents and Product Rights in the Territory. 
  
 (a)
Xcel will have the first right, but not the obligation, to institute, prosecute and control at its own expense any action or proceeding with respect to infringement or misappropriation of Product Rights, by counsel of its own choice, and will
consult with POZEN on any actions that Xcel proposes to take in such action or proceeding. POZEN will have the right, at its own expense, to be represented in any such action by counsel of its own choice. 
  
 (b) If Xcel fails to bring an action or proceeding or otherwise take
appropriate action in Xcel’s discretion to abate such infringement or misappropriation in the Field and in the Territory within a period of 90 days of written notice by POZEN to Xcel requesting such action, POZEN will have the right, but not
the obligation, to bring and control, by counsel of its own choice, any such infringement or misappropriation action or proceeding; 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 provided, however, that POZEN will not be entitled to bring any such action or proceeding if Xcel reasonably
objects thereto on the grounds that such action or proceeding could threaten the validity or enforceability of the Licensed Technology or Product Trademarks in the Territory. Xcel will cooperate with POZEN in any such action or proceeding brought by
POZEN against a Third Party, and will have the right to consult with POZEN and to participate in and be represented by independent counsel in such litigation at its own expense. 
  
 (c) If a Party brings any action or proceeding under this Section 9.4.2, the other Party agrees, at the request and
expense of the first Party, to be joined as a party plaintiff to the extent necessary to prosecute the action or proceeding and to give the first Party reasonable assistance and authority to file and prosecute the suit, including reasonable access
to the inventors and records related to such action which are under the control of such other Party. 
  
 9.4.3 Settlement with a Third Party. The Party that controls the prosecution of a given action under this Section 9.4 will also have the right to
control settlement of such action; provided, however, that no settlement will be entered into concerning or affecting the validity or enforceability of (i) the Licensed Technology or the Product Trademarks without the written consent of POZEN
or (ii) the Xcel Technology without the written consent of Xcel. 
  
 9.4.4 Enforcement Costs and Awards. Each Party will bear its own costs incurred in connection with an action or proceeding brought by a Party pursuant to Section 9.4.2. In the case of an action or proceeding initiated by Xcel, any
resulting damage award, after reimbursement of each Party’s expenses, will be deemed Net Sales of Xcel in the Territory and will be subject to the royalty payment obligations set forth in Section 8.3. In the case of an action or proceeding
initiated by POZEN, any resulting damage award, after reimbursement of each Party’s expenses, will be shared between the Parties proportionate to each Party’s share of costs and expenses incurred in connection with such action or
proceeding. 
  
 9.5 Defense and Settlement of Third Party
Claims. 
  
 9.5.1 Defense. If a Third Party asserts
that a patent, trade secret, or other intangible right owned or exclusively licensed by it is infringed or misappropriated by the manufacture, use, sale, or offer for sale of any Licensed Product in the Field in the Territory during the Term, Xcel
will establish a plan for a common defense and manage such common defense plan, subject to Section 9.5.2 below. Except as provided in Section 9.5.2, each Party will bear its own costs incurred in connection with any such defense, and POZEN will give
Xcel reasonable assistance and authority to defend, including reasonable access to the inventors and records relating to such action which are under the control of POZEN. 
  
 9.5.2 Settlement and Damages. Xcel will control settlement of any claim 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 described in Section 9.5.1 above; provided, however, that no settlement will be entered into concerning or
affecting the validity or enforceability of the Licensed Technology or the Product Trademarks without the written consent of POZEN. Xcel will be responsible for [***]. 
  
 9.6 Consequence of Patent Challenge. If Xcel challenges the validity or enforceability of any of the POZEN Patents by
any opposition, reexamination request, action for declaratory judgment, nullity action, interference or other attack upon the validity, title or enforceability thereof before any governmental agency, court or other similar adjudicative forum (any
such proceeding, a “Patent Challenge”), such Patent Challenge will be deemed to be a material breach of this Agreement and POZEN will have the right to terminate this Agreement as provided in Section 14.2 or to terminate all
licenses granted under any of the POZEN Patents subject to such Patent Challenge. 
  
 10. REPRESENTATIONS AND WARRANTIES 
  
 10.1
Mutual Representations and Warranties. Each of the Parties hereby represents and warrants to the other Party as follows: 
  
 10.1.1 Such Party is a corporation duly organized, validly existing and in good standing under the laws of the state in which it is incorporated;

  
 10.1.2 This Agreement is a legal and valid obligation
binding upon such Party and enforceable in accordance with its terms, and the execution, delivery and performance of the Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a
Party or by which it is bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it; 
  

10.1.3 Such Party has the full corporate power and authority to enter into this Agreement and to carry out the obligations contemplated hereby;

  
 10.1.4 To the best of such Party’s knowledge,
neither it, nor any of its employees, officers, subcontractors or consultants who will perform any activities under this Agreement (i) has been debarred or convicted of a crime for which an entity or person could be debarred under 21 U.S.C. Section
335a, or (ii) is under indictment for a crime for which a person or entity could be debarred under 21 U.S.C. Section 335a; and 
  
 10.1.5 It has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 10.2 POZEN Representations and Warranties. POZEN hereby represents and warrants to Xcel as
follows: 
  
 10.2.1 POZEN has not, and during the term of
the Agreement will not, grant any right to any Third Party relating to the Licensed Technology that would conflict with the rights granted to Xcel under this Agreement, and POZEN has [***] the Licensed Technology, [***] that would conflict with the
rights granted to Xcel under this Agreement; 
  
 10.2.2
POZEN has the right to grant to Xcel the rights and licenses in and to the Licensed Technology set forth in this Agreement; 
  
 10.2.3 POZEN has delivered to Xcel complete and accurate copies of all POZEN Patents and all file histories with respect thereto; 
  
 10.2.4 To the Knowledge of POZEN, without any formal investigation and
without having obtained any patent opinion, (a) the manufacture and Commercialization in the Territory of the Initial Licensed Product and the Autoinjector Presentation [***], and (b) no Third Party is, or has prior to the Effective Date been, [***]
represented in the Territory by the Licensed Technology; 
  
 10.2.5 As of the Effective Date, POZEN has not [***] (or, to the Knowledge of POZEN, any [***]) for the [***] arising out of the development, manufacture or Commercialization in the Territory of the Initial Licensed Product or the
Autoinjector Presentation; 
  
 10.2.6 To the Knowledge of
POZEN, each person [***] has complied with the obligation under United States federal regulations [***] included in the POZEN Patents, information known by any such person [***]; 
  
 10.2.7 To the Knowledge of POZEN, none of the POZEN Patents is involved in [***] and POZEN has not received [***]
with respect to any of the POZEN Patents; 
  
 10.2.8 To the
Knowledge of POZEN, without any formal investigation and without having obtained any legal opinion, (a) [***] as to each POZEN Patent [***] and (b) no information exists which could reasonably [***] any claim in any POZEN Patent; 
  
 10.2.9 As of the Effective Date, the [***] with the PTO; 

 
 10.2.10 As of the Effective Date, POZEN has not received any
written statement or assertion (or, to the Knowledge of POZEN, any other statement or assertion) that (a) [***] or (b) any Third Party is aware of any basis as to the future potential [***] any claim of any of the POZEN Patents; 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 10.2.11 To the Knowledge of POZEN, each patent application included within the POZEN Patents has
been [***]; 
  
 10.2.12 As of the Effective Date, all
registration, maintenance and renewal fees in connection with each POZEN Patent have been paid; 
  
 10.2.13 As of the Effective Date, (a) POZEN has exercised reasonable efforts to [***], (b) to the Knowledge of POZEN, POZEN has disclosed [***],
(c) to the Knowledge of POZEN, POZEN has [***] in connection with the Licensed Technology [***] under which such employees and consultants [***] by them in the course of their employment with POZEN, to the extent that [***], and (d) to the Knowledge
of POZEN, none of the activities of any such employee or consultant, in providing services to POZEN, [***]; 
  
 10.2.14 With respect to the Licensed Technology and any Licensed Product in the Territory, (a) to the Knowledge of POZEN, all required [***] have
been made to appropriate governmental or regulatory authorities, all appropriate [***] and [***] have been made and all required [***] have been made and appropriate [***] have been taken, and (b) as of the Effective Date, there is [***] pending or,
to the Knowledge of POZEN, threatened; 
  
 10.2.15 As of
the Effective Date, (a) POZEN has made available to Xcel [***] regulatory filings made by POZEN with the FDA in respect of the Initial Licensed Product, (b) such regulatory filings are [***] and [***] regulatory filings and governmental
registrations made by or issued to POZEN in the Territory that relate to the Initial Licensed Product, and (c) POZEN has made available to Xcel copies of [***] governmental correspondence in its possession (including copies of official notices,
citations or decisions) relating to such regulatory filings; 
  
 10.2.16 Other than the Licensed Technology, there are no [***] that are necessary for Xcel to (i) develop, manufacture or Commercialize the Initial Licensed Product or the Autoinjector Presentation or (ii) perform Xcel’s
obligations under this Agreement; 
  
 10.2.17 To the
Knowledge of POZEN, (a) POZEN has been at all times up to the Effective Date [***] the development of the Initial Licensed Product, and (b) POZEN has received no notice from any governmental or regulatory authority [***] the development of the
Initial Licensed Product which non-compliance would have [***] on the Commercialization of the Initial Licensed Product in the Territory; 
  
 10.2.18 As of the Effective Date, there is [***] pending or, to the Knowledge of POZEN, threatened [***] in connection with (i) any of the Licensed
Technology, (ii) any 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Licensed Product or (iii) POZEN’s performance under this Agreement; and POZEN is not subject to any order, ruling or
judgment of any governmental or regulatory authority that [***] the ability of POZEN to perform its obligations under this Agreement; and 
  
 10.2.19 As of the Effective Date POZEN has made available to Xcel [***] records and information (including all toxicology data, clinical studies,
manufacturing process data and other information) in the possession of POZEN regarding the Licensed Technology or any Licensed Product that either (i) would be [***] or (ii) would be [***]; all such records and information (including all toxicology
data, clinical studies, manufacturing process data and other information) are, to the Knowledge of POZEN, [***]. 
  
 10.3 Limitation of Warranty. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, (i) NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY AND (ii) EACH
PARTY EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT, WITH RESPECT TO ANY MATERIALS, INFORMATION, SERVICES, OR LICENSES PROVIDED TO THE OTHER PARTY PURSUANT
TO THIS AGREEMENT. 
  
 10.4 Performance by Affiliates. The
Parties recognize that each Party may elect to perform some or all of its obligations under this Agreement through Affiliates; provided, however, that each Party will remain responsible for the performance by such Affiliates and will cause
any such Affiliates to accept in writing to be bound by the terms of this Agreement, and to comply with the provisions of this Agreement in connection with such performance (such Affiliates being “Performing Affiliates”). Acts or
omissions of any Performing Affiliates or Controlled Affiliates of a Party that, if performed by such Party, would constitute a breach of this Agreement, will be deemed a breach of this Agreement by such Party. Each Party hereby expressly waives any
requirement that the other Party exhaust any right, power or remedy, or proceed against an Affiliate, for any obligation or performance hereunder prior to proceeding directly against such Party. 
  
 11. INDEMNIFICATION 
  
 11.1 Indemnification by Xcel. Except to the extent of POZEN’s indemnification obligation as set forth in Section
11.2 below, and except to the extent caused by POZEN’s or its Affiliates’ negligent, reckless or willful acts or omissions, Xcel will indemnify, defend and hold POZEN and its directors, officers, employees, agents and Affiliates harmless
from and against any liabilities, damages, costs or expenses, including reasonable attorneys’ fees (collectively, “Losses”), to the extent arising out of, relating to or resulting from (a) the development, manufacture, use, or
sale of any Licensed Product by or on behalf of Xcel after the Effective 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 Date, including any product liability regardless of whether based on strict liability, breach of warranty, tort or other
legal theory, (b) the breach by Xcel of any of its representations, warranties or obligations contained in this Agreement, or (c) the gross negligence or willful misconduct of Xcel or its Affiliates. 
  
 11.2 Indemnification by POZEN. Except for Xcel’s indemnification
obligation as set forth in the preceding Section 11.1, and except to the extent caused by Xcel’s or its Affiliates’ negligent, reckless or willful acts or omissions, POZEN will indemnify, defend and hold Xcel and its directors, officers,
employees, agents and Affiliates harmless from and against any Losses which arise from any claim, lawsuit or other action to the extent such Losses arise out of, relate to or result from (a) the development, manufacture, use, or sale of any Licensed
Product prior to the Effective Date, including any product liability regardless of whether based on strict liability, breach of warranty, tort or other legal theory, (b) the development, manufacture, use, or sale of any Licensed Product or any
Foreign Licensed Product by or on behalf of POZEN other than by or on behalf of Xcel, including any product liability regardless of whether based on strict liability, breach of warranty, tort or other legal theory, (c) the use of any Xcel Technology
or any rights referenced in Section 7.3.3 by POZEN or any sublicensee of POZEN, (d) the breach by POZEN of any of its representations, warranties or obligations contained in this Agreement, or (e) the gross negligence or willful misconduct of POZEN
or its Affiliates. 
  
 11.3 Indemnification Procedures. A
Party which intends to claim indemnification under Section 11.1 or 11.2 of this Agreement (the “Indemnitee”) will promptly notify the other Party (the “Indemnitor”) in writing of any claim, lawsuit or other action
in respect of which the Indemnitee or any of its directors, officers, employees, and Affiliates intend to claim such indemnification within a reasonable period of time after the assertion of such claim; provided, however, that the failure to
provide written notice of such claim within a reasonable period of time will not relieve the Indemnitor of any of its obligations hereunder, except to the extent that the Indemnitor is prejudiced by such failure to provide prompt notice. The
Indemnitor will have the right to assume the complete control of the defense, compromise or settlement of any such claim without the prior written consent of such Indemnitee (although no settlement will be entered into concerning or affecting the
validity or enforceability of (a) the Licensed Technology or the Product Trademarks without the written consent of POZEN or (b) the Xcel Technology without the written consent of Xcel). The Indemnitor will, if it elects to assume control, at its own
expense employ legal counsel to defend the claim at issue. At any time after the Indemnitor has assumed defense of a claim, the Indemnitor may exercise, on behalf of the Indemnitee, any rights which may mitigate the extent or amount of such claim;
provided, however, that the Indemnitee: (x) may, in its sole discretion and at its own expense, employ legal counsel to represent it (in addition to the legal counsel employed by the Indemnitor) in any such matter, and in such event legal
counsel selected by the Indemnitee will be required to confer and cooperate with such counsel of the Indemnitor in such defense, compromise or settlement for the purpose 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 of informing and sharing information with the Indemnitor; (y) will, at its own expense, make available to Indemnitor
those employees, officers and directors of Indemnitee whose assistance, testimony or presence is necessary, useful or appropriate to assist the Indemnitor in evaluating and in defending any such claim; provided, however, that any such access
will be conducted in such a manner as not to interfere unreasonably with the operations of the businesses of Indemnitee; and (z) will otherwise fully cooperate with the Indemnitor and its legal counsel in the investigation and defense of such claim.

  
 11.4 Insurance. Each Party will maintain commercially
reasonable insurance coverage commensurate with its obligations under this Agreement. As regards Xcel, such commercially reasonable insurance coverage will include comprehensive general liability insurance coverage, including products liability
which carries a minimum limit of not less than US $10,000,000 upon the Commercial Launch of the Initial Licensed Product, and Xcel will provide POZEN with a certificate of insurance, naming POZEN as additionally insured, evidencing to POZEN such
coverage. 
  
 12. LIMITATION OF LIABILITY 
  
 IN NO EVENT WILL ANY PARTY BE LIABLE TO THE OTHER PARTY FOR LOST PROFITS,
LOSS OF DATA, OR FOR ANY SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OF SUCH OTHER PARTY, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING
UNDER ANY CAUSE OF ACTION AND ARISING IN ANY WAY OUT OF THIS AGREEMENT. THE FOREGOING LIMITATIONS WILL NOT APPLY TO DAMAGES ARISING FROM A BREACH OF SECTION 13 OR AN AWARD OF ENHANCED DAMAGES AVAILABLE UNDER THE PATENT LAWS FOR WILLFUL PATENT
INFRINGEMENT. 
  
 13. CONFIDENTIALITY, PUBLICATIONS, PUBLICITY 

 
 13.1 Confidential Information. Any information or materials
communicated by one Party to the other Party pursuant to this Agreement or the Confidential Disclosure Agreement between the Parties dated February 27, 2003 will be deemed “Confidential Information” of the disclosing Party if (a)
such information or materials are marked “confidential” or with a similar legend, or (b) such information or materials, if disclosed orally or visually, are identified as being confidential at the time of such oral or visual
disclosure, and thereafter reduced to writing, marked “confidential” or with a similar legend, and sent to the other Party within 30 days of such oral or visual disclosure, or (c) such information or materials would, due to the nature
thereof or the circumstances surrounding disclosure, appear to a reasonable person to be confidential or proprietary. Notwithstanding the preceding sentence, “Confidential Information” will not be deemed to include information that the
receiving Party can demonstrate, by competent written proof: 
  
 13.1.1 At the time of disclosure is published or is publicly known or otherwise in the public domain, other than through any act or omission by the receiving Party; 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 13.1.2 Was already known to the receiving Party, other than under an obligation of confidentiality
or non-use, prior to the time of disclosure; 
  
 13.1.3 Is
disclosed to the receiving Party in good faith, without an obligation of confidentiality, by a Third Party not under any obligation of confidence with respect to such information; or 
  
 13.1.4 Is independently developed by the receiving Party without use of or reference to the disclosing Party’s
Confidential Information. 
  
 13.2 Treatment of Confidential
Information. The Parties agree that during the Term and for 7 years after its expiration or termination for any reason whatsoever, a Party receiving Confidential Information of the other Party will: (a) treat any such Confidential Information
disclosed to it by the other Party as strictly confidential; (b) except as necessary in the performance of this Agreement, not disclose such Confidential Information to Third Parties without the prior written consent of the other Party, other than
to its Affiliates, collaborators or any consultants, provided that such disclosure be under confidentiality agreements with provisions comparable to those contained in this Agreement; (c) not use such Confidential Information for purposes other than
those authorized expressly herein; and (d) use reasonable efforts to prevent inadvertent disclosure of such Confidential Information. 
  
 13.3 Access. Access to Confidential Information will be limited to those employees or consultants of the Party receiving such information or of
such Party’s Affiliates who reasonably require such information in order to carry out activities authorized pursuant to this Agreement. Such employees or consultants will be advised of the confidential nature of the Confidential Information and
the related confidentiality undertaking. 
  
 13.4 Permitted
Disclosures. 
  
 13.4.1 Notwithstanding any other
provision in this Agreement, a receiving Party may disclose Confidential Information of the disclosing Party to the extent such disclosure is required by law or court order, provided that the receiving Party gives the disclosing Party prompt written
notice of the requirement to disclose and reasonably cooperates with the disclosing Party to seek a protective order or other restrictions on the disclosure of such Confidential Information of the disclosing Party. Any such required disclosure will
be limited 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 only to that Confidential Information that is required to be disclosed and such disclosed Confidential Information will
remain Confidential Information hereunder despite the required disclosure. 
  
 13.4.2 Notwithstanding anything herein to the contrary, any Party (and any employee, representative, or other agent of any Party) may disclose to any and all persons, without limitation of any kind, the tax
treatment and tax structure of the transactions contemplated by this Agreement and all materials of any kind (including opinions or other tax analyses) that are provided to it relating to such tax treatment and tax structure; provided,
however, that no Party will be permitted to disclose such tax treatment or tax structure to the extent that such disclosure would constitute a violation of federal or state securities laws. For the purposes of the foregoing sentence, (i) the
“tax treatment” of a transaction means the purported or claimed federal income tax treatment of the transaction, and (ii) the “tax structure” of a transaction means any fact that may be relevant to understanding the purported or
claimed federal income tax treatment of the transaction. Thus, for the avoidance of doubt, the Parties acknowledge and agree that the tax treatment and tax structure of any transaction does not include the name of any Party to a transaction or any
sensitive business information (including, without limitation, the name and other specific information about any Party’s intellectual property or other proprietary assets) unless such information may be related or relevant to the purported or
claimed federal income tax treatment of the transaction. 
  
 13.5 Return of Confidential Information. Upon termination or expiration of this Agreement, each Party hereto and its Affiliates will return all Confidential Information of the other Party in their possession to the other Party;
provided, however, that each Party may retain: (a) a single archival copy of the Confidential Information of the other Party solely for the purpose of determining the extent of disclosure of Confidential Information hereunder and assuring
compliance with the surviving provisions of this Agreement; (b) any portion of the Confidential Information of the other Party which is contained in a Party’s laboratory notebooks; and (c) any portion of the Confidential Information of the
other Party which a Party is required by mandatory applicable law to retain. 
  
 13.6 Confidentiality of the Agreement Terms. Neither Party will disclose the terms of this Agreement to any Third Party without the prior written consent of the other Party; provided, however, that
either Party may disclose the terms of this Agreement (a) to actual or prospective investors and corporate partners, (b) to a Party’s accountants, attorneys and other professional advisors, and (c) as required by applicable laws and regulations
of the U.S. Securities and Exchange Commission, any stock exchange on which a Party’s stock is traded and any inter-dealer quotation system on which trading information for a Party’s stock is quoted. As part of any filing of this Agreement
pursuant to the foregoing clause (c), the filing Party will provide the other Party with the opportunity to review and comment on proposed redactions to this Agreement for purposes of such filing (although the filing Party will have no obligation in
the event that such redactions are not made or accepted as part of such filing). 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 13.7 Publications. Except for Excepted Communications and information which has already been
published or is otherwise within the public domain, neither Party may present or publish research results arising from this Agreement, including, without limitation, any research results which relate to the use of the Licensed Technology in the
Field, whether in a thesis, scientific publication, conference or otherwise, without the prior written consent of the other Party. Intended presentations or publications will be presented in writing to the other Party in the English language for
review and comment at least 30 days prior to the time which the presentation or publication is proposed for submission to any Third Party. Within such 30-day period and at least 5 business days prior to the time which the presentation or publication
is proposed for submission to any Third Party, the other Party will provide notice whether it has any comments or objection to the proposed presentation or publication. The submitting Party will consider in good faith all comments by the reviewing
Party. If a reasonable objection is raised (because, for example, the contents of the presentation or publication contain patentable subject matter for which patent protection should be sought, or because the presentation or publication discloses
Confidential Information of the other Party which constitutes proprietary trade secrets or Know-How), then submission of the presentation or publication will be delayed, unless and until such time as consent to submission of the presentation or
publication is given. Each Party may be acknowledged on any publication or presentation by the other Party in accordance with generally accepted rules of authorship. 
  
 13.8 Publicity. Promptly following the Effective Date, the Parties will publish a mutually agreed joint press
release. Neither Party will make any public announcement concerning the existence of or the terms of this Agreement, without the prior written approval of the other Party with regard to the form, content and precise timing of such announcement,
except such as may be required to be made by either Party in order to comply with applicable law, regulations, court order, or tax or securities filings. Prior to any such public announcement, the Party wishing to make the announcement will submit a
draft of the proposed announcement to the other Party not less than 3 business days in advance to enable the other Party to consider and comment thereon. Notwithstanding anything to the contrary in this Agreement, nothing in this Section 13.8 is
intended to prohibit either Party from republishing or restating information relating to this Agreement that has already been approved by the other Party for use in a prior press release or public announcement. 
  
 14. TERM AND TERMINATION 
  
 14.1 Term of the Agreement. The term of this Agreement (the
“Term”) will commence on the Effective Date and, unless terminated earlier pursuant to Section 3.4.4 or this Section 14, will expire at the end of the Royalty Term. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 14.2 Termination for Material Breach. In the event of a material breach of this Agreement by
either Party which is not cured within 60 days following receipt of written notice of such breach from the non-breaching Party (or, as applicable, (i) 15 days following receipt of such written notice in the event the breach involves a payment which
is not the subject of a bona fide dispute or (ii) 180 days following receipt of such written notice if the breaching party is attempting to cure the breach at issue and is exercising Commercially Reasonable Efforts with respect thereto), the
non-breaching Party will have the right to terminate this Agreement by written notification to the other Party, effective immediately upon receipt. 
  
 14.3 Termination for Abandonment of POZEN NDA. If this Agreement terminates pursuant to Section 3.1.5, POZEN will pay to Xcel a withdrawal fee in
the amount set forth in Exhibit A attached hereto within 15 days of such termination. 
  
 14.4 Termination at Will. Xcel will have the right to terminate this Agreement for any or no reason by providing written notice of such termination not less than 12 months prior to the date of termination;
provided that Xcel may not provide such notice of termination prior to the fifth anniversary of the First Commercial Sale Date of the first Licensed Product sold by Xcel under this Agreement. Promptly after receipt of such notice, the Parties will
meet to prepare a transition plan for the orderly transfer of the Commercialization and the development (if any) of the Licensed Products from Xcel to POZEN or a Third Party designated by POZEN. If POZEN or a Third Party designated by POZEN are in a
position to assume such Commercialization or development prior to the termination date identified in the termination notice in accordance with this Section 14.4, such termination date will be accelerated upon POZEN’s request. 
  
 15. CONSEQUENCES OF TERMINATION 
  
 15.1 General. No termination of this Agreement will relieve any Party
from any liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination, nor preclude either Party from pursuing any rights and remedies it may have under this
Agreement or at law or in equity which accrued or are based upon any event occurring prior to such termination. 
  
 15.2 Termination Prior to Expiration. If this Agreement is terminated prior to its expiration, then: 
  
 (a) the rights and licenses granted by POZEN to Xcel under this
Agreement will terminate immediately; 
  
 (b) all
Regulatory Approvals will be assigned and transferred by Xcel to POZEN, and Xcel will promptly take all actions and execute such documents as requested by POZEN to effect such transfer to POZEN; 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 (c) Xcel will transfer to POZEN such quantities of Licensed Product in Xcel’s inventory as
may be requested by POZEN no later than 30 days of such termination and POZEN will pay to Xcel an amount equivalent to [***] such Licensed Product, provided POZEN will buy all such Licensed Product that has at least [***] of shelf life at the time
this Agreement is terminated and Xcel will be entitled, notwithstanding any provision herein to the contrary, to sell (or have sold) all other Licensed Product in its inventory for up to three months following the termination of this Agreement
provided that the terms of this Agreement, including Xcel’s royalty payment obligations in Section 8, will apply with respect to such sales (excluding any transfers to POZEN) as if this Agreement was still in effect; 
  
 (d) at POZEN’s election, Xcel will transfer and cause its
Affiliates and agents to transfer to POZEN any or all Promotional Materials, and POZEN will (i) pay to Xcel an amount [***] of such Promotional Materials, and (ii) sticker-over any Xcel Trademarks prior to the use of any such Promotional Materials;

  
 (e) POZEN will, insofar as Xcel is concerned, have the
exclusive right to develop, make, have made, use, and Commercialize Licensed Products in the Territory alone or with or through a Third Party; and 
  
 (f) the licenses granted to POZEN in Section 7.3 are worldwide (but non-exclusive in the Territory), fully paid, perpetual and irrevocable.

  
 15.3 Manufacturing Agreements. With respect to any
agreements entered into by Xcel with [***]: (i) if this Agreement is terminated by POZEN pursuant to Section 14.2, POZEN will assume such agreements (if permitted by such agreements); (ii) if this Agreement is terminated by Xcel pursuant to Section
3.4.4 or Section 14.2, POZEN will assume such agreements if Xcel so elects (and if permitted by such agreements); and (iii) if this Agreement is terminated by [***] pursuant to Section 14.4, [***] may assume such agreements if [***] so elects (and
if permitted by such agreements). 
  
 15.4 Licenses Upon
Expiration. Upon expiration of this Agreement pursuant to Section 14.1: (a) the licenses granted to Xcel in Section 7.1 are fully paid, perpetual and irrevocable, subject to the provisions of Section 5.4 relating to payment of a royalty for use
of the Product Trademarks; and (b) the licenses granted to POZEN in Section 7.3 are fully paid, perpetual and irrevocable. 
  
 15.5 Survival. 
  
 15.5.1 In the event of any expiration or termination of this Agreement, the 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 following sections will survive (together with the definitions of any defined terms used therein as well as any other
provisions to the extent cross-referenced or invoked thereby): Sections 3.5, 3.7, 4.1.2 (unless this Agreement is terminated pursuant to Section 3.4.4 or 3.1.5 or pursuant to POZEN’s breach under Section 14.2), 5.4.6, 8.4, 8.5, 8.6, 8.7, 8.8,
8.9, 9.1, 10.3, 11, 12, 13, 15, 16, and 17. All other provisions, including all rights and obligations thereunder, will terminate and be of no further force and effect. 
  
 15.5.2 Section 5.4 (together with the definitions of any defined terms used therein as well as any other provisions
to the extent cross-referenced or invoked thereby) and Section 9 (with respect to the provisions pertaining to the Product Trademarks and Designated POZEN Trademarks, together with the applicable definitions of any defined terms used therein as well
as any other applicable provisions cross-referenced or invoked thereby) will survive the expiration of this Agreement. 
  
 16. DISPUTE RESOLUTION 
  
 16.1 Discussions. The Parties will try to settle their differences amicably between themselves. In the event of any controversy or claim arising
out of or relating to any provision of this Agreement or the performance or alleged non-performance of a Party of its obligations under this Agreement (a “Dispute”), a Party may notify the other Party in writing of such Dispute. If
the Parties are unable to resolve the Dispute within 20 days of receipt of the written notice by the other Party, such Dispute will be referred to the Chief Executive Officers of each of the Parties (or their respective designees) who will use their
good faith efforts to resolve the Dispute within 10 days after it was referred to the Chief Executive Officers. 
  
 16.2 Arbitration. 
  
 16.2.1 Any Dispute that is not resolved as provided in the preceding Section 16.1, whether before or after termination of this Agreement, will be
referred to binding arbitration under the rules of the American Arbitration Association, to the extent such rules are not inconsistent with this Section 16.2. Judgment upon the award of the arbitrators may be entered in any court having jurisdiction
thereof or such court may be asked to judicially confirm the award and order its enforcement, as the case may be. 
  
 16.2.2 The demand for arbitration will be made within a reasonable time after the Dispute has arisen, and in any event will not be made after the
date when institution of legal or equitable proceedings, based on such Dispute, would be barred by the applicable statute of limitations. The arbitration panel will consist of three (3) arbitrators, one (1) of whom will be appointed by each Party.
The two (2) arbitrators thus appointed will choose the third arbitrator; provided, however, that if the two (2) arbitrators are unable to agree on the appointment of the third arbitrator, either arbitrator may petition the American
Arbitration Association to make the appointment. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 16.2.3 The provisions of Federal Rules of Civil Procedure sections governing discovery are
incorporated in and made a part of this Agreement. Depositions may be taken and full discovery may be obtained in any arbitration commenced under this provision. 
  
 16.2.4 The arbitrators will, within 15 days after the conclusion of the arbitration hearing, issue a written award
and statement of decision describing the essential findings and conclusions on which the award is based, including the calculation of any damages awarded. The Arbitrator are authorized to award compensatory damages consistent with the terms of this
Agreement, but are NOT authorized (i) to award non-economic damages, such as for emotional distress, pain and suffering or loss of consortium, (ii) to award punitive damages, or (iii) to reform, modify or materially change this Agreement or any
other agreements contemplated hereunder; provided, however, that the damage limitations described in parts (i) and (ii) of this sentence will not apply if such damages are statutorily imposed. The arbitrators are authorized to grant any
temporary, preliminary or permanent equitable remedy or relief they deem just and equitable and within the scope of this Agreement, including, without limitation, an injunction or order for specific performance. 
  
 16.2.5 The place of arbitration will be New York, New York. Each Party
will bear and pay its own expenses incurred in connection with any dispute resolution under this Section 16.2. 
  
 16.3 Patents and Other Intellectual Property. Notwithstanding any provision of this Agreement to the contrary, any Dispute relating to a
Party’s intellectual property rights or Confidential Information will be submitted exclusively to any court of competent jurisdiction in the State of New York and, by execution and delivery of this Agreement, each party (a) accepts, generally
and unconditionally, the exclusive jurisdiction of such courts and any related appellate court, and irrevocably agrees to be bound by any judgment rendered thereby as contemplated by this Section 16.3, and (b) irrevocably waives any objection it may
now or hereafter have as to the venue of any such suit, action or proceeding brought in such a court or that such a court is an inconvenient forum. 
  
 17. MISCELLANEOUS 
  
 17.1 Further Assurances. At any time during the Term, Xcel and POZEN each will, at the request of the other Party, use reasonable efforts to (a)
deliver to the other Party such records, data or other documents consistent with the provisions of this Agreement, (b) execute, and deliver or cause to be delivered, all such assignments, consents, documents or further 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 instruments of transfer or license, and (c) take or cause to be taken all such other actions, as a Party may reasonably
deem necessary or desirable in order for such Party to obtain the full benefits of this Agreement and the transactions contemplated hereby. 
  
 17.2 Assignment. Neither Party will assign its rights or obligations under this Agreement to any Third Party, without the prior written consent of
the other Party; except that either Party may assign such rights and obligations to a Third Party in connection with a merger, acquisition, consolidation, transfer or sale of all or substantially all of the assets of a Party (collectively, a
“Change of Control Event”) provided that such Third Party agrees in writing to be bound by all of the terms and conditions of this Agreement. All permitted assignments by either Party of any of its rights under this Agreement will
be subject to all of the terms and conditions of this Agreement. Any purported assignment not permitted under the terms of this Agreement will be null, void, and of no effect. Notwithstanding anything in this Agreement, the POZEN Know-How, POZEN
Improvements, and POZEN Patents, as well as the Xcel Know-How, Xcel Improvements, and Xcel Patents do not include any intellectual property held by a permitted successor prior to the Change of Control Event of the relevant Party. 
  
 17.3 Independent Contractors. The Parties are independent contractors.
Nothing contained herein will constitute either Party the agent of the other Party for any purpose whatsoever, or constitute the Parties as partners or joint venturers. Employees of each Party remain employees of said Party and will be considered at
no time agents of or owing a fiduciary duty to the other Party. Neither Party will have any implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any other
contract, agreement or undertaking with any Third Party. 
  
 17.4 Waiver. The failure of either Party to enforce any provision of this Agreement at any time will not be construed as a present or future waiver of such or any other provision of this Agreement. The express waiver by either Party
of any provision or requirement hereunder will not operate as a future waiver of such or any other provision or requirement and will be effective only if set forth in a written instrument signed by a duly authorized representative of the Party
waiving such provision or requirement. 
  
 17.5 Amendment.
The Parties may amend, modify or alter any of the provisions of this Agreement, but such amendment, modification or alteration will be valid and binding on either Party only if made by a written instrument that explicitly refers to this Agreement
and that is signed by a duly authorized representative of each Party. 
  
 17.6 Severability. In the event that any provision in this Agreement is held to be unlawful or invalid in any jurisdiction, the meaning of such provision will be construed to the greatest extent possible so as to render it
enforceable. If no such construction can render such 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 provision enforceable, it will be severed. The remainder of this Agreement will remain in full force and effect, and the
Parties will negotiate in good faith a reasonable substitute provision that is valid and enforceable in such jurisdiction. If the Parties are unable to agree on a substitute provision, and if the unlawful or invalid provision was an essential
element of this Agreement without which one of the Parties would not have entered into this Agreement, as evidenced by this Agreement as a whole, then such Party may terminate this Agreement by written notice to the other Party effective upon
receipt. 
  
 17.7 Notice. All notices hereunder must be
given in writing and will be deemed given if delivered personally or by facsimile transmission (receipt confirmed), mailed by registered or certified mail (return receipt requested) with postage prepaid, or sent by express courier service (FedEx or
other reputable, internationally recognized courier service), to the Parties at the following addresses (or at such other address for a Party as will be specified by like notice; provided that notices of a change of address will be effective only
upon receipt thereof): 
  

			
	 If to POZEN:
	  	 POZEN, Inc.

	 	  	 1414 Raleigh Road

	 	  	 Suite 400

	 	  	 Chapel Hill, NC 27517

	 	  	 Attention: President

	 	  	 Facsimile: (919) 913-1039

		
	 With copies to:
	  	 Cooley Godward LLP

	 	  	 One Freedom Square

	 	  	 Reston Town Center

	 	  	 11951 Freedom Drive

	 	  	 Reston, VA 20190-5656

	 	  	 Attention: Matthias Alder

	 	  	 Facsimile: (703) 456-8100

		
	 If to Xcel:
	  	 Xcel Pharmaceuticals, Inc.

	 	  	 6363 Greenwich Drive

	 	  	 Suite 100

	 	  	 San Diego, CA 92122

	 	  	 Attention: Chief Financial Officer

	 	  	 Facsimile: (858) 202-2799

		
	 With copies to:
	  	 Pillsbury Winthrop LLP

	 	  	 11682 El Camino Real

	 	  	 Suite 200

	 	  	 San Diego, CA 92130

	 	  	 Attention: Mike Hird

	 	  	 Facsimile: (858) 509-4010

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 17.8 Force Majeure. Neither Party will be deemed to be in breach of this Agreement as a result of
default, delay or failure to perform by such Party which is due to any cause beyond the reasonable control of such Party, including without limitation, fire, earthquake, acts of God, severe weather, acts of war, strikes, lockouts or other labor
disputes, riots, civil disturbances, actions or inactions of governmental authorities (except actions in response to a breach of applicable laws by such Party), or epidemics. In the event of any such force majeure, the Party affected will promptly
notify the other Party, will use commercially reasonable efforts to overcome such force majeure, and will keep the other Party informed with respect thereto. If such force majeure continues for a period of more than 180 days, the Party not subject
to such force majeure may terminate this Agreement by written notice to the other Party. 
  
 17.9 Counterparts. This Agreement may be executed by the Parties in one or more identical counterparts, all of which together will constitute this Agreement. If this Agreement is executed in counterparts, no
signatory hereto will be bound until both Parties have duly executed a counterpart of this Agreement. Delivery of an executed counterpart of a signature page of this Agreement by facsimile will be effective as delivery of the originally executed
counterpart of this Agreement. 
  
 17.10 Governing Law.
This Agreement will be governed by, and construed an interpreted in accordance with, the laws of the State of New York without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the
internal laws of the State of New York to the right and duties of the Parties. 
  
 17.11 Construction. Unless used in combination with the word “either,” the word “or” is used throughout this Agreement in the inclusive sense (and/or). The captions of this Agreement are for
convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. References to Sections are references to Sections of this Agreement. The
term “including” as used herein will mean including, without limiting the generality of any description preceding such term. Whenever, in this Agreement, the consent, approval or agreement of the other Party is required in order for a
Party to take certain actions, the Parties agree that such consent, approval or agreement may not be unreasonably withheld or delayed. No rule of strict construction will be applied against either Party. Unless expressly provided herein to the
contrary, all time limits, notice periods, deadlines or the like described herein will be governed by the follow parameters: (i) for all time periods that are 5 days in length or less, such periods will be deemed to be business days, and (ii) for
all time periods greater than 5 days in length will be deemed to be calendar days. References to “$” or “dollars” mean US dollars. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 17.12 Entire Agreement. This Agreement, including any Exhibits attached hereto, constitutes the
entire agreement of the Parties with respect to the subject matter hereof, and supersedes all prior and contemporaneous agreements, understandings and negotiations, whether oral or written, with respect to such subject matter. 
  
 The Parties have caused this Agreement to be executed as of the Effective
Date by signature of their duly authorized representatives. 
  

			
	POZEN Inc.
		
	 By:
	 	  

	 	 	 John R. Plachetka, Pharm. D.

		
	 Title:
	 	 Chairman, President and CEO

	
	Xcel Pharmaceuticals, Inc.
		
	 By:
	 	  

	 	 	 Michael T. Borer

		
	 Title:
	 	 President and CEO

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 EXHIBIT A 
  
 WITHDRAWAL FEE 
  
 US$1,000,000 

 EXHIBIT B 
  
 OUTLINE OF AUTOINJECTOR DEVELOPMENT PLAN

  
 Outline of Development Program: 
  

	*	Selection of design features for autoinjector 

  

	*	Manufacturing and packaging of cGMP batch 

  

	*	Phase I Bioequivalency study 

  

	*	Completion of sNDA 

  

	*	Filing of sNDA 

  
 SNDA Target Submission Timeline: 
  

	*	September 2004 

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 EXHIBIT C 
  
 OUTLINE OF MARKETING PLAN FOR
INITIAL LICENSED PRODUCT 
  

					
	 1.
	  	 Situational Analysis

	 	  	 1.1.
	 	 Market Assessment

	 	  	 	 	 1.1.1. Market Definition

	 	  	 	 	 1.1.2. Market Trends

	 	  	 	 	 1.1.3. Prescription Trends

	 	  	 1.2.
	 	 Competitive Assessment

	 	  	 	 	 1.2.1. Current Competitors

	 	  	 	 	 1.2.2. Near-term Competitors

	 	  	 1.3.
	 	 Customer Assessment

	 	  	 	 	 1.3.1. Target Audiences

	 	  	 	 	 1.3.2. Sales Force Deployment

	 	  	 1.4.
	 	 Pricing Analysis

	 	  	 1.5.
	 	 Sales Projection

		
	 2.
	  	 Brand Objectives

		
	 3.
	  	 Key Strategic Objectives

	 	  	 3.1.
	 	 Marketing Strategies

	 	  	 	 	 3.1.1. Product Profile

	 	  	 	 	 3.1.2. Product Assessment

	 	  	 	 	 3.1.3. Positioning

	 	  	 	 	 3.1.4. Branding

	 	  	 3.2.
	 	 Third Party Access

	 	  	 3.3.
	 	 Distribution Strategies

	 	  	3.4.	 	Training Strategies
		
	4.	  	Tactical Initiatives
	 	  	4.1.	 	Trade Name
	 	  	4.2.	 	Branding
	 	  	4.3.	 	Packaging Design
	 	  	4.4.	 	Distribution
	 	  	4.5.	 	Publications
	 	  	4.6.	 	Thought Leader Development
	 	  	4.7.	 	Association Relations
	 	  	4.8.	 	Medical Education
	 	  	4.9.	 	Patient Education
	 	  	4.10.	 	Stocking
	 	  	4.11.	 	Promotional Materials
	 	  	4.12.	 	Journal Advertising
	 	  	4.13.	 	Website/Internet
	 	  	4.14.	 	Direct Mail
	 	  	4.15.	 	Conventions

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

					
	 5.
	  	 Development Plan

	 	  	 5.1
	 	 Investigator sponsored Studies (Xcel Post-Approval Studies)

	 	  	 5.2
	 	 Other Development Programs

  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 EXHIBIT D 
  
 CERTAIN POZEN PATENTS 
  
 US Patent No. 6,495,535 
  
 US Patent Application 10/281,982 
  
 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS AND BRACKETS ([***]). A COMPLETE COPY OF THIS
AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 EXHIBIT E 
  
 CERTAIN XCEL PATENTS 
  
 None. 
  

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 EXHIBIT F 
  
 Co-Promotion Agreement Dispute Resolution Procedure 
  
 The Parties will enter into Dispute Resolution pursuant to Section 16.2 of the Agreement, although as part of any arbitration regarding the
negotiation of a co-promotion agreement pursuant to Section 5.3.2 of the Agreement, each Party will prepare and deliver to both the arbitrators and the other Party its proposed co-promotion agreement and a memorandum (the “Support
Memorandum”) in support thereof. The arbitrators will also be provided with a copy of the Agreement. Within 10 days after receipt of the other Party’s Support Memorandum, each Party may submit to the arbitrators (with a copy to the
other Party) a rebuttal to the other Party’s Support Memorandum, which may include a revision, marked to show changes, of either Party’s proposed co-promotion agreement. Neither Party may have communications (either written or oral) with
the arbitrators other than for the sole purpose of engaging the arbitrators or as expressly permitted in this paragraph. 
  
 Within 10 days after the Arbitration Commencement Date, the arbitrators will select from the two co-promotion agreements provided by the Parties the co-promotion
agreement that a majority of the arbitrators believe most accurately reflects the intention of the Parties to this Agreement and the industry customs regarding the co-promotion of comparable pharmaceutical products (the “Selected
Agreement”). The Selected Agreement will become a binding and enforceable agreement between POZEN and Xcel. 
  
 The arbitrators will have reasonable discretion to request additional information, hold a hearing, and extend the time frame for reaching their decision regarding the
dispute at issue. 
  
 The arbitrators’ fees and expenses will be paid by the
Party whose form of co-promotion agreement is not selected by the arbitrators. Each Party will bear and pay its own expenses incurred in connection with any dispute resolution under this Exhibit. 
  
 Except as noted, the other provisions relevant to Dispute Resolution will apply. 

 

 CONFIDENTIAL TREATMENT HAS BEEN GRANTED FOR THE REDACTED PORTIONS OF THE AGREEMENT THAT ARE MARKED WITH ASTERISKS
AND BRACKETS ([***]). A COMPLETE COPY OF THIS AGREEMENT, INCLUDING THE REDACTED PORTIONS, HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.Receivables Purchase Agreement

 Exhibit 4.25 
  
 $100,000,000 
  
 RECEIVABLES PURCHASE AGREEMENT 
  
 Dated as of December 17, 2003 
  
 among 
  
 LYONDELL FUNDING II, LLC, as the Seller, 
  
 LYONDELL CHEMICAL COMPANY 
 as the
Servicer, 
  
 THE BANKS AND OTHER FINANCIAL INSTITUTIONS
PARTY HERETO, 
 as Purchasers, 
  
 CITICORP USA, INC. 
 as Asset Agent

 and Administrative Agent 
  
 AND 
  
 CITIGROUP GLOBAL MARKETS INC. 
 as
Sole Lead Arranger 
 and Sole Bookrunner 

 TABLE OF CONTENTS 
  

							
	 	  	 	 	 	  	Page

	 EXHIBITS      1
	  	 
		
	 SCHEDULES 2
	  	 
		
	 RECEIVABLES PURCHASE AGREEMENT
	  	1
		
	 PRELIMINARY STATEMENTS:
	  	1
		
	 ARTICLE I Definitions
	  	1
				
	 	  	Section 1.1	 	Certain Defined Terms.	  	1
				
	 	  	Section 1.2	 	Other Terms.	  	24
				
	 	  	Section 1.3	 	Computation of Time Periods.	  	25
		
	 ARTICLE II Amounts and Terms of the Purchases
	  	25
				
	 	  	Section 2.1	 	Commitment.	  	25
				
	 	  	Section 2.2	 	Making Purchases.	  	25
				
	 	  	Section 2.3	 	Swing Purchases	  	26
				
	 	  	Section 2.4	 	Termination or Reduction of the Commitments; Voluntary Reductions of Capital.	  	28
				
	 	  	Section 2.5	 	Receivable Interest.	  	28
				
	 	  	Section 2.6	 	Ordinary Settlement Procedures.	  	28
				
	 	  	Section 2.7	 	Triggering Event Settlement Procedures.	  	30
				
	 	  	Section 2.8	 	Liquidation Settlement Procedures.	  	32
				
	 	  	Section 2.9	 	General Settlement Procedures.	  	32
				
	 	  	Section 2.10	 	Payments and Computations, Etc.	  	33
				
	 	  	Section 2.11	 	Yield and Fees.	  	34
				
	 	  	Section 2.12	 	Special Provisions Governing Capital Investments at the Applicable LIBO Rate.	  	34
				
	 	  	Section 2.13	 	Increased Capital.	  	36
				
	 	  	Section 2.14	 	Taxes.	  	36
				
	 	  	Section 2.15	 	Sharing of Payments, Etc.	  	38
				
	 	  	Section 2.16	 	Conversion/Continuation Option.	  	38
				
	 	  	Section 2.17	 	Duty to Mitigate; Assignment of Commitments Under Certain Circumstances.	  	39

  

 i 

 TABLE OF CONTENTS 
 (continued) 
  

							
	 	  	 	 	 	  	Page

	 	  	Section 2.18	 	Restricted Accounts; Investment of Amounts in the Cash Assets Account.	  	39
		
	 ARTICLE III Conditions of Purchases
	  	40
				
	 	  	Section 3.1	 	Conditions Precedent to the Effectiveness of this Agreement.	  	40
				
	 	  	Section 3.2	 	Conditions Precedent to All Investment Events.	  	42
		
	 ARTICLE IV Representations and Warranties
	  	43
				
	 	  	Section 4.1	 	Representations and Warranties of the Seller.	  	43
				
	 	  	Section 4.2	 	Representations and Warranties of the Servicer.	  	46
		
	 ARTICLE V General Covenants of the Seller and the Servicer
	  	49
				
	 	  	Section 5.1	 	Affirmative Covenants of the Seller.	  	49
				
	 	  	Section 5.2	 	Reporting Requirements of the Seller.	  	52
				
	 	  	Section 5.3	 	Negative Covenants of the Seller.	  	52
				
	 	  	Section 5.4	 	Affirmative Covenants of the Servicer.	  	54
				
	 	  	Section 5.5	 	Reporting Requirements of the Servicer.	  	57
				
	 	  	Section 5.6	 	Negative Covenants of the Servicer.	  	60
		
	 ARTICLE VI Administration and Collection
	  	61
				
	 	  	Section 6.1	 	Designation of Servicer.	  	61
				
	 	  	Section 6.2	 	Duties of Servicer.	  	62
				
	 	  	Section 6.3	 	Rights of the Agent.	  	62
				
	 	  	Section 6.4	 	Responsibilities of the Seller.	  	63
				
	 	  	Section 6.5	 	Further Assurances.	  	63
		
	 ARTICLE VII Events of Termination
	  	64
				
	 	  	Section 7.1	 	Events of Termination.	  	64
		
	 ARTICLE VIII The Agent
	  	67
				
	 	  	Section 8.1	 	Authorization and Action.	  	67
				
	 	  	Section 8.2	 	Agent’s Reliance, Etc.	  	68
				
	 	  	Section 8.3	 	CUSA and Affiliates.	  	68
				
	 	  	Section 8.4	 	Purchase Decisions.	  	68
				
	 	  	Section 8.5	 	Indemnification.	  	69
				
	 	  	Section 8.6	 	Successor Agent	  	69

  

 ii 

 TABLE OF CONTENTS 
 (continued) 
  

							
	 	  	 	 	 	  	Page

	 	  	Section 8.7	 	Posting of Approved Electronic Communications.	  	69
		
	 ARTICLE IX Assignment of Receivable Interests
	  	70
				
	 	  	Section 9.1	 	Purchaser’s Assignment of Rights and Obligations.	  	70
				
	 	  	Section 9.2	 	The Register.	  	72
				
	 	  	Section 9.3	 	Participations.	  	72
		
	 ARTICLE X Indemnification
	  	73
				
	 	  	Section 10.1	 	Indemnities.	  	73
		
	 ARTICLE XI Miscellaneous
	  	75
				
	 	  	Section 11.1	 	Amendments, Etc.	  	75
				
	 	  	Section 11.2	 	Right of Set-off.	  	77
				
	 	  	Section 11.3	 	Notices, Etc.	  	77
				
	 	  	Section 11.4	 	Binding Effect; Assignability.	  	78
				
	 	  	Section 11.5	 	Costs and Expenses.	  	78
				
	 	  	Section 11.6	 	Confidentiality.	  	78
				
	 	  	Section 11.7	 	Governing Law.	  	79
				
	 	  	Section 11.8	 	Jurisdiction, Etc.	  	79
				
	 	  	Section 11.9	 	Execution in Counterparts.	  	80
				
	 	  	Section 11.10	 	Intent of the Parties.	  	80
				
	 	  	Section 11.11	 	Entire Agreement.	  	80
				
	 	  	Section 11.12	 	Severability of Provisions.	  	80
				
	 	  	Section 11.13	 	Waiver of Jury Trial.	  	80

  

 iii 

 EXHIBITS 
  

			
	 EXHIBIT A
	 	Form of Assignment and Acceptance
		
	 EXHIBIT B
	 	Form of Seller Report
		
	 EXHIBIT C
	 	Form of Lock-Box Agreement
		
	 EXHIBIT D
	 	Form of Receivables Sale Agreement
		
	 EXHIBIT E
	 	Form of Consent and Agreement
		
	 EXHIBIT F
	 	Form of Notice of Purchase
		
	 EXHIBIT G
	 	Form of Swing Purchase Request
		
	 EXHIBIT H
	 	Form of Notice of Conversion or Continuation
		
	 EXHIBIT I-l
	 	Form of Opinion of Baker Botts LLP, Counsel to the Seller and each Originator
		
	 EXHIBIT I-2
	 	Form of Opinion of Internal Counsel to the Seller and each Originator
		
	 EXHIBIT I-3
	 	Form of Opinion of Baker Botts LLP, Counsel to the Seller and each Originator (“true sale” and “no substantive consolidation” opinion)
		
	 EXHIBIT J
	 	Form of Lyondell Undertaking

 SCHEDULES 
  

			
	 SCHEDULE I
	 	Lock-Box Banks and Lock-Box Accounts
		
	 SCHEDULE II
	 	Credit and Collection Policy
		
	 SCHEDULE III
	 	Jurisdiction of Incorporation, Organizational Identification Number and Location of the Seller’s Principal Place of Business, Chief Executive Office and Office Where Records are
Kept
		
	 SCHEDULE IV
	 	Financing Statements
		
	 SCHEDULE V
	 	Approved Non-U.S./Canadian Jurisdictions
		
	 SCHEDULE VI
	 	Certain Obligors
		
	 SCHEDULE VII
	 	Commitment Schedule

 RECEIVABLES PURCHASE AGREEMENT 
  
 RECEIVABLES PURCHASE AGREEMENT dated as of December 17, 2003 (this “Agreement”) among LYONDELL FUNDING II,
LLC, a Delaware limited liability company (the “Seller”), LYONDELL CHEMICAL COMPANY, a Delaware corporation, as the Servicer (as hereinafter defined), the banks and other financial institutions listed on the signature pages hereof
as the Initial Purchasers (the “Initial Purchasers”), and CITICORP USA, INC., a Delaware corporation (“CUSA”), as asset agent and administrative agent (the “Agent”) for the Purchasers. 

 
 PRELIMINARY STATEMENTS: 
  
 The Seller will from time to time purchase or otherwise acquire from the
Originators Pool Receivables in which the Seller intends to sell interests referred to herein as Receivable Interests. 
  
 The Purchasers may at any time and from time to time purchase Receivable Interests from the Seller. 
  
 Lyondell Chemical Company has been requested and is willing to act as the
Servicer upon the terms and subject to the conditions set forth herein. 
  
 CUSA has been requested and is willing to act as the Agent upon the terms and subject to the conditions set forth herein. 
  
 Certain terms which are capitalized and used throughout this Agreement (in addition to those defined above) are defined in Article I of this Agreement.

  
 NOW, THEREFORE, in consideration of the premises, the parties
hereto agree as follows: 
  
 ARTICLE I 
  
 DEFINITIONS 
  
 Section 1.1 Certain Defined Terms. 
  
 As used in this Agreement, the following terms shall have the following
meanings: 
  
 “Adjusted LIBO Rate” means, with
respect to any Yield Period for any Capital Investment, an interest rate per annum equal to the rate per annum obtained by dividing (a) the LIBO Rate by (b) a percentage equal to (i) 100% minus (ii) the reserve percentage applicable 2 Business Days
before the first day of such Yield Period under regulations issued from time to time by the Board for determining the maximum reserve requirement (including any emergency, supplemental or other marginal reserve requirement) for a member bank of the
Federal Reserve System in New York City with respect to liabilities or assets consisting of or including Eurocurrency Liabilities (or with respect to any other category of liabilities that includes deposits by reference to which the LIBO Rate is
determined) having a term equal to such Yield Period. 
  
 “Affiliate” (a) when used with respect to Lyondell only, means (i) any Person that directly, or indirectly through one or more intermediaries, controls Lyondell (a “Controlling Person”), (ii) any Person
(other than a Subsidiary) which is controlled by or is under common control with a Controlling Person, (iii) any Lyondell Joint Venture or (iv) any Person (other than a Subsidiary) holding a direct or indirect equity interest in any Lyondell Joint
Venture; and 

 (b) when used with respect to any Person other than Lyondell, means any other Person that, directly or
indirectly, is in control of, is controlled by or is under common control with such Person. 
  
 The term “control” (including, with correlative meanings, “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power
to direct or cause the direction of the management or policies of a Person, whether through the ownership of voting securities, by contract or otherwise. No director or officer of Lyondell shall be considered an Affiliate of Lyondell solely by
virtue of holding such position. 
  
 “Agent’s
Account” means the Deposit Account of the Agent (account number 3685-2248, ABA 021000089, Reference: CUSA – Medium Term Finance) maintained with Citibank at its office at 388 Greenwich Street, New York, New York 10013, Attention: David
Jaffe, or such other account as the Agent shall specify in writing to the Seller, the Servicer and the Purchasers. 
  
 “Agent’s Fee” means those agency fees set forth in the Citicorp Fee Letter. 
  
 “Alternate Base Rate” means, for any period, a fluctuating
interest rate per annum as shall be in effect from time to time, which rate per annum shall be equal at all times to the highest of the following: 
  
 (a) the rate of interest announced publicly by Citibank in New York, New York, from time to time, as Citibank’s base rate (or equivalent rate
otherwise named); 
  
 (b) the sum (adjusted to the nearest 0.25%
or, if there is no nearest 0.25%, to the next higher 0.25%) of (i) 0.5% per annum, (ii) the rate per annum obtained by dividing (A) the latest three-week moving average of secondary market morning offering rates in the United States for three-month
certificates of deposit of major United States money market banks, such three-week moving average being determined weekly on each Monday (or, if any such day is not a Business Day, on the next succeeding Business Day) for the three-week period
ending on the previous Friday by Citibank on the basis of such rates reported by certificate of deposit dealers to and published by the Federal Reserve Bank of New York or, if such publication shall be suspended or terminated, on the basis of
quotations for such rates received by Citibank from 3 New York certificate of deposit dealers of recognized standing selected by Citibank, by (B) a percentage equal to 100% minus the average of the daily percentages specified during such three-week
period by the Board for determining the maximum reserve requirement (including any emergency, supplemental or other marginal reserve requirement) for Citibank in respect of liabilities consisting of or including (among other liabilities) three-month
U.S. dollar nonpersonal time deposits in the United States and (iii) the average during such three-week period of the maximum annual assessment rates estimated by Citibank for determining the then current annual assessment payable by Citibank to the
Federal Deposit Insurance Corporation (or any successor) for insuring Dollar deposits in the United States; and 
  
 (c) 0.5% per annum plus the Federal Funds Rate. 
  
 “Applicable Base Rate” for any period for any Capital Investment, an interest rate per annum equal to the sum of (a) the Alternate Base
Rate in effect from time to time plus (b) the Applicable Margin. 
  

 2 

 “Applicable LIBO Rate” for any Yield Period for any Capital Investment, an interest rate
per annum equal to the sum of (a) the Adjusted LIBO Rate for such Yield Period plus (b) the Applicable Margin. 
  
 “Applicable Margin” means (a) for the initial period commencing on the Closing Date and ending on the last day of the calendar month in
which the Agent receives unaudited financial statements of Lyondell and its Consolidated Subsidiaries as of, and for the fiscal quarter ending, June 30, 2004 in accordance with and satisfying the requirements of Section 5.5(b), in the case of
Capital Investments having a Yield determined with reference to the Alternate Base Rate, 1.25% per annum and, in the case of Capital Investments having a Yield determined with reference to the Adjusted LIBO Rate, 2.25% per annum; and (b) thereafter,
as of any date of determination, a per annum rate equal to the rate set forth below opposite the then applicable Average Monthly Excess Availability (determined as of the last day of the most recently concluded calendar month): 
  

							
	 AVERAGE MONTHLY EXCESS AVAILABILITY

	  	ALTERNATE
BASE RATE

	 	 	ADJUSTED LIBO
RATE

	 
	 Greater than or equal to $600,000,000
	  	1.00	%	 	2.00	%
	 Less than $600,000,000 and greater than or equal to $300,000,000
	  	1.25	%	 	2.25	%
	 Less than $300,000,000
	  	1.50	%	 	2.50	%

  
 provided, however, that upon
the occurrence and during the continuance of an Event of Termination, the “Applicable Margin” shall be the sum of the otherwise applicable rate set forth in the table above for Alternate Base Rate or Adjusted LIBO Rate, as the case
may be, plus 2.00% per annum. Changes in the Applicable Margin resulting from a change in the Average Monthly Excess Availability for any calendar month shall become effective as to all Capital Investments on the first day of the next calendar
month. 
  
 “Applicable Reserve” means, at any
date, an amount equal to (NRPB x RP) plus such reserves as agreed upon by the Agent and the Seller, with adjustments effective upon at least five Business Days’ notice by the Agent, where: 
  
 NRPB = the Net Receivables Pool Balance at the close of business of the
Servicer on such date. 
  
 RP = the Reserve Percentage at the
close of business of the Servicer on such date. 
  
 “Applicable Yield” means (a) for any Capital Investment (other than in respect of Swing Purchases), at the Seller’s election upon written notice to the Agent, given not later than 11:00 A.M. (New York time) on the
third Business Day preceding (in the case of the Applicable LIBO Rate) or the Business Day of (in the case of the Applicable Base Rate) the applicable Investment Event, the Applicable LIBO Rate or the Applicable Base Rate, as the case may be and (b)
for any Capital Investment in respect of a Swing Purchase, and for each other Obligation hereunder, the Applicable Base Rate. 
  
 “Approved Electronic Communications” means each notice, demand, communication, information, document and other material that the Seller
or Servicer is obligated to, or otherwise chooses to, provide to the Agent pursuant to any Transaction Document or the transactions contemplated therein, including any financial statement, financial and other report, notice, request, certificate and
other 
  

 3 

 information material; provided, however, that “Approved Electronic Communication” shall, unless
otherwise agreed by the Agent, exclude (x) any Notice of Purchase, Swing Purchase Request, Notice of Conversion or Continuation, and any other notice, demand, communication, information, document and other material relating to a request for a new,
or a conversion of an existing, Purchase, (ii) any notice relating to the payment due under any Transaction Document prior to the scheduled date therefor, (iii) any notice of any Potential Event of Termination or Event of Termination and (iv) any
notice, demand, communication, information, document and other material required to be delivered to satisfy any of the conditions set forth in Article III or any other condition to any Purchase or other Investment Event. 
  
 “Approved Electronic Platform” has the meaning specified in
Section 8.7. 
  
 “Assignee” means in the case of
any assignment of any rights and obligations pursuant to Section 9.1, any Eligible Assignee as the assignee of such rights and obligations. 
  
 “Assignment and Acceptance” means an assignment and acceptance, in substantially the form of Exhibit A hereto, entered into by any
Purchaser and an Assignee pursuant to Section 9.1. 
  
 “Available Capital” means, at any time (a) the Maximum Capital minus (b) the aggregate Capital outstanding at such time. 
  
 “Average Monthly Excess Availability” means, for any calendar month, the sum, without duplication, of (i) the average daily Total Excess
Availability plus (ii) the average daily unrestricted cash of Lyondell and its Subsidiaries (as determined by Lyondell from treasury records on a non-GAAP basis), in each case for such calendar month. 
  
 “Bankruptcy Code” means title 11, United States Code.

  
 “Board” means the Board of Governors of the
Federal Reserve System of the United States. 
  
 “Business
Day” means any day (other than a Saturday or Sunday) on which (i) banks are not authorized or required to close in New York, New York or Houston, Texas and (ii) if the term “Business Day” is used in connection with the
Adjusted LIBO Rate, dealings in United States dollars are carried on in the London interbank market. 
  
 “CA Administrative Agent” means JPMorgan Chase Bank, as administrative agent under the CA Collateral Documents, and any successor in such
capacity. 
  
 “CA Collateral Documents” means the
“Collateral Documents” as defined in the Credit Agreement. 
  
 “CA Excess Availability” means, at any time, the amount, if any, by which the aggregate available “Commitments” under (and as defined in) the Credit Agreement exceeds the aggregate amount of the “Revolving
Outstandings” under (and as defined in) in the Credit Agreement, in each case, at such time. 
  
 “Capital” means, at any time, the sum of all Capital Investments outstanding of all Purchasers and the Swing Purchaser at such time.

  
 “Capital Investment” means, with respect to
any Purchaser, or Swing Purchaser, as the case may be, and in respect of any Receivable Interest, the original amount paid to the Seller for such 
  

 4 

 Receivable Interest at the time of its acquisition by such Purchaser or Swing Purchaser, as the case may be, pursuant to
Section 2.1, 2.2 or 2.3, reduced from time to time by such Purchaser’s Ratable Portion of Collections received and distributed on account of such Capital pursuant to Section 2.6, 2.7 or 2.8, or with respect to the Swing Purchaser, any amounts
received pursuant to Section 2.3(e); provided, however, that if such Capital Investment in respect of such Receivable Interest shall have been reduced by any distribution of any portion of Collections and thereafter such distribution is
rescinded or must otherwise be returned for any reason, such Capital Investment in respect of such Receivable Interest shall be increased by the amount of such distribution, all as though such distribution had not been made. 
  
 “Cash Assets Account” means collectively, the Deposit
Account of the Seller (account number 30553415, ABA 021000089, Reference: Lyondell Funding II, LLC/Cash Assets) and the Deposit Account of the Seller (account number 30553423, ABA 021000089, Reference: Lyondell Funding II, LLC/Cash Assets II), in
each case maintained with Citibank at its office at 388 Greenwich Street, New York, New York 10013, Attention: David Jaffe, or such other account as the Seller and the Agent may agree. 
  
 “Cash Assets” means any cash on deposit in, and Liquid Investments held in, the Cash Assets Account.

  
 “Cash Management Obligation” means any direct
or indirect liability, contingent or otherwise, of the Seller in respect of cash management services (including treasury, depository, overdraft, electronic funds transfer and other cash management arrangements) provided after the date hereof
(regardless of whether these or similar services were provided prior to the date hereof by the Agent, any Purchaser or any Affiliate or any of them) by the Agent in connection with this Agreement or any other Transaction Document, including
obligations for the payment of fees, interest, charges, expenses, attorneys’ fees and disbursements in connection therewith. 
  
 “Change of Control” shall occur if at any time: 
  

(a) any Person or group (within the meaning of Section 13 or 14 of the Exchange Act) of Persons (other than Millennium, Occidental and/or their
Affiliates) shall have acquired Voting Control of 20% or more of the outstanding shares of common stock of Lyondell; or 
  
 (b) Continuing Directors shall cease to constitute a majority of Lyondell’s board of directors; or 
  
 (c) Lyondell shall cease to own, directly or indirectly, 100% of the Equity
Interests in (x) the Seller or (y) any Originator (other than Lyondell) unless such other Originator ceases to be an Originator in accordance with Section 7.03 of the Receivables Sale Agreement. 
  
 “Citibank” means Citibank, N.A., a national banking
association, and its successors. 
  
 “Citicorp Fee
Letter” means the Administrative Agency and Collateral Monitoring Fee Letter dated November 12, 2003 among Lyondell, CUSA and Citigroup Global Markets Inc. 
  
 “Closing Date” means December 17, 2003. 
  
 “Code” means the Internal Revenue Code of 1986, as amended from time to time. 
  
 “Collections” means, with respect to any Pool Receivable,
all cash collections and other cash proceeds of such Pool Receivable, including (i) all cash proceeds of the Related Security with respect to such Pool Receivable and (ii) any amounts in respect of such Pool Receivable deemed to have been received,
and actually paid, pursuant to Section 2.9(b) or Section 2.9(c). 
  

 5 

 “Commitment” means (i) in respect of each Initial Purchaser, the commitment of such
Purchaser to make Purchases and acquire other Capital Investments in the aggregate amount set forth as the “Commitment” under the name of such Initial Purchaser on the signature pages hereto and (ii) in respect of each other
Purchaser that became a Purchaser by entering into an Assignment and Acceptance, the amount set forth as the “Commitment” for such Purchaser in the Register maintained by the Agent pursuant to Section 9.2, in each case, as such
amount may be reduced from time to time as the result of any assignment of any Commitment or any portion thereof pursuant to Section 9.1 or as such amount may be reduced from time to time pursuant to Section 2.4(a). 
  
 “Commitment Termination Date” means the fourth anniversary
of the Closing Date. 
  
 “Concentration Account”
means the Deposit Account of the Seller (account number 3751447168, ABA 111000012, Reference: Lyondell Funding II, LLC/A/R Concentration) maintained with Bank of America, N.A. at its office at 901 Main Street, Dallas, TX 75202 – 3714, or such
other account as the Seller and the Agent may agree. 
  
 “Confidential Information Memorandum” means the Confidential Information Memorandum dated November 2003 relating to Lyondell and the transactions contemplated by the Transaction Documents. 
  
 “Consent and Agreement” means a consent and agreement dated
the Closing Date, in substantially the form of Exhibit E hereto, with respect to the Receivables Sale Agreement, duly executed by the Seller and each Originator. 
  
 “consolidated” means, with respect to any Person, the consolidation of accounts of such Person and its
Subsidiaries in accordance with GAAP. 
  
 “Consolidated
Subsidiary” means at any date any Subsidiary or other entity the accounts of which would be consolidated with those of Lyondell in its consolidated financial statements if such statements were prepared as of such date. 
  
 “Constituent Documents” means, with respect to any Person,
(a) the articles of incorporation, certificate of incorporation or certificate of formation (or the equivalent organizational documents) of such Person, (b) the by-laws, partnership agreement or operating agreement (or the equivalent governing
documents) of such Person and (c) any document setting forth the manner of election and duties of the directors, general partners or managing members of such Person (if any) and the designation, amount or relative rights, limitations and preferences
of any class or series of such Person’s Stock. 
  
 “Continuing Directors” means (i) directors of Lyondell on the date hereof and (ii) individuals who were recommended for election or elected to become directors of Lyondell by a majority of the Continuing Directors then in
office. 
  
 “Contract” means an agreement between
any Originator and an Obligor in any written form acceptable to such Originator, or, in the case of any open account agreement, as evidenced by an invoice (x) setting forth the amount payable, the payment due date and other relevant terms of payment
and a description, in reasonable detail, of the goods or services covered thereby or (y) otherwise approved by the Agent in its Discretion from time to time (which approval shall not be unreasonably withheld), in each case pursuant to or under which
such Obligor shall be obligated to pay for goods or services from time to time. 
  

 6 

 “Controlling Person” means any Person that directly, or indirectly through one or more
intermediaries, controls Lyondell. As used herein, “control” has the meaning specified in connection with the definition of “Affiliate”. 
  
 “Credit Agreement” means the Credit Agreement dated as of June 27, 2002, among Lyondell, the lenders,
co-syndication agents and co-documentation agents party thereto and JPMorgan Chase Bank, as administrative agent, or any restatement, extension, renewal, refunding, replacement or refinancing, in whole or in part, thereof. 
  
 “Credit and Collection Policy” means those credit and
collection policies and practices in effect on the date hereof relating to Contracts and Receivables and described in Schedule II hereto, as modified from time to time in compliance with Section 5.3(f) and Section 5.6(a). 
  
 “CUSA” has the meaning assigned to that term in the recital
of parties hereto. 
  
 “Deposit Account” has the
meaning set forth in Article 9 of the UCC. 
  
 “Derivatives Obligations” of any Person means all obligations of such Person in respect of any rate swap transaction, basis swap, forward rate transaction, commodity swap, commodity option, equity or equity index swap,
equity or equity index option, bond option, interest rate option, foreign exchange transaction, cap transaction, floor transaction, collar transaction, currency swap transaction, cross-currency rate swap transaction, currency option or any other
similar transaction (including any option with respect to any of the foregoing transactions) or any combination of the foregoing transactions. 
  
 “Discretion” refers to the Agent’s good faith exercise of its discretion in a manner consistent with its customary credit policies
for receivables purchase or receivables-based credit facilities. Except where a different standard of conduct is expressly provided for in the proviso to clause (d) of the definition of “Eligible Receivable”, actions by the Agent in
respect of the determination of Eligible Receivables or the Net Receivables Pool Balance or the Applicable Reserve or in connection with any approval by the Agent of Contracts or other matters relating to the Pool Receivables and Related Security
shall be taken by the Agent in its Discretion. 
  
 “Eligible Assignee” means (a) a Purchaser or any Affiliate of such Purchaser, (b) a commercial bank having total assets in excess of $5,000,000,000, (c) a Person reasonably acceptable to the Agent and regularly engaged in
making, purchasing or investing in loans and having a net worth, determined in accordance with GAAP, in excess of $250,000,000 or, to the extent net worth is less than such amount, a Person reasonably acceptable to the Agent or (d) a savings and
loan association or savings bank organized under the laws of the United States or any State thereof having a net worth, determined in accordance with GAAP, in excess of $250,000,000; provided, however, that neither an Originator nor the
Seller nor any of their respective Affiliates or Subsidiaries may be an Eligible Assignee. 
  
 “Eligible Receivable” means each Pool Receivable arising out of the sale of inventory or the performance of services in the ordinary course of business by an Originator to a Person that is not
Equistar or a subsidiary of Equistar, LCR or a Subsidiary of LCR, Occidental or a subsidiary of Occidental, Millennium or a subsidiary of Millenium (but only if Millennium holds an Equity Interest in Lyondell that is greater than or equal to 5% of
the aggregate outstanding Equity Interests in Lyondell), or an Affiliate or Subsidiary of any Originator; provided, however, that a Pool Receivable shall not be an “Eligible Receivable” if any of the following shall be true:

  
 (a) any warranty contained in Section 4.1(h)
of this Agreement with respect to such specific Receivable is not true and correct with respect to such Receivable; or 
  

 7 

 (b) the Obligor on such Receivable has disputed liability or made any claim with respect
to such Receivable or any other Receivable due from such Obligor to the Seller or any Originator but only to the extent of such dispute or claim; or 
  
 (c) the Obligor in respect of such Receivable, or any Person that the Agent or any Transaction Party knows or reasonably believes is an
Affiliate of such Obligor, is also a supplier to or creditor of any Transaction Party, unless such Obligor has executed a no-offset letter satisfactory to the Agent, in its Discretion; provided, however, that if such Obligor has not
executed a no-offset letter satisfactory to the Agent, in its Discretion, such Receivables shall be Eligible Receivables pursuant to this clause (c) only to the extent the aggregate Outstanding Balance of such Receivables exceeds the aggregate
amount of accounts payable and, to the extent known to any Responsible Officer of the Servicer, other indebtedness owing by the Originators to such Obligor or any such Affiliate as at such date; or 
  
 (d) the transaction represented by such Receivable is to an
Obligor which, if a natural person, is not a resident of the United States or, if not a natural person, is organized under the laws of a jurisdiction outside the United States or has its chief executive office outside the United States (it being
understood for purposes of this clause (d) that a territory of the United States that has enacted Revised Article 9 of the Uniform Commercial Code and Puerto Rico are considered to be part of the United States), unless (i) such Receivable is backed
by a letter of credit acceptable to the Agent, in its reasonable discretion and (x) such letter of credit names the Agent (for the benefit itself and each Purchaser) as the beneficiary or (y) the issuer of such letter of credit has consented to the
assignment of the proceeds thereof to the Agent, (ii) such Obligor is, if a natural person, a resident of Canada or, if not a natural person, is organized under the laws of Canada or a province thereof and has its chief executive office in Canada
and such Receivable is denominated in U.S. Dollars or (iii) such Receivable is backed by insurance reasonably acceptable to the Agent and the relevant insurance policy names the Agent (for the benefit itself and each Purchaser) as additional insured
and loss payee; provided, however, that the Receivables of any Obligor located in a jurisdiction outside the United States or Canada approved by the Agent in its sole discretion, which jurisdiction shall be listed in Schedule V
hereto as and when approved by the Agent, and which Obligor is listed on Schedule VI-A hereto (as of the date hereof and as such Schedule may be updated from time to time by the Originators upon five Business Days’ prior written notice
to the Agent), shall be Eligible Receivables pursuant to this clause (d) to the extent that (A) such Receivables are denominated in U.S. Dollars and arise from sales of inventory shipped from the United States and (B) the aggregate Outstanding
Balance of all such Receivables does not exceed 15% of the Outstanding Balance of all Eligible Receivables; or 
  
 (e) the sale to such Obligor represented by such Receivable is not a final sale (e.g., such sale is on a bill-and-hold, guaranteed sale,
sale-and-return or sale-on-approval basis or, until billed, a consignment basis); or 
  
 (f) such Receivable is subject to any Lien other than a Permitted Lien described in clause (i) or (ii) of the definition thereof; or

  
 (g) such Receivable is subject to any
deduction, offset, counterclaim, return privilege or other conditions (other than (i) sales discounts given in the ordinary course of the Originators’ business and reflected in the amount of such Receivable as set forth in the invoice or other

  

 8 

 supporting material therefor or (ii) an offset or counterclaim of a nature specifically addressed in
another clause of this definition) but only to the extent of the amount of such deduction, offset, counterclaim, return privilege or other condition being asserted by the Obligor; or 
  
 (h) the Obligor on such Receivable is located in any State of the United States requiring the holder of such
Receivable, as a precondition to commencing or maintaining any action in the courts of such State either to (i) receive a certificate of authorization to do business in such State or be in good standing in such State or (ii) file a Notice of
Business Activities Report with the appropriate office or agency of such State, in each case unless the holder of such Receivable has received such a certificate of authority to do business, is in good standing or, as the case may be, has duly filed
such a notice in such State; or 
  
 (i) the
Obligor on such Receivable is a Governmental Authority, unless the applicable Originator and the Seller have each assigned its rights to payment of such Receivable to the Agent pursuant to the Assignment of Claims Act of 1940, as amended, in the
case of a federal Governmental Authority, and pursuant to applicable law, if any, in the case of any other Governmental Authority, and such assignment has been accepted and acknowledged by the appropriate government officers; or 
  
 (j) 50% or more of the Outstanding Balance of the
Receivables of the Obligor are not Eligible Receivables by reason of clause (b) or (g) above or clause (o) below; provided that Receivables that are determined not to be Eligible Receivables, solely as a result of the provisions of clause (n)
below, shall be excluded in calculating such percentage; or 
  
 (k) the payment obligation represented by such Receivable is denominated in a currency other than U.S. Dollars; or 
  
 (l) such Receivable is not evidenced by an invoice that would be a Contract or by other supporting material acceptable to the Agent, in
its Discretion; or 
  
 (m) any Originator, the
Seller or any other Person, in order to be entitled to collect such Receivable, is required to deliver any additional goods or merchandise to, perform any additional service for, or perform or incur any additional obligation to, the Person to whom
or to which it was made; or 
  
 (n) the total
Receivables of such Obligor to the Originators (taken as a whole) represent more than 15% (or such lesser percentage with respect to certain Obligors as the Agent may determine in its Discretion) of the Outstanding Balance of the Eligible
Receivables of the Originators (taken as a whole) at such time, but only to the extent of such excess; or 
  
 (o) such Receivable (or any portion thereof) remains unpaid for more than (i) 60 days from the original payment due date, or (ii) if such
Receivable arises from the sale of inventory, 90 days from the original invoice date thereof or, in the case of any such Receivable from an Obligor listed, and with the payment terms described, in Schedule VI-B hereto (as of the date hereof
and as such Schedule may be updated from time to time by the Originators upon five Business Days’ prior written notice to the Agent), 120 days from the original invoice date thereof, provided that such Receivables from such Obligors
listed in Schedule VI-B shall be Eligible Receivables under this clause (o) only to the extent that the Outstanding Balance of all such Receivables does not exceed 10% of the Outstanding Balance of all Eligible Receivables; or 
  

 9 

 (p) the Obligor on such Receivable (i) has (A) pending, by or against such Obligor, a
petition for bankruptcy or any other relief under the Bankruptcy Code or any other law relating to bankruptcy, insolvency, reorganization or relief of debtors, (B) an assignment for the benefit of creditors, (C) any other application for relief
under the Bankruptcy Code or any such other law or (D) the appointment of a receiver or a trustee for all or a substantial part of its assets or affairs or (ii) has, while such Receivable remains outstanding, failed, suspended business operations,
become insolvent or called a meeting of its creditors for the purpose of obtaining any financial concession or accommodation; or 
  
 (q) consistent with the Credit and Collection Policy, such Receivable is or should be written off the Seller’s or any
Originator’s books as uncollectible; or 
  
 (r) such Receivable is not payable into a Lock-Box Account that is the subject of a Lock-Box Agreement; or 
  
 (s) such Receivable does not arise under a Contract which has been duly authorized and which, together with such Receivable, is in full
force and effect and constitutes the legal, valid and binding obligation of the Obligor of such Receivable enforceable against such Obligor in accordance with its terms; or 
  
 (t) such Receivable, together with the Contract related thereto, contravenes in any material respect any
laws, rules or regulations applicable thereto (including, without limitation, laws, rules and regulations relating to usury, consumer protection, truth in lending, fair credit billing, fair credit reporting, equal credit opportunity, fair debt
collection practices and privacy) or with respect to which the applicable Originator is in violation of any such law, rule or regulation in any material respect; or 
  
 (u) such Receivable does not satisfy the requirements of the Credit and Collection Policy in all material
respects; or 
  
 (v) such Receivable does not
constitute an “account” within the meaning of Section 9-102(a)(2) of the UCC of the jurisdiction the law of which governs the perfection of the interest created by a Receivable Interest; or 
  
 (w) the sale to such Obligor on such Receivable is on a
F.O.B. customer basis but only for so long as the inventory giving rise to such Receivable has not yet arrived at its destination and possession thereof has not been taken by the Obligor; or 
  
 (x) such Receivable (i) is subject to an unsecured claim in
favor of a surety or (ii) arises under a Contract that is not governed by the laws of the United States or a State thereof; or 
  
 (y) there is a chargeback represented by the unpaid portion of such Receivable as to which less than full payment was made; or 

 
 (z) such Receivable is billed in advance of the relevant
shipment of inventory or performance of services; or 
  
 (aa) such Receivable arises under a Contract that (i) specifies a fixed price and fixed volume for 90 or more days and (ii) provides for material liquidated damages; or 
  

 10 

 (bb) (i) such Receivable does not comply with such other reasonable criteria and
requirements (other than those relating to the collectibility of such Receivable) as the Agent, in its Discretion, may from time to time specify to the Seller upon 30 days’ notice, or (ii) the Agent, based upon such credit and collateral
considerations as it may deem appropriate, in the exercise of its Discretion, and upon at least five Business Days’ notice, notifies the Seller of its determination that such Receivable might not be paid or is otherwise ineligible, in which
event such Receivable shall not be an Eligible Receivable on the effective date of ineligibility specified in such notice. 
  
 For the avoidance of doubt, it is acknowledged and agreed that any calculation of ineligibility made pursuant to more than one clause above shall be made without
duplication. 
  
 “Environmental Laws” means any
federal, state, local or foreign law, treaty, judicial decision, regulation, rule, judgment, order, decree, injunction, permit or governmental restriction or requirement, whether now or hereafter in effect, relating to human health and safety, the
environment or the protection of the environment. 
  
 “Equistar” means Equistar Chemicals, LP, a Delaware limited partnership. 
  
 “Equity Equivalent” means (i) any equity securities of a special purpose Subsidiary of Lyondell, whose only assets consist of the
proceeds of such issuance and a debt obligation of Lyondell which matures more than one year after the Termination Date and is subordinated in right of payment to Capital and the Obligations on terms satisfactory to the Agent and (ii) any other
equity-like securities the form and substance of which are reasonably acceptable to the Agent. 
  
 “Equity Interest” means, with respect to any Person, shares of capital stock of (or other ownership or profit interests in) such Person, warrants, options or other rights for the purchase or other
acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such Person, securities convertible into or exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or
warrants, rights or options for the purchase or other acquisition from such Person of such shares (or such other interests), and other ownership or profit interests in such Person (including, without limitation, partnership, member or trust
interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other interests are authorized or otherwise existing on any date of determination. 
  
 “ERISA” means the Employee Retirement Income Security Act of
1974, as amended, or any successor statute. 
  
 “ERISA
Group” means Lyondell, any Subsidiary and all members of a controlled group of corporations and all trades or businesses (whether or not incorporated) under common control which, together with Lyondell or any Subsidiary, are treated as a
single employer under Section 414 of the Code. 
  
 “Eurocurrency Liabilities” has the meaning assigned to that term in Regulation D of the Board. 
  
 “Events of Termination” has the meaning specified in Section 7.1. 
  
 “Existing Program” means the receivables securitization facility established pursuant to the Purchase and
Sale Agreement dated as of December 18, 1998 between ARCO Chemical Company, as Seller, and Lyondell Funding, LLC, as Purchaser, and the Receivables Purchase Agreement dated as of December 18, 1998 among Lyondell Funding, LLC, as Seller, ARCO
Chemical Company as Collection Agent and Originator, the Investors and Banks party thereto and Citicorp North America, Inc., as Agent. 
  

 11 

 “Federal Funds Rate” means, for any period, a fluctuating interest rate per annum equal
for each day during such period to the weighted average of the rates on overnight Federal funds transactions with members of the Federal Reserve System arranged by Federal funds brokers, as published for such day (or, if such day is not a Business
Day, for the next preceding Business Day) by the Federal Reserve Bank of New York, or, if such rate is not so published for any day that is a Business Day, the average of the quotations for such day on such transactions received by the Agent from
three Federal funds brokers of recognized standing selected by it. 
  
 “Fiscal Year” means the fiscal year of Lyondell. 
  
 “Future Joint Venture” means any joint venture (i) in which Lyondell acquires a direct or indirect Equity Interest after July 28, 1998 and (ii) which is accounted for by Lyondell on the equity method.

  
 “GAAP” means generally accepted accounting
principles as in effect from time to time, applied on a basis consistent (except for changes concurred in by Lyondell’s independent public accountants) with the most recent audited consolidated financial statements of Lyondell and its
Consolidated Subsidiaries delivered to the Agent. 
  
 “General Partner” means a Subsidiary of Lyondell or any of its Subsidiaries that has no assets and conducts no operations other than its ownership of a general partnership interest in a Lyondell Joint Venture. 

 
 “Governmental Authority” means any nation, sovereign or
government, any state or other political subdivision thereof and any entity exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to government, including any central bank. 
  
 “Guarantee” by any Person means any obligation, contingent
or otherwise, of such Person directly or indirectly guaranteeing any Indebtedness or other obligation of any other Person and, without limiting the generality of the foregoing, any obligation, direct or indirect, contingent or otherwise, of such
Person (i) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation (whether arising by virtue of partnership arrangements (other than, in the case of Lyondell or a Subsidiary, with respect
to the obligations of a Lyondell Joint Venture, solely by virtue of a Subsidiary of Lyondell being the General Partner of such Lyondell Joint Venture if, as of the date of determination, no payment on such Indebtedness or other obligation has been
made by such General Partner of such Lyondell Joint Venture and such arrangement would not be classified and accounted for, in accordance with GAAP, as a liability on a consolidated balance sheet of Lyondell), by virtue of an agreement to keep-well,
to purchase assets, goods, securities or services, to take-or-pay, or to maintain financial statement conditions or otherwise), (ii) to reimburse a bank for amounts drawn under a letter of credit for the purpose of paying such Indebtedness or other
obligation or (iii) entered into for the purpose of assuring in any other manner the holder of such Indebtedness or other obligation of the payment thereof or to protect such holder against loss in respect thereof (in whole or in part),
provided that the term “Guarantee” shall not include endorsements for collection or deposit in the ordinary course of business. The term “Guarantee” used as a verb has a corresponding meaning. 
  
 “Indebtedness” of any Person means, at any date, without
duplication, (a) the principal amounts of all obligations of such Person for borrowed money, (b) the principal amount of all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (c) all obligations of such Person
to pay the deferred purchase price of property or services (except trade accounts payable, accrued expenses and deferred compensation and other pension, benefit and welfare expenses, in each case arising in the ordinary course of business) if and to
the extent the foregoing would appear as a liability on a 
  

 12 

 balance sheet of such Person in accordance with GAAP, (d) all obligations of such Person as lessee which are capitalized
in accordance with GAAP, (e) all non-contingent obligations (and, solely for purposes of Section 5.3(a) hereof and Section 3.08 of the Lyondell Undertaking, all contingent obligations, which contingent obligations shall for such purposes be deemed
to be in an outstanding principal amount equal to the maximum contingent amount thereof) of such Person to reimburse any bank or other Person in respect of amounts paid under a letter of credit or similar instrument, (f) all capital stock of such
Person which is subject to redemption otherwise than at the sole option of such Person at any time prior to the date 12 months after the Commitment Termination Date; (g) all Indebtedness secured by a Lien on any asset of such Person, whether or not
such Indebtedness is otherwise an obligation of such Person; provided that, for purposes of determining the amount of any Indebtedness of the type described in this clause (g), if recourse with respect to such Indebtedness is limited to such
asset, the amount of such Indebtedness shall be limited to the lesser of (A) the greater of (x) the book value of such asset or (y) the fair market value of such asset or (B) the amount of such Indebtedness and (viii) all Guarantees by such Person
of Indebtedness of another Person (each such Guarantee to constitute Indebtedness in an amount equal to the amount of such other Person’s Indebtedness Guaranteed thereby). For avoidance of doubt, Indebtedness does not include an Equity
Equivalent or a Securitization Transaction. 
  
 “Indemnified Amounts” has the meaning specified in Section 10.1. 
  
 “Indemnified Party” means the Agent, each Purchaser and each of their respective Affiliates, and each of the directors, officers, employees, agents, representative, attorneys, consultants and advisors
of or to any of the foregoing. 
  
 “Indentures”
has the meaning specified in the Lyondell Undertaking. 
  
 “Intercreditor Agreement” means any intercreditor agreement entered into pursuant to Section 3.18 of the Lyondell Undertaking. 
  
 “Investment” means any investment in any Person, whether by means of purchase of equity securities, capital contribution (in cash,
property or services), loan, Guarantee, time deposit or otherwise (but not including any demand deposit). 
  
 “Investment Event” means any Purchase, any conversion of Capital Investments bearing Yield at the Applicable LIBO Rate to Capital
Investments bearing Yield at the Applicable Base Rate, any conversion of Capital Investments bearing Yield at the Applicable Base Rate to Capital Investments bearing Yield at the Applicable LIBO Rate and any continuation of Capital Investments
bearing Yield at the Applicable LIBO Rate for an additional Yield Period. 
  
 “LCR” means LYONDELL-CITGO Refining LP, a Delaware limited partnership (and as of the date hereof a joint venture between Lyondell and CITGO Petroleum Corporation) in which Lyondell holds at the date
hereof 58.75% indirect Equity Interest, the successor to LYONDELL-CITGO Refining Company, Ltd., a Texas limited liability company. 
  
 “LIBO Rate” means, with respect to any Yield Period for any Capital Investment as to which Yield is based on the Applicable LIBO Rate,
the rate appearing on Page 3750 of the MoneyLine Telerate Markets (or on any successor or substitute page of such service) at approximately 11:00 a.m., London time, two Business Days prior to the commencement of such Yield Period, as the rate for
Dollar deposits with a maturity comparable to such Yield Period. In the event that such rate is not available at such time for any reason, then the LIBO Rate shall be the rate at which Dollar deposits in an amount approximately equal to the Capital
Investment of CUSA and for a period comparable to such Yield Period are offered by the principal office of Citibank in London to prime banks in the London interbank market at approximately 11:00 a.m. (London time) two Business Days prior to the
commencement of such Yield Period. 
  

 13 

 “Lien” means, with respect to any asset, any mortgage, lien, pledge, charge, security
interest or encumbrance of any kind, or any other type of preferential arrangement that has substantially the same practical effect as a security interest, in respect of such asset. For purposes hereof, Lyondell or any Subsidiary shall be deemed to
own subject to a Lien any asset which it has acquired or holds subject to the interest of a vendor or lessor under any conditional sale agreement, capital lease or other title retention agreement relating to such asset. 
  
 “Liquid Investments” has the meaning set forth in Section
2.18(b). 
  
 “Liquidation Cost” has the meaning
set forth in Section 2.12(d). 
  
 “Liquidation
Day” means, for any Receivable Interest, each Business Day that occurs on or after the Termination Date. 
  
 “Lock-Box Account” means a Deposit Account (including, without limitation, any concentration account) maintained at a Lock-Box Bank for
the purpose of receiving Collections and subject to a valid Lock-Box Agreement. 
  
 “Lock-Box Agreement” means an agreement, in substantially the form of Exhibit C hereto (with such modifications thereto as consented to by the Agent), between any Originator or the Seller, as
the case may be, the Agent, and a Lock-Box Bank. 
  
 “Lock-Box Bank” means any of the banks specified on Schedule I hereof and any other bank specified as a “Lock-Box Bank” in accordance with this Agreement, in each case holding one or more Lock-Box
Accounts. 
  
 “Lyondell” means Lyondell Chemical
Company, a Delaware corporation. 
  
 “Lyondell
Funding” means Lyondell Funding II, LLC, a Delaware limited liability company. 
  
 “Lyondell Joint Ventures” means Equistar, LCR and any Future Joint Venture, and “Lyondell Joint Venture” means any of them, as the context may require. 
  
 “Lyondell Undertaking” means the Undertaking Agreement dated
as of the Closing Date, in substantially the form of Exhibit J hereto, by Lyondell in favor of the Agent and the Purchasers. 
  
 “Material Adverse Effect” means (a) a material adverse effect on the business, assets, operations or financial condition of Lyondell and
its Subsidiaries, taken as a whole, (b) material impairment of the ability of the Transaction Parties to perform any of their obligations under the Transaction Documents, (c) material impairment of the collectibility of the Pool Receivables
generally or of any material portion of the Pool Receivables or the ability of the Servicer (if the Servicer is Lyondell or an Affiliate or Subsidiary of Lyondell) to collect Pool Receivables or (d) material impairment of the rights of or benefits
available to the Agent or the Purchasers under the Transaction Documents; provided, however, that a downgrade in any debt rating of Lyondell or any of its Subsidiaries shall not, by itself, constitute a Material Adverse Effect.

  

 14 

 “Material Debt” means Indebtedness of Lyondell and/or one or more of its Subsidiaries
(including for this purpose the Lyondell Joint Ventures, but excluding LCR so long as LCR is not at the time a “Significant Subsidiary” for purposes of the instruments governing the Senior Notes or the Senior Subordinated Notes), arising
in one or more related or unrelated transactions, in an aggregate principal amount exceeding $50,000,000. 
  
 “Material Subsidiary” means (a) any Subsidiary having consolidated assets equal to or greater than 5% of the consolidated assets of
Lyondell and its Consolidated Subsidiaries at such time and (b) any Subsidiary designated by Lyondell as a Material Subsidiary for purposes of the Transaction Documents by notice to the Agent; provided that (i) the term “Material
Subsidiary” shall exclude the Seller and shall include any other Transaction Party other than Lyondell and (ii) neither POSM nor any Subsidiary whose only significant assets are partnership interests in POSM shall be a Material Subsidiary for
purposes of Section 2.03 of the Lyondell Undertaking. 
  
 “Maximum Capital” means, at any time, the lesser of (a) the Total Commitments and (b)(i) the Net Receivables Pool Balance minus (ii) the Applicable Reserve in effect at such time. 
  
 “Medium Term Notes” has the meaning specified in the
Lyondell Undertaking. 
  
 “Millennium” means
Millennium Chemicals Inc., a Delaware corporation. 
  
 “Moody’s” means Moody’s Investors Service, Inc., and its successors. 
  
 “Multiemployer Plan” means, at any time, an employee pension benefit plan within the meaning of Section 4001(a)(3) of ERISA to which any
member of the ERISA Group is then making or accruing an obligation to make contributions or has within the preceding five plan years made contributions, including for these purposes any Person which ceased to be a member of the ERISA Group during
such five year period. 
  
 “Net Receivables Pool
Balance” means, at any time, the Outstanding Balance of the Eligible Receivables in the Receivables Pool as at such time reduced by (a) Unapplied Cash and Credits (to the extent not already deducted in determining the Outstanding Balance),
(b) the Yield and Fee Reserve at such time, and (c) to the extent not already deducted in determining Eligible Receivables, (i) amounts accrued or recorded by the Originators as a reserve in respect of volume rebates or other offsetting deductions
or in respect of credits in past due and (ii) such dilution reserves and other reductions as the Agent in its Discretion deems appropriate and as notified by the Agent to the Seller at least five Business Days prior to the effectiveness thereof.

  
 “Notice of Conversion or Continuation” has
the meaning specified in Section 2.16(a). 
  
 “Notice of
Purchase” has the meaning specified in Section 2.2(a). 
  
 “Obligations” means, with respect to any Transaction Party, the obligations of such Transaction Party under the Transaction Documents (as the same may hereafter be amended, restated, extended, supplemented or otherwise
modified from time to time) with respect to the due and punctual payment, whether at maturity, by acceleration or otherwise, of all monetary obligations of such Transaction Party, whether for fees, costs, indemnification or otherwise (other than
Capital), including, with respect to the Seller, Yield, amounts payable as deemed Collections pursuant to Section 2.9(b) or 2.9(c), the Agent’s Fee, the Unused Commitment Fee, the Servicer Fee, Cash Management Obligations and amounts payable by
the Seller pursuant to Section 2.12, 2.13, 2.14, 10.1 and 11.5. 
  

 15 

 “Obligor” means a Person obligated to make payments pursuant to a Contract. 

 
 “Occidental” means Occidental Petroleum Corporation, a
Delaware corporation. 
  
 “Originator” means
Lyondell and any wholly owned Subsidiaries of Lyondell from time to time party to the Receivables Sale Agreement as “Sellers” thereunder. 
  
 “Other Taxes” has the meaning specified in Section 2.14(b). 
  
 “Outstanding Balance” of any Receivable at any time means the then outstanding principal balance thereof.

  
 “Payment Date” means (a) in respect of Yield,
the Unused Commitment Fee and the Servicer Fee, (i) the second Business Day of each calendar month, commencing on the first such day following the Closing Date and (ii) if not previously paid in full, the Termination Date, and (b) with respect to
all other Obligations of the Seller hereunder, the date such Obligation is due or otherwise on demand by the Agent from and after the time such Obligation becomes due and payable (whether by acceleration or otherwise). 
  
 “PBGC” means the Pension Benefit Guaranty Corporation or any
entity succeeding to any or all of its functions under ERISA. 
  
 “PBGC Settlement Agreement” means the settlement agreement effective as of July 28, 1998 between Lyondell and the PBGC. 
  
 “Permitted Lien” means (i) an inchoate tax or PBGC Lien, (ii) a Lien created by the Transaction Documents, (iii) a Lien in favor of a
Lock-Box Bank in respect of a Lock-Box Amount or (iv) a Lien in favor of a securities intermediary in respect of any securities account, or any securities entitlement therein, under the “control” (within the meaning of Section 9-104 of the
UCC) of the Agent. 
  
 “Person” means an
individual, partnership, corporation (including a business trust), limited liability company, joint stock company, trust, unincorporated association, joint venture or other entity, or a government or any political subdivision or agency thereof.

  
 “Plan” means, at any time, an employee
pension benefit plan (other than a Multiemployer Plan) which is covered by Title IV of ERISA or subject to the minimum funding standards under Section 412 of the Code and either (i) is maintained, or contributed to, by any member of the ERISA Group
for employees of any member of the ERISA Group or (ii) has at any time within the preceding five years been maintained, or contributed to, by any Person which was at such time a member of the ERISA Group for employees of any Person which was at such
time a member of the ERISA Group. 
  
 “Pool
Receivable” means a Receivable in the Receivables Pool. 
  
 “POSM” means POSM II Limited Partnership, L.P., a Delaware limited partnership. 
  
 “Potential Event of Termination” means any event that, with the giving of notice or the passage of time or both, would constitute an
Event of Termination. 
  
 “Principal Financial
Officer” of any Person means the chief financial officer, the treasurer or the principal accounting officer of such Person (including any Person designated by the board of directors of such Person as a Principal Financial Officer for
purposes of this Agreement or any other Transaction Document). Any action taken or document delivered by a Principal Financial Officer pursuant to the Transaction Documents shall be taken or delivered in his capacity as such. 
  

 16 

 “Purchase” means a purchase by the Purchasers or the Swing Purchaser of a Receivable
Interest from the Seller pursuant to Article II. 
  
 “Purchasers” means the Initial Purchasers and each Assignee that shall become a party hereto pursuant to Section 9.1. 
  
 “Ratable Portion” or “ratably” means, with respect to any Purchaser, the percentage obtained by dividing (a) the
Commitment of such Purchaser by (b) the Total Commitments (or, at any time after the Termination Date, the percentage obtained by dividing the aggregate Capital Investments then owing to such Purchaser by the Capital then owing). 
  
 “Receivable” means the indebtedness (whether constituting
accounts or general intangibles or chattel paper or otherwise) of any Obligor under a Contract, and includes the right to payment of any interest or finance charges and other obligations of such Obligor with respect thereto, but excludes any such
indebtedness arising from the sale of goods or services originating outside of the United States. 
  
 “Receivable Asset Availability” means, at any time, (i) the sum of (x) the Net Receivables Pool Balance minus the Applicable Reserve in
effect at such time, plus (y) Cash Assets at such time, minus (ii) the aggregate Capital outstanding at such time. 
  
 “Receivables Excess Availability” means, at any time, the sum of (i) Available Capital plus (ii) Cash Assets at such time. Receivables
Excess Availability shall be determined, on a pro forma basis, based on the first monthly Seller Report delivered pursuant to Section 3.2(a)(i), to the extent required to be determined in respect of days prior to the Closing Date. 
  
 “Receivable Interest” means, at any time, an undivided
percentage ownership interest at such time in (a) all then outstanding Pool Receivables arising prior to the time of the most recent computation or recomputation of such undivided percentage interest pursuant to Section 2.5, (b) all Related Security
with respect to such Pool Receivables and (c) all Collections with respect to, and other proceeds of, such Pool Receivables. Such undivided percentage interest for such Receivable Interest shall be computed as: 
  
 C + AR 
 NRPB 
  
 where: 

 
 C = the outstanding Capital Investments made by the Purchasers or the
Swing Purchasers, as the case may be, in connection with such Receivable Interest at such time; 
  
 AR = the Purchaser’s or Swing Purchasers’ (as the case may be) Ratable Portion of the aggregate Applicable Reserve at such time; and 

 
 NRPB = the Net Receivables Pool Balance at such time; 
  
 provided, however, that upon the occurrence of the Termination Date, the Receivable
Interests then outstanding under this Agreement, if more than one Receivable Interest, shall be combined into one Receivable Interest hereunder (such one Receivable Interest, whether the one Receivable Interest then outstanding or the one Receivable
Interest resulting from such combination of Receivable Interests, being 
  

 17 

 the “Special Receivable Interest”) and such Special Receivable Interest shall be senior and prior to any
undivided percentage ownership interest held by the Seller in (and, for the avoidance of doubt, while the Special Receivable Interest is greater than zero, the Seller shall not be entitled to assert or enforce any claim in respect of such retained
undivided percentage ownership interest in) (i) all then outstanding Pool Receivables arising prior to the Termination Date, (ii) all Related Security with respect to such Pool Receivables and (iii) all Collections with respect to, and other
proceeds of, such Pool Receivables. 
  
 Each Receivable Interest shall be
determined from time to time pursuant to the provisions of Section 2.5. 
  
 “Receivables Pool” means at any time the aggregation of all then outstanding Receivables. 
  
 “Receivables Sale Agreement” means the Receivables Sale Agreement, dated as of the Closing Date, in substantially the form of Exhibit
D hereto, among each Originator, as seller and, if applicable, as buyer’s servicer, and Lyondell Funding, as buyer. 
  
 “Records” means, with respect to any Receivable, all Contracts and other documents, books, records and other information (including,
without limitation, computer programs, tapes, disks, punch cards, data processing software and related property and rights) relating to such Receivable and the related Obligor. 
  
 “Register” has the meaning specified in Section 9.2. 
  
 “Regulation U” means Regulation U of the Board, as the same
is from time to time in effect, and all official rulings and interpretations thereunder or thereof. 
  
 “Regulation X” means Regulation X of the Board, as the same is from time to time in effect, and all official rulings and interpretations
thereunder or thereof. 
  
 “Related Security”
means with respect to any Receivable: 
  
 (i)
all right, title and interest of the Seller in, under and to all security agreements and other Contracts that relate to such Receivable; 
  
 (ii) all of the Seller’s interest in the goods (including returned goods), if any, relating to the sale which gave rise to such
Receivable; 
  
 (iii) all other security
interests or liens and property subject thereto from time to time purporting to secure payment of such Receivable, whether pursuant to the Contract relating to such Receivable or otherwise, together with all financing statements signed by an Obligor
describing any collateral securing such Receivable; 
  
 (iv) all letter of credit rights, guarantees, insurance and other agreements or arrangements of whatever character from time to time supporting or securing payment of such Receivable, whether pursuant to the Contract relating to such
Receivable or otherwise; 
  
 (v) all Records
relating to such Receivable (subject, in the case of Records consisting of computer programs, data processing software and other intellectual property under license from third parties, to restrictions imposed by such license on the sublicensing or
transfer thereof); 
  

 18 

 (vi) all of the Seller’s right, title and interest in and to the following: (x) the
Receivables Sale Agreement, including, without limitation, (A) all rights to receive moneys due and to become due under or pursuant to the Receivables Sale Agreement, (B) all rights to receive proceeds of any indemnity, warranty or guaranty with
respect to the Receivables Sale Agreement, (C) claims for damages arising out of or for breach of or default under the Receivables Sale Agreement, and (D) the right to perform under the Receivables Sale Agreement and to compel performance and
otherwise exercise all remedies thereunder and (y) all lock-boxes to which Collections are sent and all Restricted Accounts, and all funds and investments therein; and 
  
 (vii) all proceeds of any and all of the foregoing (including, without limitation, proceeds which constitute
property of the types described in clause (vi) above). 
  
 “Required Net Receivables Pool Balance” means, at any time, the sum of (i) the Capital at such time plus (ii) the aggregate Applicable Reserve at such time. 
  
 “Required Purchasers” means, at any time, Purchasers holding more than 50% of the aggregate Total
Commitments or, after the Termination Date, more than fifty percent (50%) of the aggregate Capital at such time. 
  
 “Requirement of Law” means, with respect to any Person, the common law and all federal, state, local and foreign laws, rules and
regulations, orders, judgments, decrees and other determinations of any Governmental Authority or arbitrator, applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject. 
  
 “Reserve Percentage” means, as of the Closing Date, 15%,
provided that the Reserve Percentage may, upon five Business Days’ notice by the Agent to the Seller and the Servicer, be increased or, subject to Section 11.1, decreased by the Agent at any time in its Discretion. 
  
 “Responsible Officer” means the President and Chief
Executive Officer, any Executive Vice President, any Senior Vice President, the Treasurer or the Controller of Lyondell. Any action taken or document delivered by a Responsible Officer pursuant to the Transaction Documents shall be taken or
delivered in his capacity as such. 
  
 “Restricted
Accounts” means the Seller’s Account, the Lock-Box Accounts, the Concentration Account, the Sweep Account and the Cash Assets Account. 
  
 “S&P” means Standard & Poor’s Ratings Service. 
  
 “SEC” means the Securities and Exchange Commission. 
  
 “Security” means any Stock, Stock Equivalent, voting trust
certificate, bond, debenture, note or other evidence of Indebtedness, whether secured, unsecured, convertible or subordinated, or any certificate of interest, share or participation in, any temporary or interim certificate for the purchase or
acquisition of, or any right to subscribe to, purchase or acquire, any of the foregoing, but shall not include any evidence of the obligations of the Transaction Parties hereunder. 
  
 “Securitization Transaction” means (1) the transactions contemplated by the Transaction Documents or (2)
any transaction in which Lyondell or any Subsidiary sells or otherwise transfers an interest in accounts receivable not constituting Receivables (A) to one or more third party purchasers or (B) to a special purpose entity that borrows against such
accounts receivable or sells such accounts receivable to one or more third party purchasers, but only to the extent that amounts received in connection with the sale or other transfer of such accounts receivable would not under GAAP be accounted for
as liabilities on a consolidated balance sheet of Lyondell. 
  

 19 

 “Seller” has the meaning specified in the first paragraph of this Agreement. 

 
 “Seller Party” means the Seller or the Servicer.

  
 “Seller Report” means a report, in
substantially the form of Exhibit B hereto, furnished by the Servicer to the Agent for the benefit of each Purchaser pursuant to Section 5.5(f). 
  
 “Seller’s Account” means the Deposit Account of the Seller (account number 3756315059, ABA 111000012, Reference: Lyondell Funding
II, LLC/Multipurpose Account) maintained with Bank of America, N.A. at its office at 901 Main Street, Dallas, Texas 75202-3714, Attention: Sharon V. Hamm. 
  
 “Senior Notes” has the meaning specified in the Lyondell Undertaking. 
  
 “Senior Subordinated Notes” has the meaning specified in the Lyondell Undertaking. 
  
 “Servicer” has the meaning specified in Section 6.1.

  
 “Servicer Fee” has the meaning specified in
Section 2.11. 
  
 “Shortfall Condition” exists on
any day if the aggregate Receivable Interests on such day would exceed 100% (after giving effect to any calculated reduction of Capital by an amount equal to the amount on deposit in the Cash Assets Account as of the close of business on such day
pursuant to Section 2.6(a)(iii) or 2.7(a)(iii), as applicable). 
  
 “Solvent” means, with respect to any Person as of any date of determination, that, as of such date, (a) the fair value of the assets of such Person, at a fair valuation, will exceed its debts and liabilities, subordinated,
contingent or otherwise, (b) the present fair saleable value of the property of such Person will be greater than the amount that will be required to pay the probable liability of its debts and other liabilities, subordinated, contingent or
otherwise, as such debts and other liabilities become absolute and matured, (c) such Person is able to pay all liabilities of such Person as such liabilities mature and (d) such Person does not have unreasonably small capital with which to conduct
the business in which it is engaged as such business is now conducted and is proposed to be conducted following the Closing Date. In computing the amount of contingent or unliquidated liabilities at any time, such liabilities shall be computed at
the amount that, in light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability. 
  
 “Special Receivable Interest” has the meaning specified in the definition of “Receivable
Interest” contained in this Section 1.1. 
  
 “Stock” means shares of capital stock (whether denominated as common stock or preferred stock), beneficial, partnership or membership interests, participations or other equivalents (regardless of how designated) of or in a
corporation, partnership, limited liability company or equivalent entity, whether voting or non-voting. 
  
 “Stock Equivalents” means all securities convertible into or exchangeable for Stock and all warrants, options or other rights to purchase
or subscribe for any Stock, whether or not presently convertible, exchangeable or exercisable. 
  

 20 

 “Subordinated Note” has the meaning specified in the Receivables Sale Agreement.

  
 “Subsidiary” means, as to any Person, any
corporation or other entity of which securities or other ownership interests having ordinary voting power to elect a majority of the board of directors or other persons performing similar functions are at the time directly or indirectly owned by
such Person. Unless otherwise specified, “Subsidiary” (i) means a Subsidiary of Lyondell and (ii) does not, except where otherwise specifically indicated, include any Lyondell Joint Venture. 
  
 “subsidiary” means, with respect to any Person (the
“parent”), any corporation, association or other business entity of which Securities or other ownership interests representing 50% or more of the ordinary voting power are, at the time as of which any determination is being made,
beneficially owned by the parent, by one or more subsidiaries of the parent or by the parent and one or more subsidiaries of the parent. 
  
 “Super Majority Purchasers” means at any time Purchasers holding more than 66 2/3% of the aggregate Total Commitments or, after the
Termination Date, more than 66 2/3% of the aggregate Capital outstanding at such time. 
  
 “Sweep Account” means the Deposit Account of the Seller (account number 30553431, ABA 021000089, Reference: Lyondell Funding II, LLC/ Sweep) maintained with Citibank at its office at 388 Greenwich
Street, New York, New York 10013, Attention: David Jaffe, or such other account as the Seller and the Agent may agree. 
  
 “Swing Purchase” has the meaning specified in Section 2.3. 
  
 “Swing Purchase Request” has the meaning specified in Section 2.3(b). 
  
 “Swing Purchase Sublimit” means, at any time, $35,000,000.

  
 “Swing Purchaser” means CUSA or any other
Purchaser that becomes the Agent or agrees, with the approval of the Agent and the Seller, to act as the Swing Purchaser hereunder, in each case in its capacity as the Swing Purchaser hereunder. 
  
 “Syndication Completion Date” has the meaning specified in
the Underwriting Fee Letter dated November 12, 2003 between Lyondell and Citigroup Global Markets Inc. 
  
 “Taxes” has the meaning specified in Section 2.14(a). 
  
 “Termination Date” means the earlier of (i) the Commitment Termination Date, and (ii) the date of
termination in whole of the aggregate Commitments pursuant to Section 2.4 or 7.1. 
  
 “Total Asset Availability” means, at any time, the sum of (i) Receivable Asset Availability plus (ii) CA Excess Availability, in each case at such time. 
  
 “Total Commitments” means the aggregate of all Commitments
of all Purchasers, as such amount may be reduced from time to time pursuant to Section 2.4. On the Closing Date, the Total Commitments aggregate $100,000,000. 
  

“Total Excess Availability” means, at any time, the sum of (i) Receivables Excess Availability plus (ii) CA Excess Availability at
such time. 
  

 21 

 “Transaction Documents” means this Agreement, the Receivables Sale Agreement, each
Subordinated Note, the Lyondell Undertaking, the Lock-Box Agreements, the Consent and Agreement, the Intercreditor Agreement, and each additional security or control documentation delivered or required to be delivered pursuant to any of the
foregoing to evidence the interests of the Seller and of Agent and the Purchasers, as applicable, in and to the Restricted Accounts, Receivables, Related Security, Collections and proceeds thereof. 
  
 “Transaction Parties” means the Seller, each Originator and
the Servicer (if the Servicer is Lyondell or an Affiliate or Subsidiary of Lyondell). 
  
 “Triggering Event” means any of the following events: (i) the Termination Date, (ii) the occurrence of an Event of Termination, (iii) Total Asset Availability being less than $150,000,000 for any
period of five consecutive Business Days, (iv) Total Excess Availability being less than $100,000,000 for any period of five consecutive Business Days or (v) Total Asset Availability being less than $125,000,000 on any day; provided that if,
following a Triggering Event described in clause (iii), (iv) or (v), Total Asset Availability subsequently equals or exceeds $175,000,000 for a period of 20 consecutive Business Days, such Triggering Event shall cease to exist upon the first day
following such 20-Business Day period (unless the Servicer otherwise elects by notice to the Agent); and provided, further, that if, following a Triggering Event described in clause (ii), the related Event of Termination shall cease to
exist, such Triggering Event shall cease to exist. For the avoidance of doubt, the cessation of an existing Triggering Event does not preclude the occurrence of a subsequent Triggering Event. 
  
 “UCC” means, at any time, the Uniform Commercial Code as
from time to time in effect in the State of New York at such time; provided, however, that in the event that, by reason of mandatory provisions of law, the perfection, effect of perfection or non-perfection or priority of the interests
of the Agent or the Purchasers in the Pool Receivables, Related Security and Collections created by the Transaction Documents is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of New York, the term
“UCC” shall mean the Uniform Commercial Code as in effect in such other jurisdiction for purposes of the provisions hereof relating to such perfection, effect of perfection or non-perfection or priority. 
  
 “Unapplied Cash and Credits” means, at any time, the
aggregate amount of Collections or other cash or credits then held by or for the account of the Servicer, any Originator or the Seller in respect of the payment of Pool Receivables, but not yet applied or reinvested pursuant to Section 2.6 or
Section 2.7 or applied pursuant to Section 2.8. 
  
 “United States” and “U.S.” each means United States of America. 
  
 “Unused Commitment Fee” has the meaning specified in Section 2.11. 
  
 “U.S. Dollars” and “$” each means the lawful currency of the United States. 
  
 “Voting Control” means with respect to any Security the
right to exercise, or to direct the exercise of, the voting rights of a holder of such security; provided that a Person shall not be deemed to have Voting Control of shares of common stock of Lyondell if such Person is or such shares are
subject to a valid contract arrangement whereby such shares are voted as directed by the board of directors of Lyondell and/or in the same proportions as all other shares of common stock of Lyondell are voted. 
  
 “Welfare Plan” means a welfare plan, as defined in Section
3(1) of ERISA. 
  

 22 

 “Yield” means (a) for each Capital Investment made at the Applicable LIBO Rate, for any
Yield Period: 
  

			
	 AR x C x ED    +
	 	LC
	                 360
	 	 

  
 where: 
  

					
	 AR
	  	=	  	the Applicable LIBO Rate for such Capital Investment for such Yield Period;
			
	 C
	  	=	  	the amount of such Capital Investment;
			
	 ED
	  	=	  	the actual number of days elapsed during such Yield Period; and
			
	 LC
	  	=	  	all Liquidation Costs, if any, for such Receivable Interest for such Yield Period; and
	  
 (b) for each
Capital Investment made at the Applicable Base Rate for any period of time:

  

	
	AR x C x
ED                                    
	360                                    

  
 where: 
  

					
	 AR
	  	=	  	the Applicable Base Rate from time to time;
			
	 C
	  	=	  	the amount of such Capital Investment; and
			
	 ED
	  	=	  	the actual number of days elapsed;

  
 provided, that no provision of
this Agreement shall require the payment or permit the collection of Yield in excess of the maximum permitted by applicable law; provided, further, that Yield for any Capital Investment shall not be considered paid by any distribution to the
extent that at any time all or a portion of such distribution is rescinded or must otherwise be returned for any reason. 
  
 “Yield and Fee Reserve” means, as of any date of determination an amount in U.S. Dollars equal to the sum of (A) the Servicer Fee accrued
and unpaid through such date, (B) the aggregate Yield, Unused Commitment Fee and Agent’s Fee accrued and unpaid through such date and (C) the aggregate of any other Obligations then accrued and owing hereunder by the Seller to the Purchasers or
the Agent. 
  
 “Yield Period” means, in the case
of any Capital Investment made at the Adjusted LIBO Rate, (a) initially, the period commencing on the date such Capital Investment is made or on the date of conversion of a Capital Investment made at the Alternate Base Rate to a Capital Investment
made at the Adjusted LIBO Rate and ending on the seventh day thereafter (if at the time of the relevant Notice of Purchase, all Purchasers participating therein agree to make a seven-day Yield Period available) or one, two, three or six months
thereafter, as selected by the Seller in its Notice of Purchase and (b) thereafter, if such Capital Investment is continued, in whole or in part, as a Capital Investment made at the Adjusted LIBO Rate, a period commencing on the last day of the
immediately preceding Yield Period therefor and ending on the seventh day thereafter (if at the time of the relevant Notice of Conversion or Continuation, all Purchasers participating therein agree to make a seven-day Yield Period available) or one,
two, three or six months thereafter, as selected by the Seller in its Notice of Conversion or Continuation given to the Agent; provided, however, that all of the foregoing provisions relating to Yield Periods in respect of Capital Investment
made at the Adjusted LIBO Rates are subject to the following: 
  
 (a) prior to the Syndication Completion Date, each Yield Period shall be for a period of seven days and all Yield Periods shall commence and end on the same day; 
  

 23 

 (b) if any Yield Period would otherwise end on a day that is not a Business Day, such
Yield Period shall be extended to the next succeeding Business Day, unless the result of such extension would be to extend such Yield Period into another calendar month, in which event such Yield Period shall end on the immediately preceding
Business Day; 
  
 (c) any Yield Period that
begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Yield Period) shall end on the last Business Day of a calendar month; 
  
 (d) the Seller may not select any Yield Period that ends
after the Commitment Termination Date; and 
  
 (e) there shall be outstanding at any one time no more than 10 Yield Periods in the aggregate. 
  
 Section 1.2 Other Terms. 
  
 (a) Except as otherwise expressly provided herein, all terms of an accounting or financial nature shall be construed in accordance with GAAP, as in effect
from time to time; provided that if any Transaction Party notifies the Agent that it requests an amendment to any provision hereof to eliminate the effect of any change occurring after the date hereof in GAAP or in the application thereof on
the operation of such provision (or if the Agent notifies the Transaction Parties that the Required Purchasers request an amendment to any provision hereof for such purpose), then such provision shall be interpreted on the basis of GAAP as in effect
and applied immediately before such change shall have become effective until such notice shall have been withdrawn or such provision amended in accordance herewith. 
  
 (b) Except where the context requires otherwise, the definitions in Section 1.1 shall apply equally to the singular and
plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include”, “includes” and “including”
shall be deemed to be followed by the phrase “without limitation”. Unless otherwise stated, references to Sections, Articles, Schedules and Exhibits made herein are to Sections, Articles, Schedules or Exhibits, as the case may be,
of this Agreement. “Writing”, “written” and comparable terms refer to printing, typing and other means of reproducing words in a visible form. References to any agreement or contract are to such agreement or
contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of such Person. 
  
 (c) All terms used in Article 9 of the UCC in the State of New York and not
specifically defined herein are used herein as defined in such Article 9. 
  

 24 

 Section 1.3 Computation of Time Periods. 
  
 Unless otherwise stated in this Agreement, in the computation of a period of
time from a specified date to a later specified date, the word “from” means “from and including”, the words “to” and “until” each means “to but excluding” and the
word “through” means “through and including”. 
  
 ARTICLE II 
  
 AMOUNTS AND TERMS OF THE PURCHASES 
  
 Section 2.1 Commitment. 
  
 On the terms and conditions herein set forth, each Purchaser severally agrees to make Purchases (i) on the Closing Date and from time to time thereafter
on any Business Day during the period from the Closing Date to the Termination Date and (ii) in an aggregate amount for such Purchaser not to exceed at any time outstanding such Purchaser’s Commitment; provided, however, that no
Purchaser shall be obligated to make any Purchase to the extent that, after giving effect to such Purchase, the Capital then outstanding would exceed the Maximum Capital. Purchases shall be made by the Purchasers simultaneously and ratably in
accordance with their respective Commitments. 
  
 Section 2.2 Making Purchases. 
  
 (a) Each
Purchase of a Receivable Interest by the Purchasers shall be made on notice from the Seller to the Agent, given not later than 11:00 a.m. (New York time) (i) on the third Business Day before the date of such Purchase in the case of the Purchase of
any Receivable Interest initially bearing Yield at the Applicable LIBO Rate and (ii) on the Business Day of such Purchase in the case of the Purchase of any Receivable Interest initially bearing Yield at the Applicable Base Rate. Each such notice of
a proposed Purchase of a Receivable Interest (a “Notice of Purchase”) shall be by telephone (confirmed promptly thereafter in writing) or facsimile, in substantially the form of Exhibit F hereto, and shall specify the requested
aggregate amount of such Purchase to be paid to the Seller and the requested Business Day of such Purchase. Each Purchase of any Receivable Interest under this Section 2.2 shall be in an aggregate amount which is an integral multiple of $1,000,000
and which is not less than the lesser of $10,000,000 and the remaining available balance of the Commitments. 
  
 (b) The Agent shall give each Purchaser prompt notice of such notice of such proposed Purchase, the date of such Purchase, and the amount of such
Purchaser’s Capital Investment in connection with such Purchase, by telephone or telefax. On the date of such Purchase, each Purchaser shall, upon satisfaction of the applicable conditions set forth in Section 3.2, make available to the Agent
its Ratable Portion of the aggregate amount of such Purchase by deposit of such Ratable Portion in same day funds to the Agent’s Account, and, after receipt by the Agent of such funds, the Agent shall cause such funds to be made immediately
available to the Seller at the Seller’s Account. 
  
 (c) Each
Notice of Purchase delivered pursuant to Section 2.2(a) shall be irrevocable and binding on the Seller. 
  
 (d) Unless the Agent shall have received notice from a Purchaser prior to the date of any Purchase that such Purchaser will not make available to the
Agent such Purchaser’s Ratable Portion of such Purchase, the Agent may assume that such Purchaser has made such Ratable Portion available to the Agent on the date of such Purchase in accordance with Section 2.2(b), and the Agent may, in
reliance upon such assumption, make available to the Seller on such date a corresponding amount. However, if the Agent has received such notice from such Purchaser, the Agent may not make such assumption and 
  

 25 

 may not make available to the Seller on such date such corresponding amount. If and to the extent that such Purchaser
(other than a Purchaser that has delivered to the Agent a notice of the type described in the two immediately preceding sentences) shall not have made such Ratable Portion available to the Agent and the Agent has made such Ratable Portion available
to the Seller, such Purchaser and the Seller severally agree to pay (to the extent not repaid by the Seller or such Purchaser, respectively) to the Agent promptly on demand such corresponding amount together with interest thereon, for each day from
the date such amount is made available to the Seller until the date such amount is repaid to the Agent, at (i) in the case of the Seller, the Yield applicable to such amount and (ii) in the case of such Purchaser, the Federal Funds Rate. If such
Purchaser shall repay to the Agent such corresponding amount, such amount so repaid shall constitute such Purchaser’s Ratable Portion of such Purchase for purposes of this Agreement. 
  
 (e) The failure of any Purchaser to make available such Purchaser’s Ratable Portion of any Purchase shall not relieve
any other Purchaser of its obligation, if any, hereunder to make available such other Purchaser’s Ratable Portion of such Purchase on the date of such Purchase, but no Purchaser shall be responsible for the failure of any other Purchaser to
make available such other Purchaser’s Ratable Portion of such Purchase on the date of any Purchase. Nothing herein shall prejudice any rights that the Seller may have against any Purchaser as a result of any default by such Purchaser hereunder.

  
 Section 2.3 Swing Purchases

  
 (a) On the terms and subject to the conditions
contained in this Agreement, the Swing Purchaser agrees to make, in U.S. Dollars, Purchases (each a “Swing Purchase”) otherwise committed to the Seller hereunder from time to time on any Business Day during the period from the
Closing Date until the Termination Date representing an aggregate Capital Investment at any time outstanding (together with the aggregate outstanding Capital Investment relating to any other Purchase made by the Swing Purchaser hereunder in its
capacity as the Swing Purchaser) not to exceed the Swing Purchase Sublimit; provided, however, that at no time shall the Swing Purchaser make any Swing Purchase to the extent that, after giving effect to such Swing Purchase, the
Capital then outstanding would exceed the Maximum Capital. 
  
 (b)
In order to request a Swing Purchase, the Seller may telephone the Agent (to be promptly confirmed thereafter in writing) or send the Agent by telecopy (or by electronic mail or similar means) a duly completed request in substantially the form of
Exhibit G, setting forth the requested amount and date of such Swing Purchase (a “Swing Purchase Request”), to be received by the Agent not later than 12:00 p.m. (New York time) on the day of the proposed purchase. The Agent shall
promptly notify the Swing Purchaser of the details of the requested Swing Purchase. Subject to the terms of this Agreement, the Swing Purchaser may make the Capital Investment in connection with such Swing Purchase available to the Agent and, in
turn, the Agent shall make such amounts available to the Seller on the date of the relevant Swing Purchase Request. The Swing Purchaser shall not make any Swing Purchase in the period commencing on the first Business Day after it receives written
notice from the Agent or any Purchaser that one or more of the conditions precedent contained in Section 3.2 shall not on such date be satisfied, and ending when such conditions are satisfied. The Swing Purchaser shall not otherwise be required to
determine that, or take notice whether, the conditions precedent set forth in Section 3.2 have been satisfied in connection with the making of any Swing Purchase. The Capital Investment relating to each Swing Purchase shall be in an aggregate amount
of not less than $100,000. 
  
 (c) The Swing Purchaser shall
notify the Agent in writing (which writing may be a telecopy or electronic mail) weekly, by no later than 10:00 a.m. (New York time) on the first Business Day of each week, of the aggregate amount of its Capital Investments at such time in respect
of Swing Purchases. 
  

 26 

 (d) The Swing Purchaser may demand at any time that each Purchaser pay to the Agent, for the account of
the Swing Purchaser, in the manner provided in clause (e) below, such Purchaser’s Ratable Portion of all or a portion of the Swing Purchaser’s Capital Investments at such time in respect of Swing Purchases, which demand shall be made
through the Agent, shall be in writing and shall specify the amount of the Capital Investments demanded to be so reduced; provided that if the aggregate amount of the Swing Purchaser’s Capital Investments in respect of Swing Purchases on
the last Business Day of any week exceeds $5,000,000, then the Swing Purchaser shall make such demand to the Agent on such last Business Day of such week and require each Purchaser to pay to the Agent, for the account of the Swing Purchaser, on such
last Business Day of such week such Purchaser’s Ratable Portion of the Swing Purchaser’s Capital Investments in respect of Swing Purchases then outstanding. 
  
 (e) The Agent shall forward each notice referred to in clause (c) above and each demand referred to in clause (d) above to
each Purchaser on the day such notice or such demand is received by the Agent (except that any such notice or demand received by the Agent after 2:00 p.m. (New York time) on any Business Day or any such demand received on a day that is not a
Business Day shall not be required to be forwarded to the Purchasers by the Agent until the next succeeding Business Day), together with a statement prepared by the Agent specifying the amount of each Purchaser’s Ratable Portion of the
aggregate amount of the Capital Investments in respect of Swing Purchases stated to be outstanding in such notice or demanded to be paid pursuant to such demand, and, notwithstanding whether or not the conditions precedent set forth in Section 3.2
and Section 2.1 shall have been satisfied (which conditions precedent the Purchasers hereby irrevocably waive), each Purchaser shall, before 12:00 noon (New York time) on the Business Day next succeeding the date of such Purchaser’s receipt of
such notice or demand, make available to the Agent, in immediately available funds, for the account of the Swing Purchaser, the amount specified in such statement; provided, however, that notwithstanding anything to the contrary in the
foregoing, no Purchaser shall be obligated to purchase a Ratable Portion of, or otherwise pay any sum in respect of, the Capital Investments in respect of a Swing Purchase to the extent that the purchase by such Purchaser of a Ratable Portion of, or
payment of other sum in respect of, the Capital Investments in respect of such Swing Purchase would cause such Purchaser’s aggregate Capital Investment to exceed its Commitment. Upon such purchase by a Purchaser, such Purchaser shall, except as
provided in clause (f), be deemed to have made a Purchase with a Capital Investment equal to the amount actually paid by such Purchaser. The Agent shall use such funds to reduce the Swing Purchaser’s Capital Investments in respect of Swing
Purchases. 
  
 (f) Upon the occurrence of an Event of Termination
under Section 7.1(f), each Purchaser shall acquire, without recourse or warranty, an undivided participation in the Swing Purchaser’s Capital Investments in respect of each Swing Purchase otherwise required to be repaid by such Purchaser
pursuant to clause (e) above, which participation shall be in an amount equal to such Purchaser’s Ratable Portion of the Swing Purchaser’s Capital Investments in respect of such Swing Purchase, by paying to the Swing Purchaser on the date
on which such Purchaser would otherwise have been required to make a payment in respect of such Swing Purchaser’s Capital Investments pursuant to clause (e) above, in immediately available funds, an amount equal to such Purchaser’s Ratable
Portion of such Swing Purchaser’s Capital Investments. If all or part of such amount is not in fact made available by such Purchaser to the Swing Purchaser on such date, the Swing Purchaser shall be entitled to recover any such unpaid amount on
demand from such Purchaser together with interest accrued from such date at the Federal Funds Rate for the first Business Day after such payment was due and thereafter at the Applicable Base Rate. 
  
 (g) From and after the date on which any Purchaser (i) is deemed to have made
a Purchase pursuant to clause (e) above with respect to any Swing Purchase or (ii) purchases an undivided participation interest in the Swing Purchaser’s Capital Investments in respect of a Swing Purchase pursuant to clause (f) above, the Swing
Purchaser shall promptly distribute to such Purchaser such 
  

 27 

 Purchaser’s Ratable Portion of all payments in respect of Capital Investments and Yield received by the Swing
Purchaser on account of such Swing Purchase other than those received from a Purchaser pursuant to clause (e) or (f) above. 
  
 Section 2.4 Termination or Reduction of the Commitments; Voluntary Reductions of Capital. 
  
 (a) The Seller may, upon at least 3 Business Days’ notice to the Agent,
and so long as, after giving effect to a proposed reduction, no Event of Termination or Potential Event of Termination, would exist, terminate in whole or reduce in part, the unused portions of the Commitments of the Purchasers; provided,
however, that for purposes of this Section 2.4, the unused portions of the Commitments of the Purchasers shall be computed as (a) the Total Commitments immediately prior to giving effect to such termination or reduction less (b) the
outstanding Capital at the time of such computation; provided, further, that each such partial reduction of the unused portions of the Commitments (x) shall be in an amount equal to at least $5,000,000 and shall be an integral multiple
of $1,000,000 in excess thereof, (y) shall be made ratably among the Purchasers’ Commitments according to each Purchaser’s Ratable Portion and (z) shall reduce the Total Commitments in an amount equal to each such reduction. 
  
 (b) The Seller may, upon at least 3 Business Days’ notice to the Agent,
reduce the outstanding Capital in whole or in part; provided that each such partial reduction of Capital shall be in a minimum amount of $5,000,000 and an integral multiple of $1,000,000. 
  
 Section 2.5 Receivable Interest. 
  
 (a) On the date of Purchase of any Receivable Interest, such Receivable
Interest shall be initially computed, after giving effect to such Purchase, as of the close of business of the Servicer on such date. Thereafter until the Termination Date, such Receivable Interest shall be automatically recomputed as of the close
of business of the Servicer on each day (other than a Liquidation Day). 
  
 (b) Such Receivable Interest shall remain constant from the time as of which any such computation or recomputation is made until the time as of which the next such recomputation, if any, shall be made. Each Receivable Interest, as computed
as of the day immediately preceding the Termination Date, shall remain constant at all times on and after the Termination Date; and any Special Receivable Interest, as computed as of the Termination Date, shall remain constant at all times on and
after the Termination Date. 
  
 (c) Such Receivable Interest shall
become zero at such time as the Purchasers of such Receivable Interest shall have received the accrued Yield for such Receivable Interest, shall have recovered the Capital Investment of such Receivable Interest, and shall have received payment of
all other amounts payable by the Seller to such Purchasers, and the Servicer shall have received the accrued Servicer Fee for such Receivable Interest. 
  
 Section 2.6 Ordinary Settlement Procedures. 
  
 (a) On each Business Day (other than a Liquidation Day or a day on which a Triggering Event exists) the Servicer shall, out
of Collections of Pool Receivables received on such Business Day: 
  
 (i) first, pay to the Servicer (if the Servicer is not Lyondell or an Affiliate or Subsidiary of Lyondell) or the Agent and the Purchasers, as applicable, an amount in U.S. Dollars equal to the Servicer Fee, the
Yield, the Unused Commitment Fee, the Agent’s Fee and any other Obligations of the Seller due and payable on such day; 
  

 28 

 (ii) second, distribute to the Agent for the account of the Swing Purchaser an
amount in U.S. Dollars equal to that amount, if any, then required to be applied to reduce the Swing Purchaser’s Capital Investments in respect of Swing Purchases to zero; 
  
 (iii) third, if such day is the second Business Day following the date on which a Seller Report is or is
required to be delivered, a Shortfall Condition exists as of the last day of the period covered by such Seller Report, and the Agent does not receive an updated Seller Report demonstrating that a Shortfall Condition does not exist on such second
Business Day, distribute to the Agent for the account of the Purchasers an amount in U.S. Dollars equal to that amount, if any, which would be required to reduce Capital so that the aggregate Receivable Interests would not, after giving effect to
such application and the Collections of Pool Receivables and the addition of new Pool Receivables on such day and the resulting automatic recomputation of such Receivable Interests pursuant to Section 2.5 as of the end of such day, exceed 100%;
provided that (x) the Agent shall apply such amount, first, to reduce all Capital Investments as to which Yield is determined on the basis of the Adjusted Base Rate and (y) second, to reduce all Capital Investments as to which Yield is
determined on the basis of the Adjusted LIBO Rate; provided that in lieu of immediately reducing the Capital Investments as to which Yield is determined on the basis of the Adjusted LIBO Rate, the Agent, at the direction of the Seller, may
transfer such amount to the Cash Assets Account and such amount shall be deemed to reduce Capital by the amount so held pending application thereof to reduce Capital Investments as to which Yield is calculated on the basis of the Adjusted LIBO Rate
on the last day of each Yield Period applicable thereto (occurring in chronological order); provided, further, however, that if the Agent subsequently receives a request from the Servicer for a withdrawal of all or a portion of
such amounts that are then held in the Cash Assets Account and a Seller Report demonstrating that a Shortfall Condition, after giving effect to such requested withdrawal, does not exist, then the Agent shall release such amounts to the Servicer for
further application under this Section 2.6(a); 
  
 (iv) fourth, distribute to the Agent for the account of the Purchasers of each Receivable Interest an amount in U.S. Dollars equal to that amount, if any, then required to be applied to reduce the Capital Investment of such Receivable
Interest pursuant to the notice of the Seller delivered under Section 2.4(b); 
  
 (v) fifth, distribute to the Agent for deposit into the Cash Assets Account such amount as the Seller, at its option, has specified to the Agent, which amount shall be deemed to reduce Capital by a corresponding
amount; provided, however, that if the Agent subsequently receives a request from the Servicer for a withdrawal of all or a portion of such amounts that are then held in the Cash Assets Account and a Seller Report demonstrating that a
Shortfall Condition, after giving effect to such requested withdrawal, does not exist, then the Agent shall release such amounts to the Servicer for further application under this Section 2.6(a). 
  
 (vi) sixth, distribute to the Servicer (if the Servicer is
Lyondell or an Affiliate or Subsidiary of Lyondell) the accrued Servicer Fee to the extent then due and payable; and 
  

 29 

 (vii) seventh, reinvest the remainder of such Collections, for the benefit of the
Purchasers, which reinvestment shall result in (x) an automatic recomputation of the undivided percentage interest represented by such Receivable Interest pursuant to Section 2.5 as of the end of such day and (y) the payment of such remainder to the
Seller; provided, however, that to the extent the Agent or any Purchaser shall be required for any reason to pay over any amount representing Collections which have been previously reinvested for the benefit of such Purchaser pursuant
hereto, such amount shall be deemed not to have been so reinvested but rather to have been retained by the Seller and paid over for the account of such Purchaser and, notwithstanding any provision herein to the contrary, such Purchaser shall have a
claim for such amount; 
  
 provided, however, that if sufficient funds are
not available to fund all payments to be made in respect of any amounts described in any of clauses second, third, fourth, fifth and sixth above, the available funds being applied with respect to any such amounts (unless otherwise specified in such
clause) shall be allocated to the payment of the amounts referred to in such clause ratably, based on the proportion of the Servicer’s, the Agent’s or the Purchasers’ interest in the aggregate outstanding amounts described in such
clause. 
  
 (b) Subject to Section 2.6 and Section 2.7, all
amounts in the Concentration Account shall be automatically transferred to the Seller’s Account, and payments and distributions by the Servicer pursuant to Section 2.6(a) shall be made from funds so transferred to the Seller’s Account.

  
 Section 2.7 Triggering Event Settlement
Procedures. 
  
 (a) On each Business Day (other than a
Liquidation Day) on which a Triggering Event exists, the Agent (and not the Servicer) shall, out of Collections of Pool Receivables received on such Business Day: 
  
 (i) first, pay to the Servicer (if the Servicer is not Lyondell or an Affiliate or Subsidiary of Lyondell),
the Agent and the Purchasers, as applicable, an amount in U.S. Dollars equal to the Servicer Fee, the Yield, the Unused Commitment Fee, the Agent’s Fee and any other Obligations of the Seller due and payable on such day; 
  
 (ii) second, distribute to the Swing Purchaser an amount in
U.S. Dollars necessary to reduce the Swing Purchaser’s Capital Investments in respect of Swing Purchases to zero; 
  
 (iii) third, distribute to the Purchasers an amount in U.S. Dollars necessary to reduce all Capital Investments to zero as follows: (1)
first, to reduce all Capital Investments as to which Yield is determined on the basis of the Adjusted Base Rate and (2) second, to reduce all Capital Investments as to which Yield is determined on the basis of the Adjusted LIBO Rate, provided
that in lieu of immediately reducing the Capital Investments as to which Yield is determined on the basis of the Adjusted LIBO Rate, the Agent, at the direction of the Seller, may transfer such amount to the Cash Assets Account and such amount shall
be deemed to reduce Capital by the amount so held pending application thereof to reduce Capital Investments as to which Yield is calculated on the basis of the Adjusted LIBO Rate on the last day of each Yield Period applicable thereto (occurring in
chronological order); provided, further, however, that if the Agent subsequently receives a request from the Servicer or the Seller for a withdrawal of all or a portion of such amounts that are then held in the Cash Assets
Account and either (I) the Agent receives a Seller Report demonstrating that a Shortfall Condition does not exist 
  

 30 

 and certifying that either the conditions to an Investment Event would be satisfied or a Triggering Event
does not exist, in each case after giving effect to such requested withdrawal, or (II) the aggregate Capital is zero, then the Agent shall release such amounts for reinvestment and payment to the Seller; 
  
 (iv) fourth, distribute to the Purchasers of each Receivable
Interest an amount in U.S. Dollars equal to that amount, if any, then required to be applied to reduce the Capital Investment of such Receivable Interest pursuant to the notice of the Seller delivered under Section 2.4(b); 
  
 (v) fifth, deposit into the Cash Assets Account such amount
as the Seller, at its option, has specified to the Agent, which amount shall be deemed to reduce Capital (to the extent of any Capital then outstanding) by a corresponding amount; provided, however, that if the Agent subsequently
receives a request from the Servicer or the Seller for a withdrawal of all or a portion of such amounts that are then held in the Cash Assets Account and a Seller Report demonstrating that a Shortfall Condition does not exist and certifying that
either (x) the conditions to an Investment Event would be satisfied or (y) a Triggering Event ceases to exist, in each case after giving effect to such requested withdrawal, then the Agent shall release such amounts for further application under
this Section 2.7(a); 
  
 (vi) sixth, distribute
to the Servicer (if the Servicer is Lyondell or an Affiliate or Subsidiary of Lyondell) the accrued Servicer Fee to the extent then due and payable; and 
  
 (vii) seventh, reinvest the remainder of such Collections, for the benefit of the Purchasers, which reinvestment shall result in (x) the
automatic recomputation of the undivided percentage interest represented by such Receivable Interest pursuant to Section 2.5 as of the end of such day and (y) the payment of such remainder to the Seller; provided, however, that to the
extent the Agent or any Purchaser shall be required for any reason to pay over any amount representing Collections which have been previously reinvested for the benefit of such Purchaser pursuant hereto, such amount shall be deemed not to have been
so reinvested but rather to have been retained by the Seller and paid over for the account of such Purchaser and, notwithstanding any provision herein to the contrary, such Purchaser shall have a claim for such amount; 
  
 provided, however, that if sufficient funds are not available to fund all
payments to be made in respect of any amounts described in any of clauses first, second, third, fourth, fifth and sixth above, the available funds being applied with respect to any such amounts (unless otherwise specified in such clause) shall be
allocated to the payment of the amounts referred to in such clause ratably, based on the proportion of the Servicer’s, the Agent’s or the Purchasers’ interest in the aggregate outstanding amounts described in such clause. 

 
 (b) During the existence of a Triggering Event (other than on a
Liquidation Day), all amounts in the Concentration Account shall be automatically transferred to the Sweep Account, and payments and distributions by the Agent pursuant to Section 2.7(a) shall be made from funds in the Sweep Account. 
  

 31 

 Section 2.8 Liquidation Settlement Procedures. 
  
 On each Liquidation Day, the Agent shall transfer to the Sweep Account the
Collections of Pool Receivables received on such day, and the Agent shall apply such Collections, and all amounts held in the Cash Assets Account, as follows: 
  

(i) first, to pay Obligations of the Seller to the Agent under any Transaction Document in respect of any expense reimbursements, Cash
Management Obligations or indemnities then due to the Agent; 
  
 (ii) second, to pay Obligations of the Seller to the Purchasers under any Transaction Document in respect of any expense reimbursements or indemnities then due to such Persons; 
  
 (iii) third, to the Servicer (if the Servicer is not
Lyondell or an Affiliate or Subsidiary of Lyondell) in payment of the accrued Servicer Fee then due and payable, and to the Purchasers in payment of the accrued Unused Commitment Fees then due and payable; 
  
 (iv) fourth, to the Purchasers in payment of the accrued
Yield then due and payable; 
  
 (v) fifth, to the
Purchasers in reduction (to zero) of the Capital Investments in respect of each Receivable Interest; 
  
 (vi) sixth, to the Purchasers in ratable payment of any other Obligations owed by the Seller hereunder or under any other Transaction
Document (except for the Servicer Fee); 
  
 (vii)
seventh, to the Servicer (if the Servicer is Lyondell or an Affiliate or Subsidiary of Lyondell) in payment of the accrued Servicer Fee then due and payable; and 
  
 (viii) to the extent of any remainder, to the Seller; 
  
 provided, however, that if sufficient funds are not available to fund all payments to
be made in respect of any amounts described in any of clauses first, second, third, fourth, fifth, sixth and seventh above, the available funds being applied with respect to any such amounts (unless otherwise specified in such clause) shall be
allocated to the payment of the amounts referred to in such clause ratably, based on the proportion of the Servicer’s, the Agent’s or the Purchasers’ interest in the aggregate outstanding amounts described in such clause. 

 
 Section 2.9 General Settlement Procedures.

  
 (a) Except as set forth in clauses (a) and (b) below
or as otherwise required by law or the underlying Contract, all Collections received from an Obligor of any Pool Receivable shall be applied to Pool Receivables then outstanding of such Obligor in the order of the age of such Pool Receivables,
starting with the oldest such Pool Receivable, except if payment is designated by such Obligor for application to specific Pool Receivables. 
  

 32 

 (b) If, on any day, the Outstanding Balance of a Pool Receivable is either (x) reduced as a result of any
defective, rejected or returned goods or services, any discount, or any adjustment by the Seller or any Originator, or (y) reduced or cancelled as a result of a setoff in respect of any claim by the Obligor thereof against the Seller or any
Originator (whether such claim arises out of the same or a related transaction or an unrelated transaction), the Seller shall be deemed to have received on such day a Collection of such Receivable in the amount of such reduction or cancellation and
shall make the payment required to be made by it in connection with such Collection on the day required by, and otherwise pursuant to, Section 5.1(i). 
  
 (c) If on any day (x) any of the representations or warranties in Section 4.1(h) is no longer true with respect to any Pool Receivable or (y) it is
discovered that any Receivable that was included in the Net Receivables Pool Balance as an Eligible Receivable was not an Eligible Receivable at the time of such inclusion, the Seller shall be deemed to have received on such day a Collection in full
of such Pool Receivable and shall make the payment required to be made by it in connection with such Collection on the day required by, and otherwise pursuant to, Section 5.1(i). 
  
 Section 2.10 Payments and Computations, Etc. 
  
 (a) All amounts to be paid or deposited by the Seller or the Servicer
hereunder shall be paid or deposited in accordance with the terms hereof no later than 12:00 noon (New York time) on the day when due in U.S. Dollars in same day funds to the Agent’s Account. The Servicer or the Agent, as applicable, shall
promptly thereafter cause to be distributed (i) like funds relating to the payment out of Collections in respect of Capital, Yield, Servicer Fee or other Obligations payable out of Collections, to the Purchasers (according to each Purchaser’s
Ratable Portion) and the Servicer in accordance with the provisions of Section 2.6, 2.7, or 2.8, as applicable, and (ii) like funds relating to the payment by the Seller of other Obligations payable by the Seller hereunder, to the parties hereto for
whose benefit such funds were paid (and if such funds are insufficient, such distribution shall be made, subject to Section 2.6, 2.7 or 2.8, as applicable, ratably in accordance with the respective amounts thereof). Upon the Agent’s acceptance
of an Assignment and Acceptance and recording of the information contained therein in the Register pursuant to Section 9.2, from and after the effective date specified in such Assignment and Acceptance, the Agent shall make all payments hereunder in
respect of the interest assigned thereby to the Assignee thereunder, and the parties to such Assignment and Acceptance shall make all appropriate adjustments in such payments for periods prior to such effective date directly between themselves.

  
 (b) The Seller shall, to the extent permitted by law, pay to
the Agent interest on all amounts not paid or deposited when due hereunder (except for those amounts with respect to which Yield accrues) at 2.00% per annum above the Alternate Base Rate in effect from time to time, payable on demand,
provided, however, that such interest rate shall not at any time exceed the maximum rate permitted by applicable law. Such interest shall be for the account of, and distributed by the Agent to, the applicable Purchasers ratably in
accordance with their respective interests in such overdue amount. 
  
 (c) All computations of interest and all computations of Yield, Unused Commitment Fee and other per annum fees hereunder shall be made on the basis of a year of 360 days for the actual number of days (including the first but excluding the
last day) elapsed. 
  
 (d) Unless the Agent shall have received
notice from the Servicer or the Seller prior to the date on which any payment is due to the Purchasers hereunder that the Servicer or the Seller, as the case may be, will not make such payment in full, the Agent may assume that the Servicer or the
Seller, as the case may be, has made such payment in full to the Agent on such date and the Agent may, in reliance upon such assumption, cause to be distributed to each Purchaser on such due date an amount equal to the amount then due such
Purchaser. If and to the extent the Servicer or the Seller, as the case may be, shall 
  

 33 

 not have so made such payment in full to the Agent, each Purchaser shall repay to the Agent promptly on demand such
amount distributed to such Purchaser together with interest thereon, for each day from the date such amount is distributed to such Purchaser until the date such Purchaser repays such amount to the Agent, at the Federal Funds Rate. 
  
 Section 2.11 Yield and Fees. 
  
 (a) All Capital Investments and the outstanding amount of all other
Obligations hereunder shall bear a Yield, in the case of Capital Investments, on the amount thereof from the date such Capital Investments are made and, in the case of such other Obligations, from the date such other Obligations are due and payable
until, in all cases, paid in full, at the Applicable Yield. Accrued Yield shall be payable on each Payment Date. 
  
 (b) The Seller shall pay the Agent such fees as are set forth in the Citicorp Fee Letter to which such Facility Agent is a party. 
  
 (c) The Seller shall pay to the Agent for remittance to the Servicer a fee
(the “Servicer Fee”) of 0.50% per annum on the average daily aggregate Outstanding Balance of the Pool Receivables for the most recently completed month, from the date of the initial Purchase hereunder until the later of the
Termination Date or the date on which Capital is reduced to zero, payable in arrears on the applicable Payment Date; provided, however, that, if at any time, the Servicer is not Lyondell or an Affiliate or Subsidiary of Lyondell, the
Servicer shall be paid, as such fee, the greater of (i) such amount and (ii) 120% of its reasonable out-of-pocket costs and expenses incurred by it in servicing, administering and collecting the Pool Receivables; and, provided further, that
such fee shall be payable only from Collections pursuant to, and subject to the priority of payment set forth in, Sections 2.6, 2.7 and 2.8. 
  
 (d) The Seller agrees to pay to each Purchaser an unused commitment fee on the actual daily amount by which the Commitment of such Purchaser exceeds such
Purchaser’s Capital Investments (the “Unused Commitment Fee”) from the date hereof through the Termination Date at a rate of 0.50% per annum, payable in arrears (x) on the second Business Day of each calendar month, commencing
on the first such Business Day following the Closing Date and (y) on the Termination Date. 
  
 Section 2.12 Special Provisions Governing Capital Investments at the Applicable LIBO Rate. 
  
 (a) Increased Costs. If, due to either (i) a change after the date
hereof in Regulation D of the Board (to the extent any cost incurred pursuant to such regulation is not included in the calculation of Adjusted LIBO Rate), (ii) the introduction of or any change after the date hereof in or in the interpretation of
any law or regulation (other than any law or regulation relating to taxes, as to which Section 2.14 shall govern) or (iii) the compliance with any guideline or request issued or made after the date hereof from any central bank or other Governmental
Authority (whether or not having the force of law), there shall be any increase in the cost to (or, in the case of Regulation D of the Board there shall be imposed a cost on) any Indemnified Party of agreeing to make or making any Purchase or
maintaining any Receivable Interest (or interest therein) hereunder, then the Seller shall from time to time, within five Business Days following demand and delivery to the Seller of the certificate referred to in the last sentence of this Section
2.12(a) by such Indemnified Party (or by the Agent for the account of such Indemnified Party) (with a copy of such demand and certificate to the Agent), pay to the Agent for the account of such Indemnified Party additional amounts sufficient to
compensate such Indemnified Party for such increased or imposed cost. Each Indemnified Party hereto agrees to use reasonable efforts promptly to notify the Seller of any event referred to in clause (i), (ii) or (iii) above, provided that the
failure to give such notice shall not affect the rights of any Indemnified Party under this Section 2.12(a). 
  

 34 

 A certificate in reasonable detail as to the basis for and the amount of such increased cost, submitted to the Seller and
the Agent by such Indemnified Party (or by the Agent for the account of such Indemnified Party) shall be conclusive and binding for all purposes, absent manifest error. 
  
 (b) Interest Rate Unascertainable, Inadequate or Unfair. In the event that (i) the Agent determines that adequate and
fair means do not exist for ascertaining the applicable interest rates by reference to which the Adjusted LIBO Rate then being determined is to be fixed or (ii) the Required Purchasers notify the Agent that the Adjusted LIBO Rate for any Yield
Period will not adequately reflect the cost to the Purchasers of making a Capital Investment or maintaining such Capital Investment for such Yield Period, the Agent shall forthwith so notify the Seller and the Purchasers, whereupon the Applicable
Yield for such Capital Investment shall automatically, on the last day of the current Yield Period for such Capital Investment, convert into the Applicable Base Rate and the obligations of the Purchasers to make a Capital Investment or maintain a
Capital Investment at the Applicable LIBO Rate shall be suspended until the Agent shall notify the Seller that the Required Purchasers have determined that the circumstances causing such suspension no longer exist. 
  
 (c) Illegality. Notwithstanding any other provision of this Agreement,
if any Purchaser determines that the introduction of, or any change in or in the interpretation of, any law, treaty or governmental rule, regulation or order after the date of this Agreement shall make it unlawful, or any central bank or other
Governmental Authority shall assert that it is unlawful, for any Purchaser to make a Capital Investment or maintain a Capital Investment at the Applicable LIBO Rate, then, on notice thereof and demand therefor by such Purchaser to the Seller through
the Agent, (i) the obligation of such Purchaser to make a Capital Investment or maintain a Capital Investment at the Applicable LIBO Rate shall be suspended, and each such Purchaser shall make Capital Investments at the Applicable Base Rate and (ii)
if the affected Capital Investments at the Applicable LIBO Rate are then outstanding, the Seller shall immediately convert each such Capital Investment into a Capital Investment at the Applicable Base Rate. If, at any time after a Purchaser gives
notice under this Section 2.12(c), such Purchaser determines that it may lawfully make Capital Investments at the Applicable LIBO Rate, such Purchaser shall promptly give notice of that determination to the Seller and the Agent, and the Agent shall
promptly transmit the notice to each other Purchaser. The Seller’s right to request, and such Purchaser’s obligation, if any, to make Capital Investments at the Applicable LIBO Rate shall thereupon be restored. 
  
 (d) Liquidation Costs. In addition to all amounts required to be paid
by the Seller hereunder, the Seller shall compensate each Purchaser, within five Business Days following demand therefor, for all losses, expenses and liabilities (including any loss or expense incurred by reason of the liquidation or reemployment
of deposits or other funds acquired by such Purchaser to fund or maintain such Purchaser’s Capital Investments at the Applicable LIBO Rate but excluding any loss of the Applicable Margin on the relevant Capital Investments) (each, a
“Liquidation Cost”) that such Purchaser may sustain, and any customary fees that such Purchaser may impose, (i) if for any reason a proposed Capital Investment, conversion into or continuation of Capital Investments at the
Applicable LIBO Rate does not occur on a date specified therefor in a Notice of Purchase given by the Seller or in a telephonic request by it for Purchase or a successive Yield Period does not commence after notice therefor is given hereunder, (ii)
if for any reason any Capital Investment at the Applicable LIBO Rate is reduced (including mandatorily pursuant to Section 2.7 or 2.8) on a date that is not the last day of the applicable Yield Period, (iii) as a consequence of a required conversion
of a Capital Investment at the Applicable LIBO Rate to Capital Investment at the Applicable Base Rate as a result of any of the events indicated in Section 2.12(c) above or (iv) as a consequence of any failure by the Seller to reduce Capital
Investment at the Applicable LIBO Rate when required by the terms hereof. The Purchaser making demand for such compensation shall deliver to the Seller concurrently with such demand a written statement as to such losses, expenses and liabilities and
fees, and this statement shall be conclusive as to the amount of compensation due to such Purchaser, absent manifest error. 
  

 35 

 Section 2.13 Increased Capital. 
  
 If any Indemnified Party determines that either the introduction of or any
change in or in the interpretation of any law or regulation after the date hereof or the compliance with any guideline or request issued or made after the date hereof from any central bank or other Governmental Authority (whether or not having the
force of law) affects or would affect the amount of capital required or expected to be maintained by such Indemnified Party or any corporation controlling such Indemnified Party and that the amount of such capital is increased by or based upon the
existence of such Indemnified Party’s commitment, if any, to purchase any Receivable Interest (or interest therein), or to maintain such Receivable Interest (or interest therein) hereunder, then, within five Business Days following demand and
delivery to the Seller of the certificate referred to in the last sentence of this Section 2.13 by such Indemnified Party (or by the Agent for the account of such Indemnified Party) (with a copy of such demand and certificate to the Agent) the
Seller shall pay to the Agent for the account of such Indemnified Party from time to time, as specified by such Indemnified Party, additional amounts sufficient to compensate such Indemnified Party or such corporation in the light of such
circumstances, to the extent that such Indemnified Party reasonably determines such increase in capital to be allocable to the existence of any such commitment. Each Indemnified Party hereto agrees to use reasonable efforts promptly to notify the
Seller of any event referred to in the first sentence of this Section 2.13, provided that the failure to give such notice shall not affect the rights of any Indemnified Party under this Section 2.13. A certificate in reasonable detail as to
the basis for, and the amount of, such compensation submitted to the Seller and the Agent by such Indemnified Party (or by the Agent for the account of such Indemnified Party) shall be conclusive and binding for all purposes, absent manifest error.

  
 Section 2.14 Taxes. 

 
 (a) Any and all payments by the Seller hereunder or deposits from
Collections hereunder shall be made, in accordance with Section 2.10, free and clear of and without deduction for any and all present or future taxes, levies, imposts, deductions, charges or withholdings, and all liabilities with respect thereto,
excluding, in the case of each Indemnified Party, (i) taxes that are imposed on its overall net income by the United States, (ii) taxes that are imposed on its overall net income, assets or net worth (and franchise taxes imposed in lieu thereof) by
the state or foreign jurisdiction under the laws of which such Indemnified Party is organized or qualified to do business or in which such Indemnified Party holds any asset in connection with this Agreement or, in each case, any political
subdivision thereof, and (iii) branch profits tax imposed by the United States of America or any similar tax imposed by any other jurisdiction in which any Indemnified Party is located (all such non-excluded taxes, levies, imposts, deductions,
charges, withholdings and liabilities in respect of payments hereunder or deposits from Collections hereunder being hereinafter referred to as “Taxes”). If the Seller or the Servicer or the Agent shall be required by law to deduct
any Taxes from or in respect of any sum payable hereunder or deposit from Collections hereunder to any Indemnified Party, (i) the sum payable shall be increased as may be necessary so that after making all required deductions (including deductions
applicable to additional sums payable under this Section 2.14) such Indemnified Party receives an amount equal to the sum it would have received had no such deductions been made, (ii) the Seller or the Servicer or the Agent shall make such
deductions and (iii) the Seller or the Servicer or the Agent shall pay the full amount deducted to the relevant taxation authority or other authority in accordance with applicable law. 
  
 (b) In addition, the Seller shall pay any present or future sales, stamp, documentary, excise, property or similar taxes,
charges or levies that arise from any payment made hereunder or deposit from Collections hereunder or from the execution, delivery or registration of, performing under, or otherwise with respect to, this Agreement, the Receivables Sale Agreement or
any other Transaction Document (hereinafter referred to as “Other Taxes”). 
  

 36 

 (c) The Seller shall indemnify each Indemnified Party for and hold it harmless against the full amount of
Taxes and Other Taxes (including, without limitation, taxes of any kind imposed by any jurisdiction on amounts payable under this Section 2.14) imposed on or paid by such Indemnified Party and any liability (including penalties, additions to tax,
interest and expenses) arising therefrom or with respect thereto whether or not such Taxes or Other Taxes were correctly or legally asserted. This indemnification shall be made within five Business Days from the date such Indemnified Party makes
written demand therefor (with a copy to the Agent). 
  
 (d) Within
30 days after the date of any payment of Taxes, the Seller shall furnish to the Agent and each applicable Purchaser, at its address referred to in Section 11.3, the original or a certified copy of a receipt evidencing such payment or a certificate
executed by a Responsible Officer of the Seller stating that such Taxes have been paid, together with evidence of such payment reasonably satisfactory to the Agent. 
  
 (e) Each Purchaser organized under the laws of a jurisdiction outside the United States shall, on or prior to the date of
its execution and delivery of this Agreement in the case of each Initial Purchaser, and on the date of the Assignment or the Assignment and Acceptance pursuant to which it became a Purchaser in the case of each other Purchaser, and from time to time
thereafter as requested in writing by the Seller (but only so long thereafter as such Purchaser remains lawfully able to do so), provide each of the Agent and the Seller with 2 original Internal Revenue Service forms W-8ECI or W-8BEN, as
appropriate, or any successor or other form prescribed by the Internal Revenue Service, certifying that such Purchaser is exempt from or entitled to a reduced rate of United States withholding tax on payments pursuant to this Agreement. If the forms
provided by a Purchaser at the time such Purchaser first becomes a party to this Agreement indicate a United States interest withholding tax rate in excess of zero, withholding tax at such rate shall be considered excluded from Taxes unless and
until such Purchaser provides the appropriate form certifying that a lesser rate applies, whereupon withholding tax at such lesser rate only shall be considered excluded from Taxes for periods governed by such form; provided, however,
that if, at the effective date of the Assignment or the Assignment and Acceptance pursuant to which an Assignee becomes a Purchaser hereunder, the Purchaser assignor was entitled to payments under subsection (a) of this Section 2.14 (after taking
into account subsections (e) and (f) of this Section 2.14) in respect of United States withholding tax with respect to amounts paid hereunder at such date, then, to such extent, the term Taxes shall include (in addition to withholding taxes that may
be imposed in the future or other amounts otherwise includable in Taxes) United States withholding tax, if any, applicable with respect to such Assignee on such date. If any form or document referred to in this subsection (e) requires the disclosure
of information, other than information necessary to compute the tax payable and information required on the date hereof by Internal Revenue Service form W-8ECI or W-8BEN or any successor or other form prescribed by the Internal Revenue Service, that
the Purchaser reasonably considers to be confidential, the Purchaser shall give notice thereof to the Seller and shall not be obligated to include in such form or document such confidential information. 
  
 (f) For any period with respect to which a Purchaser has failed to provide
the Seller with the appropriate form described in subsection (e) of this Section 2.14 (other than if such failure is due to a change in law occurring after the date on which a form originally was required to be provided or if such form otherwise is
not required under subsection (e) of this Section 2.14), such Purchaser shall not be entitled to indemnification under subsection (a) or (c) of this Section 2.14 with respect to Taxes imposed by the United States by reason of such failure;
provided, however, that should any Purchaser become subject to Taxes because of its failure to deliver a form required hereunder, the Seller shall take such steps as such Purchaser shall reasonably request to assist such Purchaser (at
such Purchaser’s expense) to recover such Taxes. 
  

 37 

 Section 2.15 Sharing of Payments, Etc. 
  
 If any Purchaser shall obtain any payment (whether voluntarily,
involuntarily, through the exercise of any right of set-off or otherwise) on account of the Purchases made by it (other than with respect to payments due to such Purchaser pursuant to Section 2.12, 2.13 or 2.14) in excess of its Ratable Portion of
payments on account of the Purchases obtained by all the Purchasers, such Purchaser shall forthwith purchase from the other Purchasers such interests in the Receivable Interests purchased by them as shall be necessary to cause such Purchaser to
share the excess payment ratably with each of them; provided, however, that if all or any portion of such excess payment is thereafter recovered from such Purchaser, such purchase from each other Purchaser shall be rescinded and such
other Purchaser shall repay to the Purchaser the purchase price to the extent of such recovery together with an amount equal to such other Purchaser’s Ratable Portion (according to the proportion of (a) the amount of such other Purchaser’s
required repayment to (b) the total amount so recovered from the Purchaser) of any interest or other amount paid or payable by the Purchaser in respect of the total amount so recovered. The Seller agrees that any Purchaser so purchasing an interest
in Receivable Interests from another Purchaser pursuant to this Section 2.15 may, to the fullest extent permitted by law, exercise all its rights of payment (including the right of set-off) with respect to such interest in Receivable Interests as
fully as if such Purchaser were the direct creditor of the Seller in the amount of such interest in Receivable Interests. 
  
 Section 2.16 Conversion/Continuation Option. 
  
 (a) The Seller may elect (i) at any time on any Business Day, to convert Capital Investments bearing Yield at the Applicable
Base Rate (other than Swing Purchases) or any portion thereof to Capital Investments bearing Yield at the Applicable LIBO Rate and (ii) at the end of any applicable Yield Period, to convert Capital Investments bearing Yield at the Applicable LIBO
Rate or any portion thereof into Capital Investments bearing Yield at the Applicable Base Rate or to continue such Capital Investments bearing Yield at the Applicable LIBO Rate or any portion thereof for an additional Yield Period; provided,
however, that the aggregate amount of the Capital Investments bearing Yield at the Applicable LIBO Rate for each Yield Period must be in an amount of at least $10,000,000 or an integral multiple of $1,000,000 in excess thereof. Each
conversion or continuation shall be allocated among the Capital Investments of each Purchaser in accordance with such Purchaser’s Receivable Interest. Each such election shall be in substantially the form of Exhibit H (a “Notice of
Conversion or Continuation”) and shall be made by giving the Agent at least 3 Business Days’ prior written notice specifying (A) the amount and type of Capital Investment being converted or continued, (B) in the case of a conversion to
or a continuation of Capital Investments bearing Yield at the Applicable LIBO Rate, the applicable Yield Period and (C) in the case of a conversion, the date of such conversion. 
  
 (b) The Agent shall promptly notify each Purchaser of its receipt of a Notice of Conversion or Continuation and of the
options selected therein. Notwithstanding the foregoing, no conversion in whole or in part of Capital Investments bearing Yield at the Applicable Base Rate to Capital Investments bearing Yield at the Applicable LIBO Rate and no continuation in whole
or in part of Capital Investments bearing Yield at the Applicable LIBO Rate upon the expiration of any applicable Yield Period shall be permitted at any time at which (i) a Potential Event of Termination or an Event of Termination shall have
occurred and be continuing or (ii) the continuation of, or conversion into, a Capital Investment bearing Yield at the Applicable LIBO Rate would violate any provision of Section 2.12. If, within the time period required under the terms of this
Section 2.16, the Agent does not receive a Notice of Conversion or Continuation from the Seller containing a permitted election to continue any Capital Investments bearing Yield at the Applicable LIBO Rate for an additional Yield Period or to
convert any such Capital Investments, then, upon the expiration of the applicable Yield Period, such Capital Investments shall, subject to Section 3.2, be automatically continued as Capital Investments bearing Yield at the Applicable LIBO Rate with
a Yield Period of one month. Each Notice of Conversion or Continuation shall be irrevocable. 
  

 38 

 Section 2.17 Duty to Mitigate; Assignment of Commitments Under Certain
Circumstances. 
  
 (a) If any Indemnified Party claims
any additional amounts payable pursuant to Section 2.12 or Section 2.13 or if the Seller is required to pay any additional amount to any Indemnified Party or any Governmental Authority for the account of any Purchaser pursuant to Section 2.14, then
such Indemnified Party shall use reasonable efforts (consistent with legal and regulatory restrictions) to file any certificate or document, including, without limitation, any such certificate or document reasonably requested by the Seller, or to
change the jurisdiction of the applicable office through which it holds or maintains its interest in the applicable Receivable Interest or to take other actions (including the filing of certificates or documents) known to it to be available if the
making of such a filing or change or the taking of such other action would avoid the need for or reduce the amount of any such additional amounts which may thereafter accrue or avoid the circumstances giving rise to such exercise and would not, in
the sole determination of such Indemnified Party, be otherwise disadvantageous to such Indemnified Party or its Receivable Interest. 
  
 (b) In the event that any Indemnified Party shall have delivered a notice or certificate pursuant to Section 2.12 or 2.13, or the Seller shall be required
to make additional payments to any Indemnified Party under Section 2.14, the Seller shall have the right, with the assistance of the Agent, to designate a substitute bank or banks (which may be one or more of the Purchasers) mutually satisfactory to
the Seller and the Agent (and the Swing Purchaser) to purchase for cash, pursuant to an Assignment and Acceptance, the outstanding Capital Investment of such Purchaser and assume the Commitment of such Purchaser, without recourse to or warranty by,
or expense to, such Purchaser, for a purchase price equal to the amount of all of such Purchaser’s outstanding Capital Investment plus any accrued but unpaid Yield thereon and the accrued but unpaid fees for the account of such Purchaser
hereunder plus such amount, if any, as would be payable pursuant to Section 2.12(d) if the outstanding Capital Investment of such Purchaser was prepaid in its entirety on the date of consummation of such assignment. 
  
 Section 2.18 Restricted Accounts; Investment of Amounts
in the Cash Assets Account. 
  
 (a) The Agent shall have
“control” (within the meaning of Section 9-104 of the UCC) of each of the Restricted Accounts. 
  
 (b) Funds held in the Cash Assets Account may, until withdrawn or otherwise applied pursuant hereto, be invested and reinvested in such Liquid Investments
as the Seller may request from time to time; provided that, if an Event of Termination shall have occurred and be continuing, the Agent may select such Liquid Investments. “Liquid Investments” means (i) direct obligations of
the United States or any agency thereof, (ii) obligations guaranteed by the United States or any agency thereof, (iii) time deposits and money market deposit accounts issued by or guaranteed by or placed with a financial institution reasonably
acceptable to the Agent, and (iv) fully collateralized repurchase agreements for securities described in clause (i) or (ii) above entered into with a financial institution reasonably acceptable to the Agent, provided in each case that such
Liquid Investment (x) matures within 30 days and (y) is in a form, and is issued and held in a manner, that in the reasonable judgment of the Agent permits appropriate measures to have been taken to perfect security interests therein. 
  

 39 

 ARTICLE III 
  
 CONDITIONS OF PURCHASES 
  
 Section 3.1 Conditions Precedent to the Effectiveness
of this Agreement. 
  
 The effectiveness of this
Agreement is subject to the satisfaction (or substantially simultaneous satisfaction) of the following conditions precedent: 
  
 (a) The Agent shall have received all fees and expenses (including, but not limited to, reasonable fees and expenses of counsel to the Agent) required to
be paid on the Closing Date, pursuant to the terms of this Agreement and the Citicorp Fee Letter and the Annex thereto. 
  
 (b) The Agent shall have received on or before the Closing Date, the following, each (unless otherwise indicated) dated as of the Closing Date (unless
otherwise specified), in form and substance reasonably satisfactory to the Agent: 
  
 (i) This Agreement, duly executed and delivered by the Seller and the Servicer; 
  
 (ii) The Receivables Sale Agreement, duly executed by the
Seller and each Originator, together with: 
  
 (A) Proper financing statements naming each Originator as debtor, the Seller as secured party and the Agent, as assignee, to be filed under the UCC of all jurisdictions that the Agent may deem necessary in order to perfect the Seller’s
interests created or purported to be created by the Receivables Sale Agreement; 
  
 (B) Proper financing statement terminations or releases, if any, necessary to release all security interests and other rights of any
Person in the Receivables, Related Security, Collections or Contracts previously granted by any Originator; 
  
 (C) The Consent and Agreement, duly executed by the Seller and each Originator; and 
  
 (D) A Subordinated Note, in substantially the form of
Exhibit B to the Receivables Sale Agreement, payable to the order of each Originator, and duly executed by the Seller; 
  
 (iii) The Lyondell Undertaking, duly executed and delivered by Lyondell; 
  
 (iv) A Lock-Box Agreement with each Lock-Box Bank, executed by such Lock-Box Bank, the Agent and the Seller,
the Servicer or an Originator, as applicable; 
  
 (v) Good standing certificates (or equivalent) issued by the Secretary of State of the jurisdiction of incorporation of each Transaction Party; 
  
 (vi) A copy of the articles or certificate of incorporation (or equivalent Constituent Document) of each Transaction Party, certified as
of a recent date by the Secretary of State (or equivalent body) of the state of organization of such Transaction Party; 
  

 40 

 (vii) A certificate of the Secretary or an Assistant Secretary of each Transaction Party
certifying (A) the names and true signatures of each officer of such Transaction Party that has been authorized to execute and deliver any Transaction Document or other document required hereunder to be executed and delivered by or on behalf of such
Transaction Party, (B) the by-laws (or equivalent Constituent Document) of such Transaction Party as in effect on the date of such certification, (C) the resolutions of such Transaction Party’s Board of Directors (or equivalent governing body)
approving and authorizing the execution, delivery and performance of this Agreement and the other Transaction Documents to which it is a party and (D) that there have been no changes in the certificate of incorporation (or equivalent Constituent
Document) of such Transaction Party from the certificate of incorporation (or equivalent Constituent Document) delivered pursuant to clause (vii) above; 
  
 (viii) A certificate of a Principal Financial Officer of each Transaction Party certifying that the conditions set forth in Section
3.1(a), (b), (c) and (e) have been satisfied; 
  
 (ix) A certificate of a Principal Financial Officer of each of the Seller and Originators stating that such Transaction Party is Solvent after giving effect to the transactions contemplated hereunder and under the other Transaction
Documents; 
  
 (x) Proper financing statements
naming the Seller, as debtor, and the Agent, as secured party, to be filed under the UCC of all jurisdictions that the Agent may deem necessary in order to perfect the ownership interests created or purported to be created by the Transactions
Documents; 
  
 (xi) Proper financing statement
terminations or releases, if any, necessary to release all security interests and other rights of any Person in the Pool Receivables, Contracts, Related Security or Collections previously granted by the Seller or any Originator; and 
  
 (xii) Favorable opinions of (A) Gerald A. O’Brien,
Deputy General Counsel of Lyondell, in substantially the form of Exhibit I-2 hereto and as to such other matters as the Agent may reasonably request, (B) Baker Botts L.L.P., counsel to the Transaction Parties, in substantially the forms of Exhibit
I-1 and I-3 hereto as to such other matters as the Agent may reasonably request, including without limitation (1) a “true sale” opinion with respect to the sale of Receivable Assets under and as defined in the Receivables Sale
Agreement from each Originator to the Seller, (2) an opinion with respect to the non-substantive consolidation of the Seller with each other Transaction Party or any of its Affiliates or Subsidiaries in a case under the U.S. Bankruptcy Code, and (3)
an opinion relating to the enforceability of the Transaction Documents, compliance with all laws and regulations (including Regulation U of the Board), the perfection of all ownership and other interests purported to be granted under the Transaction
Documents, and no conflicts with material agreements, and (C) special counsel to the Agent, as the Agent may reasonably request. 
  
 (c) Each of the Seller, the Originators and the Servicer shall have received all necessary governmental and third party consents and approvals necessary
in connection with Transaction 
  

 41 

 Documents and the transactions contemplated thereby (without the imposition of any conditions that are not reasonably
acceptable to the Purchasers) and shall remain in effect, and all applicable governmental filings (except for the UCC financing statements referred to in this Section 3.1) shall have been made and all applicable waiting periods shall have expired
without in either case any action being taken by any competent authority; and no law or regulation shall be applicable in the judgment of the Purchasers that restrains, prevents or imposes materially adverse conditions upon the Transaction Documents
or the transactions contemplated thereby. 
  
 (d) The Purchasers
shall have received and be satisfied with (i) audited financial statements of Lyondell and its Consolidated Subsidiaries for the Fiscal Year ending December 31, 2002 by independent nationally-recognized public accountants which statements shall be
unqualified, (ii) interim unaudited quarterly financial statements of Lyondell and its Consolidated Subsidiaries, through the fiscal quarter ending September 30, 2003, and (iii) the financial projections of Lyondell and its Consolidated Subsidiaries
covering the Fiscal Years ending in 2003 through 2007, inclusive, that are included in the Confidential Information Memorandum. 
  
 (e) (i) All obligations for outstanding capital, accrued but unpaid yield and fees and other amounts then due and payable under the Existing Program shall
have been concurrently satisfied, (ii) all documentation relating to the Existing Program shall have been concurrently terminated on terms satisfactory to the Agent and (iii) the Agent shall have received evidence of such termination in form and
substance satisfactory to the Agent. 
  
 (f) The Agent shall be
satisfied with the results of a field examination of the Originators conducted by CUSA’s internal auditors no more than 3 months prior to the Closing Date. 
  

The Agent shall promptly notify the Seller, the Servicer and the Purchasers of the Closing Date, and such notice shall be conclusive and binding on all
parties hereto. 
  
 Section 3.2 Conditions
Precedent to All Investment Events. 
  
 Each Investment
Event (including the initial Purchase by each Purchaser) shall be subject to the further conditions precedent that: 
  
 (a) on or prior to the date of such Investment Event, the Servicer shall have delivered to the Agent, in form and substance satisfactory to the Agent in
its Discretion: 
  
 (i) a completed monthly
Seller Report, signed by a Principal Financial Officer of the Servicer and dated within 31 days prior to the date of such Investment Event, together with a listing by Obligor of all Pool Receivables, and 
  
 (ii) during the existence of a Triggering Event, not later
than the second Business Day of each week, a completed weekly Seller Report, signed by a Principal Financial Officer of the Servicer and effective as of the end of the last Business Day of the then immediately preceding week, and 
  

 42 

 (b) on the date of such Investment Event the following statements shall be true (and the acceptance by
the Seller of the proceeds of the Purchase or reinvestment, as applicable, being made on the date of such Investment Event shall constitute a representation and warranty by the Servicer, or the Seller, as the case may be, that on the date of such
Investment Event, such statements are true): 
  
 (i) the representations and warranties applicable to such Transaction Party contained in Article IV of this Agreement and in Article III of the Receivables Sale Agreement are correct in all material respects on and as of the date of such
Investment Event, before and after giving effect to such Investment Event and to the application of the proceeds from the Purchase or reinvestment, as applicable, being made on the date thereof, as though made on and as of such date, except (x) in
the case of an Investment Event consisting solely of a conversion of the Applicable Yield from a rate based on the Adjusted LIBO Rate to a rate based on the Adjusted Base Rate or (y) to the extent such representations and warranties that expressly
relate to an earlier date; 
  
 (ii) no event has
occurred and is continuing, or would result from such Investment Event or from the application of the proceeds from the Purchase or reinvestment, as applicable, being made on the date of such Investment Event, which constitutes an Event of
Termination or a Potential Event of Termination; and 
  
 (iii) the Purchase or reinvestment, as applicable, being made on the same date as such Investment Event shall not violate any requirement of law and shall not be enjoined, temporarily, preliminarily or permanently. 
  
 ARTICLE IV 
  
 REPRESENTATIONS AND WARRANTIES

  
 Section 4.1 Representations and
Warranties of the Seller. 
  
 The Seller represents and
warrants as follows: 
  
 (a) (i) The Seller is a limited
liability company duly organized, validly existing and in good standing under the laws of the jurisdiction indicated at the beginning of this Agreement, has the requisite power and authority under its Constituent Documents and applicable law to own
its property and assets and to carry on its business as now conducted and proposed to be conducted after the Closing Date and is duly qualified to do business, and is in good standing, in every jurisdiction where such qualification or authorization
is required, except to the extent that any failure to be so qualified or in good standing as a foreign entity could not reasonably be expected to have a Material Adverse Effect. 
  
 (ii) The Seller has no Subsidiaries. All of the outstanding membership interests of the Seller are owned by Lyondell.

  
 (b) The Seller has the power and authority under its
Constituent Documents and applicable law to execute, deliver and carry out the provisions of the Transaction Documents to which it is a party, and all such actions have been duly and validly authorized by all necessary proceedings on its part under
its Constituent Documents and applicable law. 
  
 (c) The
execution, delivery and performance by the Seller of the Transaction Documents to which it is a party, and the transactions contemplated hereby and thereby, including the Seller’s use of the proceeds of Purchases and reinvestments, are within
the Seller’s powers, have been duly authorized and delivered by all necessary action on its part, do not (i) violate (x) any provision of the Seller’s Constituent Documents or any other agreement governing its organization and/or scope of
power and authority or any applicable law, rule, regulation (including Regulation U or X) or order, writ, judgment, injunction, decree, determination or award of any Governmental Authority binding upon it or any other Transaction Party, (ii) result
in a breach of or constitute (alone or with notice or lapse of time or 
  

 43 

 both) a default under any indenture or any agreement or other instrument to which it is a party, or by which it or any of
its properties or assets are bound, or (iii) except for the Liens created by the Transaction Documents, result in or require the creation or imposition of any Lien upon any of its property or assets. 
  
 (d) This Agreement is, and the other Transaction Documents to which the
Seller is or will be a party when delivered will be, the legal, valid and binding obligations of the Seller enforceable against the Seller in accordance with their respective terms, except as such enforceability may be limited by bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting the rights of creditors generally and by general principles of equity, including implied obligations of good faith and fair dealing. 
  
 (e) No authorization or approval or other action by, and no notice to or
filing with, any Governmental Authority is or will be required for the due execution, delivery and performance by the Seller of any Transaction Document to which it is a party or any transaction contemplated hereby or thereby, except for the filings
of the financing statements referred to in Article III. 
  
 (f)
Since the date of the Seller’s formation, there has not occurred any development or event affecting, or any change in the business, assets, results of operations, financial condition or prospects of, the Seller which has resulted or could
reasonably be expected to result in a Material Adverse Effect. 
  
 (g) There is no action, suit, investigation, litigation or proceeding at law or in equity or by or before any Governmental Authority now pending or, to the knowledge of the Seller, threatened against or affecting the Seller or its business,
assets or rights (i) as to which there is a reasonable possibility of an adverse decision and which, if adversely determined, could, individually or, in the aggregate, reasonably be expected to have a Material Adverse Effect or (ii) that in any
manner draws into question the validity or enforceability of any Transaction Document. 
  
 (h) (i) Immediately prior to the time of the initial creation of an interest hereunder in any Pool Receivable, the Seller is the legal and beneficial owner of such Pool Receivable and Related Security and Collections
with respect thereto, in each case free and clear of any Lien (other than Permitted Liens). 
  
 (ii) Upon each Purchase or reinvestment, the Seller shall transfer to the Purchaser making such Purchase or reinvestment (and such
Purchaser shall acquire) a valid interest to the extent of the pertinent Receivable Interest in each Pool Receivable then existing or thereafter arising and in the Related Security and Collections with respect thereto, free and clear of any Lien
(other than Permitted Liens), which ownership interest or security interest shall be a perfected first priority ownership interest or security interest upon the filing of the financing statements referred to in Section 3.1(b)(xii). 
  
 (iii) With respect to each transfer to it of any Pool
Receivables, the Seller has either (i) purchased such Pool Receivables from an Originator in exchange for payment (made by the Seller to an Originator in accordance with the provisions of the Receivables Sale Agreement) in an amount which
constitutes fair consideration and approximates fair market value for such Pool Receivables and in a sale the terms and conditions of which (including, without limitation, the purchase price thereof) reasonably approximate an arm’s-length
transaction between unaffiliated parties or (ii) acquired such Pool Receivables from an Originator as a capital contribution in accordance with the provisions of the Receivables Sale Agreement. No such sale, and no such contribution, has been made
for or on account of an antecedent debt owed by any Originator to the Seller and no such sale or contribution is or may be voidable or subject to avoidance under any section of the U.S. Bankruptcy Code. 
  

 44 

 (i) No report or document or other information furnished or to be furnished at any time by or on behalf
of the Seller to the Agent or any Purchaser in connection with any Transaction Document, when taken together with all other reports, documents and information then or theretofore so furnished by or on behalf of the Seller, contained or will contain,
as of the date so furnished, any untrue statement of a material fact or omitted to state, or will omit to state, as of the date so furnished, a material fact necessary in order to make the statements contained therein, in the light of the
circumstances under which they were made, not misleading. 
  
 (j)
The jurisdiction of incorporation, organizational identification number (if any), and the address(es) of the principal place of business and chief executive office of the Seller and the office where the Seller keeps its Records concerning the
Receivable Assets, are as set forth in Schedule III hereto (or, by notice to the Agent in accordance with Section 5.1(e), at such other locations in jurisdictions, within the United States, where all requested actions under Section 6.5(a)
have been taken and completed). 
  
 (k) The names and addresses of
all the Lock-Box Banks, together with the lock-box numbers related to, and the account numbers and owners of, the Lock-Box Accounts at such Lock-Box Banks, are specified in Schedule I hereto (or such other Lock-Box Banks and/or such other Lock-Box
Accounts as have been notified to the Agent in accordance with Section 5.3(m). Except pursuant to the Lock-Box Agreements, the Seller has not granted any Person dominion or control of any Lock-Box Account, or the right to take dominion or control
over any Lock-Box Account at a future time or upon the occurrence of a future event. 
  
 (l) Since the date of its formation, the Seller has not engaged in any activity other than as contemplated by the Transaction Documents or entered into any commitment or incurred any Indebtedness other than pursuant
to, or as permitted under, the Transaction Documents. 
  
 (m) The
Seller has not maintained, contributed to or incurred or assumed any obligation with respect to any Plan, Multiemployer Plan or Welfare Plan, except such obligation or contingent obligation that arises as a matter of law solely as a result of
another member of the ERISA Group’s sponsorship of a Plan, Multiemployer Plan or Welfare Plan. 
  
 (n) The Seller has complied with the Credit and Collection Policy in all material respects and since the date of this Agreement there has been no change
in the Credit and Collection Policy except as permitted hereunder. The Seller has not extended or modified the terms of any Pool Receivable or the Contract under which any such Pool Receivable arose, except in accordance with the Credit and
Collection Policy. 
  
 (o) The Seller has filed, or caused to be
filed or be included in, all tax reports and returns (federal, state, local and foreign), if any, required to be filed by it and paid, or caused to be paid, all amounts of taxes, including interest and penalties, required to be paid by it, except
for such taxes (i) as are being contested in good faith by proper proceedings and (ii) against which adequate reserves shall have been established in accordance with and to the extent required by GAAP, but only so long as the proceedings referred to
in clause (i) above would not subject the Agent or any other Indemnified Party to any civil or criminal penalty or liability or involve any material risk of the loss, sale or forfeiture of any property, rights or interests included in the Pool
Receivables, Related Security, Collections, Restricted Accounts or proceeds thereof. 
  

 45 

 (p) The Seller is not an “investment company” as defined in the Investment Company Act
of 1940, as amended. The Seller is not subject to regulation as a “holding company” under the Public Utility Holding Company Act of 1935, as amended. 
  
 (q) Both before and after giving effect to (i) each Purchase to be made on the Closing Date or such other date as Purchases
requested hereunder are made, (ii) the disbursement of the proceeds of any Capital Investment, (iii) the consummation of each other transaction contemplated by the other Transaction Documents and (iv) the payment and accrual of all transaction costs
in connection with the foregoing, the Seller is Solvent. 
  
 Section 4.2 Representations and Warranties of the Servicer. 
  
 The Servicer represents and warrants as follows: 
  
 (a) Each of the Servicer and its Material Subsidiaries (including for this purpose the Lyondell Joint Ventures) is duly organized, validly existing and in
good standing under the laws of the jurisdiction of its organization, has the requisite power and authority under its Constituent Documents and applicable law to own its property and assets and to carry on its business as now conducted and is duly
qualified and is in good standing and is authorized to do business in every jurisdiction where such qualification or authorization is required, except where the failure so to qualify, individually or in the aggregate, could not reasonably be
expected to result in a Material Adverse Effect. 
  
 (b) The
Servicer has the power and authority under its Constituent Documents and applicable law to execute, deliver and carry out the provisions of the Transaction Documents to which it is a party, and all such actions have been duly and validly authorized
by all necessary proceedings on its part under its Constituent Documents and applicable law. 
  
 (c) The execution, delivery and performance by the Servicer of the Transaction Documents to which it is a party, and the other transactions contemplated hereby and thereby, do not (i) violate (x) any provision of the
Servicer’s Constituent Documents or any other agreement governing its organization and/or scope of power and authority or any applicable law, rule, regulation (including Regulation U or X) or order, writ, judgment, injunction, decree,
determination or award of any Governmental Authority binding upon it, (ii) result in a breach of or constitute (alone or with notice or lapse of time or both) a material default under any indenture or any material agreement or other instrument to
which it or any Material Subsidiary is a party, or by which it or any Material Subsidiary or any of its or its Material Subsidiary’s properties or assets are bound, or (iii) except for the Liens created by the Transaction Documents, result in
or require the creation or imposition of any Lien upon any of its or its Material Subsidiary’s property or assets. 
  
 (d) This Agreement is, and the other Transaction Documents to which the Servicer is or will be a party when delivered will be, the legal, valid and
binding obligations of such Person enforceable against such Person in accordance with their respective terms except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws of general application
from time to time affecting the rights of creditors generally and by general principles of equity, including implied obligations of good faith and fair dealing. 
  

(e) No authorization or approval or other action by, and no notice to or filing with, any Governmental Authority is or will be required in connection
with the due execution, delivery and performance by the Servicer of any Transaction Document to which it is a party or any other transaction contemplated hereby or thereby, except for the filings of the financing statements referred to in Article
III and except for any that have been made or any the failure to obtain, give, file or take could not reasonably be expected to result in a Material Adverse Effect. 
  

 46 

 (f) Since June 30, 2003, there has not occurred any development or event affecting, or any change in the
business, assets, results of operations, financial condition or prospects of, Lyondell and its Subsidiaries, taken as a whole, which has resulted or could reasonably be expected to result in a Material Adverse Effect. 
  
 (g) There is no action, suit, investigation, litigation or proceeding at law
or in equity or by or before any Governmental Authority now pending or, to its knowledge, threatened against or affecting the Servicer or any of its Subsidiaries or the businesses, assets or rights of Servicer or any of its Subsidiaries (i) as to
which there is a reasonable possibility of an adverse determination and which, if adversely determined, could, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect or (ii) that in any manner draws into
question the validity or enforceability of any Transaction Document. 
  
 (h) No report or document or other information furnished or to be furnished at any time by or on behalf of the Servicer to the Agent or any Purchaser in connection with any Transaction Document, when taken together with all other reports,
documents and information then or theretofore so furnished by or on behalf of the Servicer, including Lyondell’s periodic reports filed with the SEC pursuant to the Securities Exchange Act of 1934, as amended, contained, or will contain as of
the date so furnished, any untrue statement of a material fact or omitted to state, or will omitted to state, as the date so furnished, a material fact necessary in order to make the statements contained therein, in the light of the circumstances
under which they were made, not misleading; provided that no representation or warranty with respect to (x) the financial projections described in Section 3.1(d)(iii), (y) any information, including financial projections, delivered pursuant
to Section 3.01(b) of the Lyondell Undertaking or (z) any financial statements delivered pursuant to Section 5.5(a) shall be made pursuant to this Section 5.3(p). 
  
 (i) The offices where the Servicer keeps its Records concerning the Receivable Assets are as set forth in Schedule
III hereto (or, by notice to the Agent in accordance with Section 5.1(e), at such other locations in jurisdictions, within the United States, where all requested actions under Section 6.5(a) have been taken and completed). 
  
 (j) The names and addresses of all the Lock-Box Banks, together with the
lock-box numbers related to, and the account numbers and owners of, the Lock-Box Accounts at such Lock-Box Banks, are specified in Schedule I hereto (or such other Lock-Box Banks and/or such other Lock-Box Accounts as have been notified to
the Agent in accordance with Section 5.3(m)). Except under the Lock-Box Agreements, the Servicer has not granted any Person dominion or control of any Lock-Box Account, or the right to take dominion or control over any Lock-Box Account at a future
time or upon the occurrence of a future event. 
  
 (k) Each member
of the ERISA Group has fulfilled its obligations under the minimum funding standards of ERISA and the Code with respect to each Plan and is in compliance (except where the failure to so comply could not reasonably be expected to have a Material
Adverse Effect) with the presently applicable provisions of ERISA and the Code with respect to each Plan. Except as reflected in the PBGC Settlement Agreement, no member of the ERISA Group has (i) sought a waiver of the minimum funding standard
under Section 412 of the Code in respect of any Plan, (ii) failed to make any contribution or payment to any Plan or Multiemployer Plan, or made any amendment to any Plan, which has resulted or could result in the imposition of a Lien or the posting
of a bond or other security under ERISA or the Code or (iii) incurred any liability under Title IV of ERISA other than a liability to the PBGC for premiums under Section 4007 of ERISA. 
  

 47 

 (l) The Servicer has complied with the Credit and Collection Policy in all material respects and since
the date of this Agreement there has been no change in the Credit and Collection Policy except as permitted hereunder. The Servicer has not extended or modified the terms of any Pool Receivable or the Contract under which any such Pool Receivable
arose, except in accordance with the Credit and Collection Policy and in accordance with Section 6.2(b). 
  
 (m) No effective financing statement or other instrument similarly in effect covering any Contract or any Pool Receivable or Related Security or
Collections with respect thereto is on file in any recording office, except those set forth on Schedule IV hereto and those filed in favor of the Agent relating to this Agreement or in favor of the Seller and the Agent relating to the
Receivables Sale Agreement. 
  
 (n) Each of the Servicer and its
Subsidiaries (including, for purposes of this Section, the Lyondell Joint Ventures) has filed all United States Federal income tax returns and all other material tax returns which are required to be filed by them and have paid or accrued all taxes
shown to be due on such returns or on any assessment received by Lyondell or any Subsidiary and required to be paid or accrued by it, except to the extent that any such taxes are being contested in good faith by appropriate proceedings. 

 
 (o) Neither the Servicer nor any of its Subsidiaries is an
“investment company” as defined in, or is otherwise subject to regulation under, the Investment Company Act of 1940. Neither the Servicer nor any of its Subsidiaries is subject to regulation as a “holding company” under the
Public Utility Holding Company Act of 1935. 
  
 (p) (i) Neither
the Servicer nor any of its Subsidiaries is in violation of any law, or in default with respect to any judgment, writ, injunction, decree, rule or regulation of any Governmental Authority, where such violation or default could reasonably be expected
to result in a Material Adverse Effect. 
  
 (ii)
No Potential Event of Termination or Event of Termination has occurred and is continuing. 
  
 (q) (i) The audited consolidated balance sheet of Lyondell and its Consolidated Subsidiaries as of December 31, 2002 and the related consolidated statements of income, of stockholders’ equity and of cash flows
for the fiscal year then ended, reported on by PricewaterhouseCoopers LLP, and set forth in the Servicer’s 2002 annual report on Form 10-K filed with the SEC, a copy of which has been furnished to the Agent for distribution to the Purchasers,
fairly present, in all material respects and in conformity with GAAP, the consolidated financial position of Lyondell and its Consolidated Subsidiaries as of such date and their consolidated results of operations and cash flows for such fiscal year.

  
 (ii) The unaudited consolidated balance sheet
of Lyondell and its Consolidated Subsidiaries as of June 30, 2003 and the related unaudited consolidated statements of income and of cash flows for the six months then ended, set forth in Lyondell’s quarterly report for the fiscal quarter ended
June 30, 2003 on Form 10-Q filed with the SEC, a copy of which has been furnished to the Agent for distribution to the Purchasers, fairly present, in all material respects and in conformity with GAAP applied on a basis consistent with the financial
statements referred to in subsection (i) of this Section 4.2(q), the consolidated financial position of Lyondell and its Consolidated Subsidiaries as of such date and their consolidated results of operations and cash flows for such six month period
(subject to normal year-end adjustments). 
  

 48 

 (iii) The financial projections provided to the Agent pursuant to Section 3.1(d)(iii) and
in the Confidential Information Memorandum were prepared in good faith on the basis of the assumptions described in the Confidential Information Memorandum, which assumptions were believed by the Servicer in good faith to be reasonable in light of
the then current and reasonable foreseeable business conditions of Lyondell and its Consolidated Subsidiaries existing at the time of preparation thereof, and the Servicer has no knowledge of any event or circumstance that would cause it to change
any such assumptions in any material respect as of the date hereof, it being understood by the Agent and the Purchasers that actual results will likely vary from the projected results set forth therein. 
  
 ARTICLE V 
  
 GENERAL COVENANTS OF
THE SELLER AND THE SERVICER 
  
 Section 5.1 Affirmative Covenants of the Seller. 
  
 Until the later of (i) the Termination Date and (ii) the date upon which no Capital shall be outstanding and no Yield or
other Obligations of the Seller remain unpaid under this Agreement, the Seller will: 
  
 (a) Compliance with Laws, Etc. Comply in all material respects with all applicable laws, rules and regulations, and all orders of any Governmental Authority applicable to it and all Pool Receivables and related
Contracts, Related Security and Collections with respect thereto. 
  
 (b) Preservation of Existence. Preserve and maintain its existence, rights, franchises and privileges in the jurisdiction of its organization, and qualify and remain qualified in good standing as a foreign entity in each jurisdiction
where the failure to preserve and maintain such qualification would materially adversely affect the interests of the Purchasers or the Agent hereunder or in the Pool Receivables and Related Security, or the ability of the Seller or the Servicer to
perform their respective obligations under the Transaction Documents. 
  
 (c) Payment of Taxes. Pay and discharge before the same shall become delinquent, all lawful governmental claims, taxes, assessments, charges and levies, except where contested in good faith, by proper proceedings and adequate
reserves therefor have been established on the books of the Seller in conformity with GAAP. 
  
 (d) Compliance with Constituent Documents. Comply with, and cause compliance with, the provisions of the Constituent Documents of the Seller delivered to the Agent pursuant to Section 3.1 as the same may, from
time to time, be amended, supplemented or otherwise modified with the prior written consent of the Agent. 
  
 (e) Offices, Records and Books of Accounts. 
  
 (i) Keep its principal place of business and chief executive office and the offices where it keeps its
Records concerning the Pool Receivables at the address of the Seller referred to in Section 4.1(j) or, upon at least 30 days’ prior written notice to the Agent, at any other location in a jurisdiction where all requested actions under Section
6.5(a) shall have been taken; 
  

 49 

 (ii) Maintain and implement administrative and operating procedures (including, without
limitation, an ability to recreate, in all material respects, records evidencing Pool Receivables in the event of the destruction of the originals thereof), and keep and maintain all documents, books, records and other information reasonably
necessary or advisable for the collection of all Pool Receivables (including, without limitation, records adequate to permit the daily identification of each Pool Receivable, the Outstanding Balance of each Pool Receivable and the dates which
payments are due thereon and all Collections of and adjustments to each existing Pool Receivable). 
  
 (iii) Keep, or cause to be kept, proper books of record and account, which shall be maintained or caused to be maintained by the Seller
and shall be separate and apart from those of any Affiliate of the Seller, in which entries that are full and correct in all material respects shall be made of all financial transactions and the assets and business of the Seller in accordance with
GAAP; 
  
 (iv) To the extent Records are in
written form, segregate such Records in file cabinets or storage containers and appropriately label such file cabinets or storage containers to reflect that the Receivable Interests have been conveyed to the Purchasers; and 
  
 (v) To the extent such Records constitute computer programs
and other non-written Records, appropriately legend such Records to reflect that the Receivable Interests have been conveyed to the Purchasers. 
  
 (f) Examination of Records; Audits. 
  
 (i) From time to time upon ten (10) Business Days’ (or, during the continuance of a Triggering Event of the type described in clause
(iii), (iv) or (v) of the definition of “Triggering Event”, five (5) Business Days’) prior notice (except that during the continuance of a Potential Event of Termination or Event of Termination, no such notice shall be required) and
during regular business hours as requested by the Agent and at the expense of the Agent, if a Potential Event of Termination or Event of Termination does not exist, and otherwise at the expense of the Seller, permit the Agent, or its agents or
representatives, (A) to examine and make copies of and abstracts from all Records in the possession or under the control of the Seller, or the agents of the Seller, relating to Pool Receivables and the Related Security, including, without
limitation, the related Contracts, and (B) to visit the offices and properties of the Seller, or the agents of the Seller, for the purpose of examining such materials described in clause (A) above, and to discuss matters relating to Pool Receivables
and the Related Security or the Seller’s performance hereunder or under the Contracts with any of the officers or employees of the Seller having knowledge of such matters and designated by the Seller to discuss such matters with the Agent or
its agents or representatives. Unless a Potential Event of Termination or Event of Termination is continuing, the Agent agrees to combine any request for any such examinations and visits with any request being made under Section 5.4(f). 

 
 (ii) The Seller shall furnish to the Agent any
information that the Agent may reasonably request regarding the determination and calculation of the Net Receivables Pool Balance including copies of any invoices, underlying agreements, instruments or other documents and the identity of all
Obligors in respect of Receivables referred to therein. 
  

 50 

 (g) Performance and Compliance with Contracts and Credit and Collection Policy. At its expense,
(i) perform, or cause to be performed, and comply in all material respects with, or cause to be complied with in all material respects, in a timely manner all provisions, covenants and other promises (if any) required to be observed by it under the
Contracts related to the Pool Receivables, and comply in all material respects and in a timely manner with the Credit and Collection Policy in regard to the Pool Receivables and the related Contracts and (ii) as beneficiary of any Related Security,
enforce such Related Security as reasonably requested by the Agent. 
  
 (h) Transaction Documents. At its expense, require each Originator and the Servicer to timely and fully perform and comply in all material respects with all provisions, covenants and other promises required to be observed by them
under each of the Transaction Documents, maintain each of the Transaction Documents to which it is a party in full force and effect, enforce in accordance with its terms, take all such action to such end as may be from time to time reasonably
requested by the Agent, and make to any party to each of such Transaction Documents such demands and requests for information and reports or for action as the Seller is entitled to make thereunder and as may be from time to time reasonably requested
by the Agent. 
  
 (i) Deposits to Lock-Box Accounts.
Instruct, or cause the Servicer to instruct, all Obligors to make payments in respect of Pool Receivables to a Lock-Box Account and, if the Seller or any Originator shall otherwise receive any Collections (including, without limitation, any
Collections deemed to have been received by the Seller pursuant to Section 2.9), segregate and hold in trust such Collections and deposit such Collections, or cause such Collections to be deposited, to a Lock-Box Account within 2 Business Days
following such receipt. 
  
 (j) Maintenance of Separate
Existence. Do all things necessary to maintain its existence separate and apart from each Originator and other Affiliates of the Seller, including, without limitation, (i) maintaining proper limited liability company records and books of account
separate from those of such Affiliates; (ii) maintaining its assets, funds and transactions separate from those of such Affiliates, reflecting such assets, funds and transactions in financial statements separate and distinct from those of such
Affiliates, and evidencing such assets, funds and transactions by appropriate entries in the records and books referred to in clause (i) above, and providing for its own operating expenses and liabilities from its own assets and funds other than
certain expenses and liabilities relating to basic corporate overhead which may be allocated between the Seller and such Affiliates; (iii) holding such appropriate meetings or obtaining such appropriate consents of its Board of Managers as are
necessary to authorize all the Seller’s actions required by law to be authorized by its Board of Managers, keeping minutes of such meetings and of meetings of its members and observing all other necessary organizational formalities (and any
successor Seller shall observe similar procedures in accordance with its governing documents and applicable law); (iv) at all times entering into its contracts and otherwise holding itself out to the public under the Seller’s own name as a
legal entity separate and distinct from such Affiliates; and (v) conducting all transactions and dealings between the Seller and such Affiliates on an arm’s-length basis. 
  
 (k) Purchase of Pool Receivables from Originators. With respect to each Pool Receivable acquired from any Originator
by the Seller other than as a capital contribution, pay to such Originator (in accordance with the Receivables Sale Agreement) an amount which constitutes fair consideration and approximates fair market value for such Pool Receivable and in a sale
the terms and conditions of which (including, without limitation, the purchase price thereof) reasonably approximates an arm’s-length transaction between unaffiliated parties. 
  

 51 

 Section 5.2 Reporting Requirements of the Seller. 
  
 Until the later of (i) the Termination Date and (ii) the date upon which no
Capital shall be outstanding and no Yield or other Obligations of the Seller remain unpaid under this Agreement, the Seller will furnish to the Agent for distribution to the Purchasers: 
  
 (a) Annual Reports. Within 100 days after the end of each Fiscal Year, financial statements (which shall include a
balance sheet and income statement, as well as statements of member’s equity and cash flow) showing the financial condition and results of operations of the Seller as of the end of and for such Fiscal Year, in each case certified by a
Responsible Officer of the Seller as presenting fairly, in all material respects, the financial position and results of operation of the Seller and as having been prepared in accordance with GAAP, together with a certificate of such Responsible
Officer stating that such financial statements present fairly, in all material respects, the financial position of the Seller as at the dates indicated and the results of their operations and cash flow for the periods indicated in conformity with
GAAP applied on a basis consistent with prior years (except for changes that shall have been disclosed in the notes to the financial statements). 
  
 (b) Notice of Even of Termination. Promptly and in any event within 2 Business Days after a Responsible Officer of the
Seller first becomes aware of each Event of Termination or Potential Event of Termination continuing on the date of such statement, a statement of a Responsible Officer of the Seller setting forth details of such Event of Termination or Potential
Event of Termination and the action which the Seller has taken and proposes to take with respect thereto. 
  
 (c) Other. Promptly, from time to time, such other information, documents, records or reports respecting this Agreement or the other Transaction
Documents, the Receivables, the Related Security, the Contracts, the Restricted Accounts or the condition or operations, financial or otherwise, of the Seller as the Agent may from time to time reasonably request. 
  
 Section 5.3 Negative Covenants of the Seller.

  
 Until the later of (i) the Termination Date and (ii)
the date upon which no Capital shall be outstanding and no Yield or other Obligations of the Seller remain unpaid under this Agreement, the Seller will not: 
  
 (a) Indebtedness. Except as otherwise provided herein or in the Receivables Sale Agreement, create, incur, assume or suffer to exist any
Indebtedness, other than (i) Indebtedness of the Seller representing fees, expenses and indemnities arising hereunder or under the Receivables Sale Agreement for the purchase price of the Receivables under the Receivables Sale Agreement, and (ii)
other Indebtedness of the Seller incurred in the ordinary course of its business in an amount not to exceed $9,500 at any time outstanding. 
  
 (b) Sales, Liens, Etc. Except as otherwise provided herein, sell, lease, transfer, assign (by operation of law or otherwise) or otherwise dispose
of, or grant any option with respect to, or create or suffer to exist any Lien upon or with respect to any of its properties or assets, whether now owned or hereafter acquired, including, but not limited to, its undivided interest in any Pool
Receivable or Related Security or Collections in respect thereof, or upon or with respect to any related Contract or any Deposit Account to which any Collections of any Pool Receivable are sent (including, without limitation, any Lock-Box Account),
or assign any right to receive income in respect thereof. 
  
 (c)
Investments. Except as otherwise provided herein or in the Receivables Sale Agreement, directly or indirectly make or maintain any Investment. 
  

 52 

 (d) Restricted Payments. Directly or indirectly, declare, order, pay, make or set apart any sum
for any redemption, retirement or cancellation of the Seller’s Equity Interests or any Subordinated Note other than pursuant to or in accordance with the Transaction Documents. 
  
 (e) Merger, Etc. Consolidate with or merge into any other Person, acquire all or substantially all of the
Stock or Stock Equivalents of any Person, acquire all or substantially all of the assets of any Person or all or substantially all of the assets constituting the business of a division, branch or other unit operation of any Person, enter into any
joint venture or partnership with any Person or acquire or create any Subsidiary. 
  
 (f) Change in Credit and Collection Policy. Make any changes in the Credit and Collection Policy that would be reasonably likely to impair the collectibility of the Pool Receivables. 
  
 (g) Organizational Documents; Change of Name, Etc. 
  
 (i) Amend, supplement or otherwise modify any of its
Constituent Documents. 
  
 (ii) Change its name,
identity, form of legal structure or jurisdiction of organization, unless, prior to the effective date of any such change, the Seller delivers to the Agent (x) UCC financing statements necessary to reflect such change and to continue the perfection
of the ownership interests in the Receivable Interests contemplated by this Agreement and (y) if the identity or structure of the Seller has changed and such change adversely affects the rights of the Agent under then existing Lock-Box Agreements
and other control agreements with the Seller to take control of the Lock-Box Accounts and other Restricted Accounts pursuant to Section 6.3(a), new Lock-Box Agreements and other control agreements executed by the Seller and the relevant banks, to
the extent necessary to reflect such changes and to continue to enable the Agent to exercise such rights. 
  
 (h) Accounting. Account for (including for accounting and tax purposes) or otherwise treat the transactions contemplated by the Receivables Sale
Agreement in any manner other than as sales of Receivables by any Originator to the Seller, or account for (other than for tax purposes) or otherwise treat the transactions contemplated by this Agreement in any manner other than as sales of
Receivable Interests by the Seller to the Agent for the account of the Purchasers. 
  
 (i) Affiliate Transactions. Except as contemplated or permitted by the Transaction Documents, enter into any other transaction directly or indirectly with or for the benefit of any Affiliate of the Seller.

  
 (j) ERISA. Adopt, maintain, contribute to or incur or
assume any obligation with respect to any Plan, Multiemployer Plan or Welfare Plan, except such obligation or contingent obligation that arises as a matter of law solely as a result of another member of the ERISA Group’s sponsorship of a Plan,
Multiemployer Plan or Welfare Plan. 
  
 (k) Lease
Obligations. Create, incur, assume or suffer to exist any obligations as lessee for the rental or lease of real or personal property, other than for the lease or rental of an office space or office equipment for use by the Seller in the ordinary
course of its business. 
  

 53 

 (l) Extension or Amendment of Receivables. Except as otherwise permitted in Section 6.2, extend,
amend or otherwise modify the terms of any Pool Receivable, or amend, modify or waive any term or condition of any Contract related thereto. 
  
 (m) Change in Payment Instructions to Obligors. Add or terminate any bank as a Lock-Box Bank or any Deposit Account as a Lock-Box Account from
those listed in Schedule I, or make any change in the instructions to Obligors regarding payments to be made to any Lock-Box Account, unless the Agent shall have received at least 20 days’ prior written notice of such addition,
termination or change and shall have received, with respect to each new Lock-Box Account, a Lock-Box Agreement executed by the Lock-Box Bank that maintains such Lock-Box Account and the Seller or any Originator, as applicable. 
  
 (n) Deposits to Lock-Box Accounts. Deposit or otherwise credit, or
cause or grant any permission to be so deposited or credited, to any Lock-Box Account cash or cash proceeds other than Collections of Pool Receivables. 
  
 (o) Receivables Sale Agreement. (i) Cancel or terminate the Receivables Sale Agreement or consent to or accept any cancellation or termination
thereof, (ii) amend, supplement or otherwise modify any term or condition of the Receivables Sale Agreement or give any consent, waiver or approval thereunder, (iii) waive any default under or breach of the Receivables Sale Agreement or (iv) take
any other action under the Receivables Sale Agreement not required by the terms thereof that would impair the value of any Receivable Assets (as defined therein) or the rights or interests of the Seller thereunder or of the Agent or any Purchaser or
Indemnified Party hereunder or thereunder. 
  
 (p) Use of
Proceeds. Use the proceeds of any Purchase or reinvestment to acquire any security in any transaction which is subject to Sections 13 and 14 of the Securities Exchange Act of 1934 (unless such transaction shall have been approved by the board of
directors (or comparable governing body) of the issuer of such Security) or, whether directly or indirectly, and whether immediately, incidentally or ultimately, for any purpose which entails a violation of the provisions of the Regulations of the
Board, including Regulation U or X thereof. 
  
 Section 5.4 Affirmative Covenants of the Servicer. 
  
 Until the later of (i) the Termination Date and (ii) the date upon which no Capital shall be outstanding and no Yield or other Obligations of the Seller remain unpaid under this Agreement, the Servicer shall:

  
 (a) Existence. Do or cause to be done all things
necessary to preserve, renew and keep in full force and effect its legal existence. 
  
 (b) Compliance with Laws, Etc. Comply, in all material respects with all applicable laws, ordinances, rules, regulations and requirements of governmental authorities (including, without limitation,
Environmental Laws and ERISA and the rules and regulations thereunder), except where the necessity of compliance therewith is contested in good faith by appropriate proceedings or where the failure to do so, individually or in the aggregate, could
not reasonably be expected to have a Material Adverse Effect. 
  
 (c) Business and Properties. Except to the extent the failure to do so, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect, at all times (a) do or cause to be done all things
reasonably necessary to preserve, renew and keep in full force and effect the rights, licenses, permits, franchises, patents, copyrights, trademarks and trade names material to the conduct of its business; and (b) maintain, preserve and protect all
property material to the conduct of such business. 
  

 54 

 (d) Payment of Taxes. Pay and discharge all material taxes, assessments and governmental charges
or levies imposed upon it or upon its income or profits or in respect of its property before the same shall become delinquent or in default, which, if unpaid, might give rise to liens or charges upon such properties or any part thereof, unless and
to the extent that any such tax, assessment, charge, or levy is being contested in good faith by appropriate proceedings and adequate reserves are being maintained on its books with respect thereto to the extent required by GAAP. 
  
 (e) Books of Accounts. 
  
 (i) To the extent Records are (A) in written form, segregate
such Records in file cabinets or storage containers and appropriately label such file cabinets or storage containers to reflect that the Receivable Interests have been conveyed to the Purchasers, or (B) constitute computer programs and other
non-written Records, appropriately legend such Records to reflect that the Receivable Interests have been conveyed to the Purchasers. 
  
 (ii) Maintain and implement administrative and operating procedures (including, without limitation, an ability to recreate, in all
material respects, records evidencing Pool Receivables in the event of the destruction of the originals thereof), and keep and maintain all documents, books, records and other information reasonably necessary or advisable for the collection of all
Pool Receivables (including, without limitation, records adequate to permit the daily identification of each Pool Receivable, the Outstanding Balance of each Pool Receivable and the dates which payments are due thereon and all Collections of and
adjustments to each existing Pool Receivable). 
  
 (f)
Examination of Records; Audits. 
  
 (i)
From time to time upon ten (10) Business Days’ (or, during the continuance of a Triggering Event of the type described in clause (iii), (iv) or (v) of the definition of “Triggering Event”, five (5) Business Days’) prior notice
(except that during the continuance of a Potential Event of Termination or Event of Termination, no such notice shall be required) and during regular business hours as requested by the Agent and at the expense of the Agent, if a Potential Event of
Termination or Event of Termination does not exist, and otherwise at the expense of the Servicer, permit the Agent, or its agents or representatives, (A) to examine and make copies of and abstracts from all Records in the possession or under the
control of any Originator, the Servicer or their respective Affiliates or Subsidiaries or the agents of such Originator, the Servicer or their respective Affiliates or Subsidiaries, relating to Pool Receivables and the Related Security, including,
without limitation, the related Contracts, and (B) to visit the offices and properties of any Originator, the Servicer, their respective Affiliates or Subsidiaries (other than the Seller) or the agents of such Originator, the Servicer or their
respective Affiliates or Subsidiaries, for the purpose of examining such materials described in clause (a) above, and to discuss matters relating to Pool Receivables and the Related Security or the Servicer’s performance hereunder or under the
Contracts with any of the officers or employees of the Servicer having knowledge of such matters and designated by the Servicer to discuss such matters with the Agent or its agents or representatives. Unless a Potential Event of Termination or Event
of Termination is continuing, the Agent agrees to combine any request for any such examinations and visits with any request being made under Section 5.1(f). 
  

 55 

 (ii) The Agent may (at its own election or at the request of the Required Purchasers), at
the Servicer’s sole cost and expense, make test verifications and other evaluations of the Receivables in any manner and through any medium that the Agent considers advisable, and the Servicer shall furnish all such assistance and information
as the Agent may require in connection therewith; provided that, unless a Potential Event of Termination or an Event of Termination has occurred and is continuing, the Agent shall conduct no more than four such evaluations pursuant to this
Section during any calendar year. The Servicer shall pay the documented fees and expenses of employees or other representatives of the Agent in connection with such evaluations. In-house examination charges shall be limited to an amount up to $1,000
per day per examiner (employee or representative) plus such examiner’s reasonable out-of-pocket expenses, including travel expenses, incurred in connection with such evaluation. The Agent shall furnish to each Purchaser a copy of the final
written report prepared in connection with any such evaluation and shall provide the Servicer and the Seller with a summary of the analysis of the Receivables contained in any such final written report not less than two Business Days prior to
delivery thereof to the Purchasers. 
  
 (iii) The
Servicer shall furnish to the Agent any information that the Agent may reasonably request regarding the determination and calculation of the Net Receivables Pool Balance including correct and complete copies of any invoices, underlying agreements,
instruments or other documents and the identity of all Obligors in respect of Receivables referred to therein. 
  
 (g) Performance and Compliance with Contracts and Credit and Collection Policy. At its own expense, timely and fully (i) perform, or cause to be
performed, and comply in all material respects with, or cause to be complied with in all material respects, all provisions, covenants and other promises required to be observed by it under the Contracts related to the Pool Receivables, and timely
and fully comply in all material respects with the Credit and Collection Policy in regard to the Pool Receivables and the related Contracts and (ii) as beneficiary of any Related Security, enforce and cause each other Originator to enforce such
Related Security as reasonably requested by the Agent. 
  
 (h)
Transaction Documents. At its expense, maintain each of the Transaction Documents to which it is a party in full force and effect, enforce in accordance with its terms, take all such action to such end as may be from time to time reasonably
requested by the Agent, and make to any party to each of such Transaction Documents such demands and requests for information and reports or for action as it is entitled to make thereunder and as may be from time to time reasonably requested by the
Agent. 
  
 (i) Deposits to Lock-Box Accounts. Instruct all
Obligors to make payments in respect of Pool Receivables to a Lock-Box Account and, if the Servicer shall otherwise receive any Collections (including, without limitation, any Collections deemed to have been received by the Seller pursuant to
Section 2.9), segregate and hold in trust such Collections and deposit such Collections, or cause such Collections to be deposited, to a Lock-Box Account within 2 Business Days following such receipt. 
  

 56 

 Section 5.5 Reporting Requirements of the Servicer. 
  
 Until the later of (i) the Termination Date and (ii) the date upon which no
Capital Investment shall be outstanding and no Yield or other Obligations of the Seller remain unpaid under this Agreement, the Servicer shall furnish to the Agent for distribution to the Purchasers: 
  
 (a) Monthly Reports. During the existence of a Triggering Event,
within 30 days after the end of each of the first two fiscal months in each fiscal quarter of Lyondell, unaudited consolidated financial statements (which shall include a balance sheet and income statement, as well as statements of
stockholders’ equity and cash flow) showing the financial condition and results of operation of Lyondell and its Consolidated Subsidiaries as of the end of and for such fiscal month and that portion of the current Fiscal Year ending as of the
close of such month, in each case certified by a Principal Financial Officer of Lyondell as being the same monthly financial statements generated in accordance with Lyondell’s normal procedures and submitted to management of Lyondell. The Agent
and the Purchasers acknowledge that any monthly unaudited consolidated financial statements furnished pursuant to this Section 5.5(a) will not be accompanied by the footnotes and other disclosures that would be necessary for fair presentation in
accordance with GAAP. 
  
 (b) Quarterly Reports.
Subject to the last paragraph of this Section 5.5, within 50 days after the end of each of the first three fiscal quarters of each Fiscal Year, unaudited consolidated financial statements (which shall include a balance sheet and income statement, as
well as statements of stockholders’ equity and cash flow) showing the financial condition and results of operations of Lyondell and its Consolidated Subsidiaries as of the end of and for such fiscal quarter, in each case certified by a
Principal Financial Officer of Lyondell as presenting fairly, in all material respects, the financial position and results of operations of Lyondell and its Consolidated Subsidiaries and as having been prepared in accordance with the rules and
regulations of the SEC applicable to quarterly reports on Form 10-Q. 
  
 (c) Annual Reports. Subject to the last paragraph of this Section 5.5, within 100 days after the end of each Fiscal Year, consolidated and consolidating financial statements (which shall include a balance sheet and income statement,
as well as statements of stockholders’ equity and cash flows) showing the financial condition and results of operations of the Servicer and its Consolidated Subsidiaries as of the end of and for such Fiscal Year. The consolidated financial
statements of the Servicer and its Consolidated Subsidiaries delivered pursuant to this paragraph will be audited and reported on by independent public accountants of recognized standing and shall be accompanied by a statement of such firm of
independent public accountants stating whether during the course of their examination of such financial statements they obtained knowledge of any Potential Event of Termination or any Event of Termination existing on the date of such statements
(which statement may be limited to the extent required by accounting rules or guidelines, including the rules and guidelines of the public accounting firm giving such statements). 
  
 (d) Principal Financial Officer’s Certification. Concurrently with (b) and (c) above, a certificate of a
Principal Financial Officer of the Servicer, 
  
 (i) certifying that to the best knowledge of such Principal Financial Officer no Potential Event of Termination or Event of Termination has occurred and is continuing or, if a Potential Event of Termination or Event of Termination has
occurred and is continuing, specifying the nature and extent thereof and any corrective action taken or proposed to be taken with respect thereto; and 
  
 (ii) solely in the case of (c) above, certifying that except as previously notified to the Agent pursuant to Section 5.3(g) or Section
5.6(b) there has been no change in any Transaction Party’s name, form of organization, jurisdiction of organization and organizational number or Federal Taxpayer Identification Number. 
  

 57 

 (e) Public Reports. Subject to the last paragraph of this Section 5.5, promptly after the same
shall have been filed or furnished as described below, copies of such registration statements (other than exhibits thereto and any registration statements on Form S-8 or its equivalent), annual, periodic and other reports, and such proxy statements
and other information, if any, as shall be filed by Lyondell or any Subsidiary with the SEC pursuant to the requirements of the Securities Act of 1933 or the Securities Exchange Act of 1934 or the rules promulgated thereunder. 
  
 (f) Seller Report. On or prior to the tenth Business Day of each
calendar month: 
  
 (i) a Seller Report relating
to each Receivable Interest, as of the close of business of the Servicer on the last day of the immediately preceding calendar month; 
  
 (ii) a listing of the ten Obligors owing the greatest dollar amount of Pool Receivables, together with a report setting forth (A) the name
of such Obligor, (B) the balance of the Pool Receivables owing by such Obligor as of such date, and (C) a summary of credit terms applicable to such Pool Receivables under the applicable Contract; 
  
 (iii) a listing by Obligor of all Pool Receivables, together
with an analysis as to the aging of such Receivables, as of such last day; and 
  
 (iv) such other information as shall be reasonably requested from time to time by the Agent or by the Agent at the request of the Required
Purchasers; 
  
 provided, that during the existence of a Triggering Event,
on the second Business Day of each calendar week, the Servicer shall deliver a Seller Report relating to each Receivable Interest as of the close of business on the last day of the immediately preceding calendar week, except that, to the extent the
information otherwise required to be set forth in a monthly Seller Report is not generally available to the Servicer on a weekly basis, the Seller Report shall be prepared on the basis of the aggregate amount of Collections from the Pool Receivables
received by or on behalf of the Servicer as of the end of the immediately preceding calendar week and the aggregate of sales and billings of each Originator as of the end of the immediately preceding calendar week and otherwise on the basis of the
applicable information contained in the most recent monthly Seller Report received by the Agent. 
  
 (g) Net Receivables Pool Balance Report. As soon as possible and in any event within 2 Business Days after a Responsible Officer of the Servicer
first becomes aware that any of the following is true: (i) the Net Receivables Pool Balance is less than 75% of the Net Receivables Pool Balance reflected in the most recent Seller Report delivered pursuant to clause (f) above, or (ii) the Net
Receivables Pool Balance is less than 105% of the Required Net Receivables Pool Balance (giving effect to any calculated reduction in Capital by an amount equal to the amount on deposit in the Cash Assets Account that is available for application
therefor pursuant to Section 2.6(a)(iii) or (iv) or Section 2.7(a)(iii) or (iv), as applicable, as of the close of business on the relevant day of determination), or (iii) the outstanding Capital exceeds the Net Receivables Pool Balance as a result
of a decrease therein, a statement of a Responsible Officer of the Servicer setting forth details of such event and, in the case of clause (iii) such notice shall also include the amount of such excess. 
  

 58 

 (h) Litigation, Etc. Give the Agent prompt written notice (which the Agent shall promptly deliver
to the Purchasers) after any Responsible Officer learns of the following: 
  
 (i) the issuance by any Governmental Authority of any injunction, order, decision or other restraint prohibiting, or having the effect of prohibiting, the transactions contemplated by the Transaction Documents,
including the making of the Capital Investments, or having the effect of invalidating any provision of this Agreement or any other Transaction Document or the initiation of any litigation or similar proceeding seeking any such injunction, order,
decision or other restraint; 
  
 (ii) the filing
or commencement of any action, suit or proceeding against any Transaction Party or any Subsidiary, whether at law or in equity or by or before any Governmental Authority or any arbitrator, as to which action, suit or proceeding there is a reasonable
likelihood of an adverse determination and which, if determined adversely to such Transaction Party or any Subsidiary, could reasonably be expected to result in a Material Adverse Effect; 
  
 (iii) any member of the ERISA Group (A) giving or being
required to give notice to the PBGC of any “reportable event” (as defined in Section 4043 of ERISA) with respect to any Plan which might constitute grounds for a termination of such Plan under Title IV of ERISA, or such ERISA Group Member
knowing that the plan administrator of any Plan has given or is required to give notice of any such reportable event, and such notice to the Agent shall attach a copy of the notice of such reportable event given or required to be given to the PBGC;
(B) receiving notice of complete or partial withdrawal liability under Title IV of ERISA or notice that any Multiemployer Plan is in reorganization, is insolvent or has been terminated, and such notice to the Agent shall attach a copy of such
notice; (C) receiving notice from the PBGC under Title IV of ERISA of an intent to terminate, impose liability (other than for premiums under Section 4007 of ERISA) in respect of, or appoint a trustee to administer any Plan, and such notice to the
Agent shall attach a copy of such notice; (D) applying for a waiver of the minimum funding standard under Section 412 of the Internal Revenue Code, and such notice to the Agent shall attach a copy of such application; (E) giving notice of intent to
terminate any Plan under Section 4041(c) of ERISA, and such notice to the Agent shall attach a copy of such notice and other information filed with the PBGC; (F) giving notice of withdrawal from any Plan pursuant to Section 4063 of ERISA, and such
notice to the Agent shall attach a copy of such notice; or (G) failing to make any payment or contribution to any Plan or Multiemployer Plan or making any amendment to any Plan which has resulted or could result in the imposition of a Lien or the
posting of a bond or other security, and such notice to the Agent shall attach a certificate of Lyondell’s chief financial officer or chief accounting officer setting forth details as to such occurrence and the action, if any, which Lyondell or
applicable member of the ERISA Group is required or proposes to take; 
  
 (iv) the existence of (i) any Triggering Event or (ii) any Potential Event of Termination or Event of Termination, specifying the nature and extent thereof and the action (if any) which is proposed to be taken with
respect thereto. 
  
 (i) Information Regarding the
Servicer. Give the Agent at least 20 days’ prior written notice of any proposal to change the Servicer’s (i) name, (ii) form of organization, (iii) jurisdiction of organization, (iv) organizational number or (v) Federal Taxpayer
Identification Number. 
  
 (j) Other. Promptly, from time
to time, such other information, documents, records or reports respecting this Agreement or the other Transaction Documents, the Receivables, the Related Security, the Contracts, the Restricted Accounts or the condition or operations, financial or
otherwise, of any Transaction Party as the Agent may from time to time reasonably request. 
  

 59 

 Information required to be delivered pursuant to Sections 5.5(b), 5.5(c) and 5.5(e) shall be deemed to
have been delivered on the date on which the Servicer provides notice to the Agent that such information has been posted on Lyondell’s website on the Internet at www.lyondell.com or at www.sec.gov or at another website identified
in such notice and accessible by the Purchasers without charge; provided that (i) such notice may be included in a certificate delivered pursuant to Section 5.5(d), (ii) the certification referred to in Section 5.5(b) shall be deemed made on
the date on which the Servicer provides notice to the Agent (as contemplated above) that the information referred to in such paragraph has been posted as described above and (iii) the Servicer shall deliver paper copies of the information referred
to in Sections 5.5(b), 5.5(c) and 5.5(e) to the Agent for distribution to (x) any Purchaser to which the above referenced websites are for any reason not available if such Purchaser has so notified the Servicer and (y) any Purchaser that has
notified the Servicer that it desires paper copies of all such information. 
  
 Section 5.6 Negative Covenants of the Servicer. 
  
 Until the later of (i) the Termination Date and (ii) the date upon which no Capital shall be outstanding and no Yield or other Obligations of the Seller remain unpaid under this Agreement, the Servicer shall not:

  
 (a) Change in Business Lines or Credit and Collection
Policy. Make any change in the character of its business or in the Credit and Collection Policy that would, in either case, be reasonably likely to impair the collectibility of the Pool Receivables. 
  
 (b) Organizational Documents; Change of Name, Etc. 
  
 (i) Amend, supplement or otherwise modify the Constituent
Documents of the Seller. 
  
 (ii) Change, or
cause any other Transaction Party to change, its name, identity, form of legal structure or jurisdiction of organization, unless, prior to the effective date of any such change, the Servicer delivers to the Agent (x) UCC financing statements
necessary to reflect such change and to continue the perfection of the ownership interests in the Receivable Interests contemplated by this Agreement and (y) if the identity or structure of a Transaction Party has changed and such change adversely
affects the rights of the Agent under then existing Lock-Box Agreements or other control agreements with such Transaction Party to take control of the Lock-Box Accounts and other Restricted Accounts pursuant to Section 6.3(a), new Lock-Box
Agreements and other control agreements executed by such Transaction Party and the relevant banks, to the extent necessary to reflect such changes and to continue to enable the Agent to exercise such rights. 
  
 (c) Accounting. Cause or permit the Seller to account for (including
for accounting and tax purposes) or otherwise treat the transactions contemplated by the Receivables Sale Agreement in any manner other than as sales of Receivables by any Originator to the Seller, or to account for (other than for tax purposes) or
otherwise treat the transactions contemplated by this Agreement in any manner other than as sales of Receivable Interests by the Seller to the Agent for the account of the Purchasers. 
  

 60 

 (d) Extension or Amendment of Receivables. Except as otherwise permitted in Section 6.2, extend,
amend or otherwise modify the terms or Outstanding Balance of any Pool Receivable, or extend, amend, modify or waive any term or condition of any Contract related thereto. 
  
 (e) Change in Payment Instructions to Obligors. Add or terminate any bank as a Lock-Box Bank or any Deposit Account
as a Lock-Box Account from those listed in Schedule I, or make any change in the instructions to Obligors regarding payments to be made to any Lock-Box Account, unless the Agent shall have received at least 20 days’ prior written notice of such
addition, termination or change and shall have received, with respect to each new Lock-Box Account, a Lock-Box Agreement executed by the Lock-Box Bank that maintains such Lock-Box Account and the Seller or any Originator, as applicable. 

 
 (f) Deposits to Lock-Box Accounts. Deposit or otherwise credit, or
cause or grant permission to be so deposited or credited, to any Lock-Box Account cash or cash proceeds other than Collections of Pool Receivables. 
  
 (g) Voluntary Petitions. Cause the Seller to file a voluntary petition under the U.S. Bankruptcy Code or any other bankruptcy or insolvency laws so
long as the Seller is not “insolvent” within the meaning of the U.S. Bankruptcy Code, and unless, and only unless, such filing has been authorized in accordance with the Seller’s Constituent Documents. 
  
 (h) Maintenance of Seller’s Separate Existence. Take any action,
or omit to take any action, if the effect is to cause the Seller to fail to perform or observe in any material respect the covenants contained in Section 5.1(d) and Section 5.1(j) above or to otherwise cause the Seller not to be considered as legal
entity separate and distinct from Lyondell or any other Affiliates or Subsidiaries. 
  
 ARTICLE VI 
  
 ADMINISTRATION AND COLLECTION 
  
 Section 6.1 Designation of Servicer. 
  
 (a) The Pool Receivables shall be serviced, administered and collected by the Person (the “Servicer”) designated to do so from time to time in accordance with this Section 6.1. Until the Agent
designates a new Servicer in accordance with Section 6.1(c), Lyondell is hereby designated as, and hereby agrees to perform the duties and obligations of, the Servicer pursuant to the terms hereof. 
  
 (b) The Servicer may subcontract with each Originator to service, administer
or collect the Pool Receivables that any Originator creates, and may, with the prior consent of the Agent (such consent not to be unreasonably withheld or delayed), subcontract with any other Person to service, administer or collect the Pool
Receivables, provided that such other Originator or other Person with whom the Servicer so subcontracts shall not become the Servicer hereunder and the Servicer shall remain liable for the performance of the duties and obligations of the
Servicer pursuant to the terms hereof. 
  
 (c) The Agent may at
any time following the occurrence of an Event of Termination designate as Servicer any Person (including itself) to succeed Lyondell, or, as the case may be, any successor Servicer, if such Person (other than itself) shall agree in writing to
perform the duties and obligations of the Servicer pursuant to the terms hereof. 
  

 61 

 Section 6.2 Duties of Servicer. 
  
 (a) The Servicer shall take or cause to be taken all such commercially
reasonable actions as may be necessary or advisable to collect each Pool Receivable from time to time, all in accordance with applicable laws, rules and regulations, with reasonable care and diligence, and in accordance with the Credit and
Collection Policy. Each of the Seller, the Purchasers and the Agent hereby appoints as its agent the Servicer, from time to time designated pursuant to Section 6.1, to enforce its respective rights and interests in and under the Pool Receivables,
the Related Security and the related Contracts. 
  
 (b) Unless an
Event of Termination shall have occurred and be continuing, the Servicer may, in accordance with the Credit and Collection Policy, (i) extend the maturity or adjust the Outstanding Balance of any Receivable as the Servicer may determine to be
appropriate to maximize Collections thereof, (ii) extend the term of any Contract and (iii) amend, modify or waive any other terms and conditions of any Contract. 
  
 (c) The Servicer shall administer the Collections in accordance with the procedures described herein and in Sections 2.6,
2.7, 2.8 and 2.9. The Servicer shall as soon as practicable following receipt, turn over to the Seller any cash collections or other cash proceeds received with respect to Receivables not constituting Pool Receivables. 
  
 (d) The Servicer shall hold in trust for the Seller and each Purchaser, in
accordance with their respective interests, all Records that evidence or relate to the Pool Receivables. The Servicer shall, upon the occurrence and during the continuance of any Event of Termination, and at the request of the Agent, provide to the
Agent the Records with respect to the Pool Receivables, provided that, in the case of Records consisting of computer programs, data processing software and any other intellectual property under license from third parties, the Servicer will
make available such Records only to the extent that the license for such property so permits. 
  
 Section 6.3 Rights of the Agent. 
  
 (a) The Seller and the Servicer each hereby transfer to the Agent the exclusive dominion and control of (x) the Lock-Box Accounts to which the Obligors of Pool Receivables shall make payments and (y) the other
Restricted Accounts, and shall take any further action that the Agent may reasonably request to effect such transfer. 
  
 (b) At any time during the continuance of an Event of Termination: 
  
 (i) The Agent may notify, at the Seller’s expense, the Obligors of Pool Receivables, or any of them, of
the ownership of Receivable Interests by the Purchasers. 
  
 (ii) The Agent may direct the Obligors of Pool Receivables, or any of them, to make payment of all amounts due or to become due to the Seller under any Pool Receivable directly to the Agent or its designee.

  
 (iii) The Seller and the Servicer each shall,
at the Agent’s request and at the Seller’s and the Servicer’s expense, give notice of such ownership to such Obligors and direct them to make such payments directly to the Agent or its designee. 
  
 (iv) The Seller and the Servicer each shall, at the
Agent’s request, (A) assemble, and make available to the Agent at a place reasonably selected by the Agent or 
  

 62 

 its designee, all of the Records which evidence or relate to the Pool Receivables, and the related
Contracts and Related Security, or which are otherwise necessary or desirable to collect the Pool Receivables, provided that, in the case of Records consisting of computer programs, data processing software and any other intellectual property
under license from third parties, the Servicer will make available such Records only to the extent that the license for such property so permits, and provided, further, that during the continuance of a Potential Event of Termination,
the Seller and the Servicer each shall, at the Agent’s request, commence the process of assembling such Records, and (B) segregate all cash, checks and other instruments received by it from time to time constituting Collections or other
proceeds of Pool Receivables in a manner reasonably acceptable to the Agent and shall, promptly upon receipt, remit all such cash, checks and instruments, duly endorsed or with duly executed instruments of transfer, to the Agent or its designee.

  
 (v) The Agent may take any and all
commercially reasonable steps in the Seller’s or the Servicer’s name and on behalf of the Seller and the Purchasers necessary or desirable, in the determination of the Agent, to collect all amounts due under any and all Pool Receivables,
including, without limitation, endorsing the Seller’s, or the Servicer’s name on checks and other instruments representing Collections or other proceeds of Pool Receivables, enforcing such Pool Receivables and the related Contracts, and
adjusting, settling or compromising the amount or payment thereof, in the same manner and to the same extent as the Seller or the Servicer might have done. 
  
 (c) At any time during the continuance of a Triggering Event, the Agent may, upon the instructions of the Required Purchasers and at the Seller’s
expense, request any of the Obligors of Pool Receivables to confirm the Outstanding Balance of such Obligor’s Pool Receivables. 
  
 Section 6.4 Responsibilities of the Seller. 
  
 Anything herein to the contrary notwithstanding: 
  
 (a) The Seller and the Servicer each shall perform all of its obligations under the Contracts related to the Pool Receivables to the same extent as if
Receivable Interests had not been sold hereunder and the exercise by the Agent of its rights hereunder shall not release the Seller or the Servicer from such obligations or its obligations with respect to Pool Receivables or under the related
Contracts; and 
  
 (b) Neither the Agent nor the Purchasers shall
have any obligation or liability with respect to any Pool Receivables or related Contracts, nor shall any of them be obligated to perform any of the obligations of the Seller or any Originator thereunder. 
  
 Section 6.5 Further Assurances. 
  
 (a) The Seller and the Servicer each agrees that from time to time, at its
expense, it will promptly execute and deliver all further instruments and documents, and take all further action, that may be necessary, or that the Agent may reasonably request, in order to perfect, protect or more fully evidence or maintain the
validity and effectiveness of the Receivable Interests purchased by the Purchasers hereunder, to carry out more effectively the purposes of the Transaction Documents and to enable any of them or the Agent to exercise and enforce any of their
respective rights and remedies under the Transaction Documents. Without limiting the generality of the foregoing, the Seller and the Servicer each will upon the request of the Agent, in order to perfect, protect or evidence such Receivable
Interests: (i) file or cause to be filed such financing or continuation statements, or amendments thereto or 
  

 63 

 assignments thereof, and such other instruments or notices, as may be necessary, or as the Agent may reasonably request;
(ii) from and after April 1, 2004, mark conspicuously each invoice evidencing each Pool Receivable with a legend stating that such Pool Receivable and related Contract has been sold, transferred and assigned to the Seller; and (iii) mark its master
data processing records evidencing such Pool Receivables and related Contracts with such legend. The Servicer also agrees to provide to the Agent, from time to time upon request, evidence reasonably satisfactory to the Agent as to the perfection and
priority of the Liens created or intended to be created by the Transaction Documents. 
  
 (b) The Seller hereby authorizes the Agent to file one or more financing or continuation statements, and amendments thereto and assignments thereof, relating to all or any of the Contracts, or Pool Receivables and the
Related Security and Collections with respect thereto, now existing or hereafter arising, without the signature of the Seller where permitted by law. A photocopy or other reproduction of this Agreement or any financing statement covering all or any
of the Contracts, or Pool Receivables and the Related Security and Collections with respect thereto shall be sufficient as a financing statement where permitted by law. 
  
 (c) If the Servicer or the Seller fails to perform any agreement contained herein, then after notice to the Servicer or the
Seller, as applicable, the Agent may itself perform, or cause performance of, such agreement, and the reasonable costs and expenses of the Agent incurred in connection therewith shall be payable by the Seller under Section 10.1 or Section 11.5, as
applicable. 
  
 ARTICLE VII 
  
 EVENTS OF TERMINATION

  
 Section 7.1 Events of Termination.

  
 If any of the following events (“Events of
Termination”) shall occur and be continuing: 
  
 (a) The
Seller or the Servicer shall fail to make any payment or deposit to be made by it hereunder when due and, except for deposits in respect of Capital, such failure shall continue for a period of at least five consecutive days; or 
  
 (b) Any representation or warranty made or deemed made by any Transaction
Party (or any of their respective officers) under or in connection with this Agreement or any other Transaction Document or in any Seller Report, or Receivables Report or any other written report, certificate or information delivered by or on behalf
of the Seller or any Originator or the Servicer (or any of their respective officers) pursuant hereto or thereto, shall prove to have been incorrect in any material respect when made or deemed made or delivered; provided, however, that
any such breach of a representation or warranty or any such inaccuracy that relates to a specific Pool Receivable shall not constitute an Event of Termination under this Section 7.1(b) if such breach or inaccuracy gives rise to an obligation of the
Seller to make a payment under Section 2.9(c) in respect of the affected Pool Receivable and the Seller has made such payment in accordance with Section 2.9(c) and, after giving effect to such payment and, if applicable, any calculated reduction in
Capital by an amount on deposit in the Cash Assets Account that is available for application therefor pursuant to Section 2.6 or 2.7, as applicable, the aggregate Receivable Interests would not exceed 100%; or 
  
 (c) (i) The Seller or the Servicer, as applicable, shall fail to perform or
observe any term, covenant or agreement contained in Section Section 5.1(b), 5.1(f), 5.1(i), 5.1(j), 5.3, Section 5.4(a), 5.4(f), 5.4(i), 5.5(f), 5.5(g) or 5.6 of this Agreement; provided, however, that a default under Section 5.3(b)
shall not constitute an Event of Termination under this Section 7.1(c)(i) if such default relates to a 
  

 64 

 specific Pool Receivable and gives rise to an obligation of the Seller to make a payment under Section 2.9(c) in respect
of the affected Pool Receivable and the Seller has made such payment in accordance with Section 2.9(c) and, after giving effect to such payment and, if applicable, any calculated reduction in Capital by an amount on deposit in the Cash Assets
Account that is available for application therefor pursuant to Section 2.6 or 2.7, as applicable, the aggregate Receivable Interests would not exceed 100%; (ii) any Originator shall fail to perform or observe any term, covenant or agreement
contained in Section 4.01(g), 4.01(i), 4.02(f) or 4.03 of the Receivables Sale Agreement; (iii) Lyondell shall fail to perform or observe any term, covenant or agreement contained in Sections 3.07 through 3.18 of the Lyondell Undertaking; (iv) (x)
the Servicer shall fail to observe or perform any term, covenant or agreement contained in any of Sections 5.5(a) through 5.5(e) or Section 5.5(h) or 5.5(i) of this Agreement, (y) any Originator shall fail to observe or perform any term, covenant or
agreement contained in Section 4.02 (excluding Section 4.02(f)) of the Receivables Sale Agreement, or (z) Lyondell shall fail to perform or observe any term, covenant or agreement contained in Section 3.01 or 3.03 of the Lyondell Undertaking, and,
in such case, such failure shall continue for a period of five days; or (v) any Transaction Party shall fail to perform or observe any other term, covenant or agreement contained in any Transaction Document on its part to be performed or observed
and any such failure shall remain unremedied for 30 days after the earlier of (A) the date on which a Responsible Officer of any Transaction Party becomes aware of such failure and (B) the date on which written notice thereof shall have been given
to the Seller by the Agent or any Purchaser; or 
  
 (d) (i)
Lyondell and its Subsidiaries shall fail to make one or more payments aggregating more than $50,000,000 in respect of Indebtedness or Derivatives Obligations when due or within any applicable grace period; or 
  
 (ii) any event or condition shall occur which results in the
acceleration of the maturity of any Material Debt or enables (or, with the giving of notice or lapse of time or both, would enable) the holder of such Indebtedness or any Person acting on such holder’s behalf to accelerate the maturity thereof;
provided that (a) an event or condition which does not presently enable such holder or other Person to accelerate the maturity of such Indebtedness and which is subsequently waived or cured will then no longer constitute an Event of
Termination hereunder; (b) the existence or exercise of rights of holders of Indebtedness under the Medium Term Notes to require repurchase thereof arising from the admission of Subsidiaries of Occidental to Equistar shall not give rise to an Event
of Termination or Potential Event of Termination under this subsection; and (c) no Event of Termination shall arise under this Section 7.1(d) in respect of Indebtedness which is Guaranteed by, but is not otherwise Indebtedness of, Lyondell or any
Material Subsidiary (including for this purpose the Lyondell Joint Ventures); or 
  
 (iii) an “Event of Default” shall exist under (and as defined in) the Credit Agreement; or, if the Intercreditor Agreement is
then in effect, a notice to terminate the sale of Receivables under the Transaction Documents shall have been delivered under the Intercreditor Agreement; or 
  
 (e) Any Purchase shall for any reason (other than pursuant to the terms hereof) cease to create, or any Receivable Interest shall for any reason cease to
be, a valid and perfected first priority undivided percentage ownership interest or security interest to the extent of the pertinent Receivable Interest in each applicable Pool Receivable and the Related Security and Collections with respect
thereto, except by reason of action taken voluntarily by the Agent, or the failure by the Agent to take action required to be taken by it under the Transaction Documents; provided, however, that any such event that relates to a
specific Pool Receivable shall not constitute an Event of Termination under this Section 7.1(e) if the occurrence of such event gives rise to an obligation of the Seller to make a payment under Section 2.9(c) 
  

 65 

 in respect of the affected Pool Receivable and the Seller has made such payment in accordance with Section 2.9(c) and,
after giving effect to such payment and, if applicable, any calculated reduction in Capital by an amount held in the Cash Assets Account that is available for application therefor pursuant to Section 2.6 or 2.7, as applicable, the aggregate
Receivable Interests would not exceed 100%; or 
  
 (f) (i) any
Transaction Party or any Material Subsidiary (x) shall commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or
hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, or shall consent to any such relief or to the appointment of or taking possession
by any such official in an involuntary case or other proceeding commenced against it, or shall make a general assignment for the benefit of creditors; or (y) shall fail generally to pay its debts as they become due; or (z) shall take any corporate
action to authorize any of the foregoing; or (ii) an involuntary case or other proceeding shall be commenced against any Transaction Party or any Material Subsidiary seeking liquidation, reorganization or other relief with respect to it or its debts
under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, and such involuntary
case or other proceeding shall remain undismissed and unstayed for a period of 60 days; or (iii) an order for relief shall be entered against any Transaction Party or any Material Subsidiary under the federal bankruptcy laws as now or hereafter in
effect (for purposes of this Section 7.1(f), a Material Subsidiary includes the Lyondell Joint Ventures, but excludes LCR so long as LCR is not at the time a “Significant Subsidiary” for purposes of the instruments governing the Senior
Notes or the Senior Subordinated Notes); or 
  
 (g) Any member of
the ERISA Group shall fail to pay when due an amount or amounts which it shall have become liable to pay under Title IV of ERISA; or notice of intent to terminate a Plan shall be filed under Title IV of ERISA by any member of the ERISA Group, any
plan administrator or any combination of the foregoing; or the PBGC shall institute proceedings under Title IV of ERISA to terminate, to impose liability (other than for premiums under Section 4007 of ERISA) in respect of, or to cause a trustee to
be appointed to administer, any Plan; or a condition shall exist by reason of which the PBGC would be entitled to obtain a decree adjudicating that any Plan must be terminated; or there shall occur a complete or partial withdrawal from, or a
default, within the meaning of Section 4219(c)(5) of ERISA, with respect to, one or more Multiemployer Plans which could cause one or more members of the ERISA Group to incur a current payment obligation, if any of the foregoing could reasonably be
expected to have a Material Adverse Effect (it being understood that the fact that Lyondell is a party to the PBGC Settlement Agreement is not, in itself, expected to have a Material Adverse Effect); or 
  
 (h) The Net Receivables Pool Balance shall be less than the Required Net
Receivables Pool Balance (giving effect to any calculated reduction in Capital by an amount equal to the amount on deposit in the Cash Assets Account that is available for application therefor pursuant to Section 2.6 or 2.7, as applicable, as of the
close of business on the relevant day of determination) for a period of 2 consecutive Business Days or more; or 
  
 (i) Any Transaction Document shall for any reason cease to be in full force and effect, or any Transaction Party shall so state in writing; or 

 
 (j) A Change of Control shall occur; or 
  
 (k) (i) one or more judgments or orders for the payment of money shall be
rendered by a court or other tribunal or governmental agency against the Seller or (ii) judgments or orders for the payment of money exceeding $50,000,000 in aggregate amount (exclusive of amounts covered by 
  

 66 

 insurance as to which the carrier has not contested coverage) shall be rendered against a Transaction Party (other than
the Seller) or any Subsidiary (including for this purpose the Lyondell Joint Ventures) and such judgments or orders shall continue undischarged, unsatisfied and unstayed for a period of 30 days; or enforcement remedies in respect of any such
judgments or orders shall be commenced; or 
  
 (l) (i) Receivables
Excess Availability shall for a period of two consecutive Business Days be less than (x) $25,000,000 from the Closing Date through June 30, 2005 or (y) $15,000,000 thereafter; or (ii) Total Excess Availability shall for a period of two consecutive
Business Days be less than $50,000,000; 
  
 then, and in any such event, the Agent
shall, at the request, or may with the consent, of the Required Purchasers, by notice to the Seller and the Servicer declare the Termination Date to have occurred, whereupon the Termination Date shall forthwith occur; provided, that, (x) if
the Intercreditor Agreement is then in effect, automatically upon the second Business Day following the effectiveness of any notice to terminate the sale of Receivables under the Transaction Documents delivered in accordance with the Intercreditor
Agreement, the Termination Date shall occur and (y) automatically upon the occurrence of any event (without any requirement for the passage of time or the giving of notice, or both) described in subsection (f) of this Section 7.1, the Termination
Date shall occur, and the Agent may replace the Servicer pursuant to Section 6.1. Upon any such occurrence of the Termination Date, the Agent and each Purchaser shall have, in addition to all other rights and remedies under this Agreement or
otherwise, all other rights and remedies provided under any and all applicable laws, which rights shall be cumulative. 
  
 ARTICLE VIII 
  
 THE AGENT 
  
 Section 8.1 Authorization and Action. 
  
 (a) Each Purchaser hereby appoints CUSA as the Agent hereunder and each Purchaser authorizes the Agent to take such action as agent on its behalf and to
exercise such powers under this Agreement and the other Transaction Documents as are delegated to the Agent under such agreements and to exercise such powers as are reasonably incidental thereto. Without limiting the foregoing, each Purchaser hereby
authorizes the Agent to execute and deliver, and to perform its obligations under, each of the Transaction Documents to which the Agent is a party, to exercise all rights, powers and remedies that the Agent may have under such Transaction Documents.

  
 (b) As to any matters not expressly provided for by this
Agreement and the other Transaction Documents (including enforcement or collection), the Agent shall not be required to exercise any discretion or take any action, but shall be required to act or to refrain from acting (and shall be fully protected
in so acting or refraining from acting) upon the instructions of the Required Purchasers, and such instructions shall be binding upon all Purchasers; provided, however, that the Agent shall not be required to take any action that (i) the
Agent in good faith believes exposes it to personal liability unless the Agent receives an indemnification satisfactory to it from the Purchasers with respect to such action or (ii) is contrary to this Agreement or applicable law. The Agent agrees
to give to each Purchaser prompt notice of each notice given to it by the Seller, Originator or Servicer pursuant to the terms of this Agreement or the other Transaction Documents. 
  
 (c) In performing its functions and duties hereunder and under the other Transaction Documents, the Agent is acting solely
on behalf of the Purchasers and its duties are entirely administrative in nature. The Agent does not assume and shall not be deemed to have assumed any obligation other than as expressly set forth herein and in the other Transaction Documents or any
other 
  

 67 

 relationship as the agent, fiduciary or trustee of or for any Purchaser or holder of any other obligation under any
Transaction Document. The Agent may perform any of its duties under any Transaction Document by or through its agents or employees. 
  
 Section 8.2 Agent’s Reliance, Etc. 
  
 Neither the Agent nor any of its directors, officers, agents or employees shall be liable for any action taken or omitted to be taken by it or them as
Agent under or in connection with this Agreement or any other Transaction Document or any other instrument or document delivered pursuant hereto (including, without limitation, the Agent’s servicing, administering or collecting Pool Receivables
as Servicer pursuant to Section 6.1), except for its or their own gross negligence or willful misconduct. Without limiting the generality of the foregoing, except as otherwise agreed by the Agent and any Purchaser, the Agent: (i) may consult with
legal counsel (including counsel for the Seller, the Servicer or any Originator), independent public accountants and other experts selected by it and shall not be liable for any action taken or omitted to be taken in good faith by it in accordance
with the advice of such counsel, accountants or experts; (ii) makes no warranty or representation to any Purchaser and shall not be responsible to any Purchaser for any statements, warranties or representations (whether written or oral) made in or
in connection with this Agreement or any other Transaction Document or any other instrument or document delivered pursuant hereto; (iii) shall not have any duty to ascertain or to inquire as to the performance or observance of any of the terms,
covenants or conditions of this Agreement or any other Transaction Document or any other instrument or document delivered pursuant hereto on the part of the Seller or any Originator or to inspect the property (including the books and records) of the
Seller or any Originator; (iv) shall not be responsible to any Purchaser for the due execution, legality, validity, enforceability, genuineness, sufficiency or value of this Agreement or any other Transaction Document or any other instrument or
document furnished pursuant hereto, or the perfection, priority or value of any ownership interest or security interest created or purported to be created hereunder or under the Receivables Sale Agreement; and (v) shall incur no liability under or
in respect of this Agreement or any other Transaction Document or any other instrument or document delivered pursuant hereto by acting upon any notice (including notice by telephone), consent, certificate or other instrument or writing (which may be
by telecopier, telegram, cable or telex) reasonably believed by it to be genuine and signed or sent by the proper party or parties. 
  
 Section 8.3 CUSA and Affiliates. 
  
 With respect to any Capital or any Receivable Interest owned by it, CUSA shall have the same rights and powers under this Agreement as any other Purchaser
and may exercise the same as though it were not the Agent. CUSA and its Affiliates may generally engage in any kind of business with the Seller or any Originator or any Obligor, any of their respective Affiliates and any Person who may do business
with or own securities of the Seller or any Originator or any Obligor or any of their respective Affiliates, all as if CUSA were not the Agent and without any duty to account therefor to the Purchasers. 
  
 Section 8.4 Purchase Decisions. 
  
 Each Purchaser acknowledges that it has, independently and without reliance
upon the Agent or any of its Affiliates or any other Purchaser and based on such documents and information as it has deemed appropriate, made its own evaluation and decision to enter into this Agreement and to purchase undivided ownership interests
in Pool Receivables hereunder. Each Purchaser also acknowledges that it shall, independently and without reliance upon the Agent, any of its Affiliates or any other Purchaser and based on such documents and information as it shall deem appropriate
at the time, continue to make its own decisions in taking or not taking action under this Agreement. 
  

 68 

 Section 8.5 Indemnification. 
  
 The Purchasers agree to indemnify the Agent (to the extent not promptly reimbursed by the Seller or the Servicer), ratably
according to their Ratable Portion from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind or nature whatsoever that may be imposed on, incurred by,
or asserted against the Agent in any way relating to or arising out of this Agreement or any other Transaction Document or any other instrument or document furnished pursuant hereto or any action taken or omitted by the Agent under this Agreement or
any other Transaction Document or any such instrument or document; provided that no Purchaser shall be liable for any portion of such liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or
disbursements resulting from the Agent’s gross negligence or willful misconduct. Without limitation of the foregoing, the Purchasers agree to reimburse the Agent, ratably according to their Ratable Portion, promptly upon demand for any costs
and expenses (including, without limitation, reasonable fees and disbursements of counsel) payable by the Seller to the Agent under Section 11.5, to the extent that the Agent is not promptly reimbursed for such costs and expenses by the Seller.

  
 Section 8.6 Successor Agent 
  
 The Agent may resign at any time by giving written notice thereof to the
Purchasers and the Seller. Upon any such resignation, the Required Purchasers shall have the right to appoint a successor Agent. If no successor Agent shall have been so appointed by the Required Purchasers, and shall have accepted such appointment,
within 30 days after the retiring Agent’s giving of notice of resignation, then the retiring Agent may, on behalf of the Purchasers, appoint a successor Agent, selected from among the Purchasers. In either case, such appointment shall be
subject to the prior written approval of the Seller (which approval may not be unreasonably withheld and shall not be required upon the occurrence and during the continuance of an Event of Termination). Upon the acceptance of any appointment as
Agent by a successor Agent, such successor Agent shall succeed to, and become vested with, all the rights, powers, privileges and duties of the retiring Agent, and the retiring Agent shall be discharged from its duties and obligations under this
Agreement and the other Transaction Documents. Prior to any retiring Agent’s resignation hereunder as Agent, the retiring Agent shall take such action as may be reasonably necessary to assign to the successor Agent its rights as Agent under the
Transaction Documents. After such resignation, the retiring Agent shall continue to have the benefit of this Article VIII as to any actions taken or omitted to be taken by it while it was Agent under this Agreement and the other Transaction
Documents. 
  
 Section 8.7 Posting of Approved Electronic
Communications. 
  
 (a) Subject to certain limited
exceptions in respect of which the Servicer or the Seller has delivered prior written notice to the Agent, each of the Purchasers, the Servicer and the Seller agree that the Agent may, but shall not be obligated to, make the Approved Electronic
Communications available to the Purchasers by posting such Approved Electronic Communications on “e-Disclosure”, the Agent’s internet delivery system that is part of Fixed Income Direct, Global Fixed Income’s primary web
portal, or successor electronic platform chosen by the Agent to be its internet delivery system (the “Approved Electronic Platform”). 
  
 (b) Although the primary web portal is secured with a dual firewall and a user ID/password authorization system and the Approved Electronic Platform is
secured through a single-user-per-deal authorization method whereby each user may access the Approved Electronic Platform only on a deal-by-deal basis, each of the Purchasers, the Servicer and the Seller acknowledges and agrees that the distribution
of material through an electronic medium is not necessarily secure and that there are 
  

 69 

 confidentiality and other risks associated with such distribution. In consideration for the convenience and other
benefits afforded by such distribution and for the other consideration provided hereunder, the receipt and sufficiency of which is hereby acknowledged, each of the Purchasers, the Servicer and the Seller hereby approves, and the Servicer shall cause
each Originator to approve, distribution of the Approved Electronic Communications through the Approved Electronic Platform and understands and assumes the risks of such distribution. 
  
 (c) The Approved Electronic Communications and the Approved Electronic Platform are provided “as is” and
“as available”. None of the Agent or any of its Affiliates or any of their respective officers, directors, employees, agents, advisors or representatives (the “Agent Affiliates”) warrants the accuracy, adequacy or
completeness of the Approved Electronic Communications and the Approved Electronic Platform and each expressly disclaims liability for errors or omissions not committed by it or in the absence of its gross negligence or willful misconduct in the
Approved Electronic Communications and the Approved Electronic Platform. No warranty of any kind, express, implied or statutory (including, without limitation, any warranty of merchantability, fitness for a particular purpose, non-infringement of
third party rights or freedom from viruses or other code defects) is made by the Agent Affiliates in connection with the Approved Electronic Platform. 
  
 ARTICLE IX 
  
 ASSIGNMENT OF RECEIVABLE INTERESTS 
  
 Section 9.1 Purchaser’s Assignment of Rights and Obligations. 
  
 (a) Each Purchaser may assign to any Eligible Assignee all or a portion of its rights and obligations under this Agreement
(including, without limitation, all or a portion of its Commitment and the Receivable Interests owned by it); provided, however, that (i) each such assignment shall be a constant, and not a varying, percentage of such Purchaser’s rights
and obligations under this Agreement and the Receivable Interests owned by it, (ii) in the case of any assignment by any Purchaser that is not assigning pursuant thereto all of its right and obligations under this Agreement, (A) the amount of the
Commitment (determined as of the date of the applicable Assignment and Acceptance) being assigned pursuant to each such assignment shall be at least $5,000,000, or (B) the aggregate amount of all Commitments (determined as of the date of the
applicable Assignments and Acceptances) being assigned by such Purchaser on such date to two or more Eligible Assignees that are Affiliates of each other shall be at least $5,000,000, (iii) each such assignment shall be to an Eligible Assignee, (iv)
the parties to each such assignment shall execute and deliver to the Agent, for its acceptance and recording in the Register, an Assignment and Acceptance, together with a processing and recording fee of $3,500, and (v) the consent of the Agent and,
unless an Event of Termination has occurred and is continuing, the Seller shall first have been obtained. Upon such execution, delivery and acceptance, from and after the effective date specified in each Assignment and Acceptance, which effective
date shall be the later of (x) the date the Agent receives the executed Assignment and Acceptance and (y) the date of such Assignment and Acceptance, (1) the Assignee thereunder shall be a party hereto and shall have all the rights and obligations
of a Purchaser hereunder and (2) the assigning Purchaser shall, to the extent that rights and obligations hereunder have been assigned by it pursuant to such assignment and acceptance, relinquish its rights and be released from its obligations under
this Agreement. 
  
 (b) By executing and delivering an Assignment
and Acceptance, the assigning Purchaser and the Assignee thereunder confirm to and agree with each other and the other parties hereto as follows: (i) other than as provided in such Assignment and Acceptance, the assigning Purchaser makes no
representation or warranty and assumes no responsibility with respect to any statements, warranties or representations made in or in connection with this Agreement or any other Transaction Document or any 
  

 70 

 other instrument or document furnished pursuant hereto or the execution, legality, validity, enforceability, genuineness,
sufficiency or value of this Agreement or any other Transaction Document or any other instrument or document furnished pursuant hereto, or the perfection, priority or value of any ownership interest or security interest created or purported to be
created hereunder or under the Receivables Sale Agreement; (ii) the assigning Purchaser makes no representation or warranty and assumes no responsibility with respect to the financial condition of the Seller, the Servicer or any Originator or the
performance or observance by the Seller, the Servicer or any Originator of any of their respective obligations under this Agreement or any other Transaction Document or any other instrument or document furnished pursuant hereto; (iii) such Assignee
confirms that it has received copies of this Agreement and the other Transaction Documents, together with such other documents and information as it has deemed appropriate to make its own analysis and decision to enter into such Assignment and
Acceptance; (iv) such Assignee will, independently and without reliance upon the Agent, any of its Affiliates, the assigning Purchaser or any other Purchaser and based on such documents and information as it shall deem appropriate at the time,
continue to make its own decisions in taking or not taking action under this Agreement and the other Transaction Documents and the other instruments and documents furnished pursuant hereto; (v) such Assignee confirms that it is an Eligible Assignee;
(vi) such Assignee appoints and authorizes the Agent to take such action as agent on its behalf and to exercise such powers and discretion under this Agreement and the other Transaction Documents and the other instruments and documents furnished
pursuant hereto as are delegated to the Agent by the terms hereof and thereof, together with such powers and discretion as are reasonably incidental thereto; (vii) such Assignee appoints as its agent the Servicer from time to time designated
pursuant to Section 6.1 to enforce its respective rights and interests in and under the Pool Receivables and the Related Security and Collections with respect thereto and the related Contracts; and (viii) such Assignee agrees that it will perform in
accordance with their terms all of the obligations which by the terms of this Agreement are required to be performed by it as a Purchaser. 
  
 (c) Upon its receipt of an Assignment and Acceptance executed by any assigning Purchaser and an assignee representing that it is an Eligible Assignee, the
Agent shall, if such Assignment and Acceptance has been completed and is in substantially the form of Exhibit A hereto, (i) accept such Assignment and Acceptance, (ii) record the information contained therein in the Register, and (iii) give prompt
notice thereof to the Seller and the Servicer. 
  
 (d) Any
Purchaser may, in connection with any assignment or proposed assignment pursuant to Section 9.1, disclose to the assignee or proposed assignee any information relating to any Transaction Party or any Affiliate or Subsidiary furnished to the
Purchasers by or on behalf of such Transaction Party or such Affiliate or Subsidiary, as applicable; provided that, prior to any such disclosure, each such assignee or proposed assignee shall execute an agreement whereby such assignee or
proposed assignee shall agree (subject to customary exceptions) to preserve the confidentiality of any confidential information relating to the Transaction Parties and any Affiliate or Subsidiary received from the Agent or the Purchasers.

  
 (e) Notwithstanding anything to the contrary contained herein,
any Purchaser (a “Granting Purchaser”) may grant to a special purpose funding vehicle (an “SPC”) of such Granting Purchaser, identified as such in writing from time to time by the Granting Purchaser to the Agent and
the Seller, the option to provide to the Seller all or any part of any Purchase that such Granting Purchaser would otherwise be obligated to make to the Seller pursuant to Section 2.2, provided that (i) nothing herein shall constitute a
commitment to make any Purchase by any SPC and (ii) if an SPC elects not to exercise such option or otherwise fails to provide all or any part of such Purchase, the Granting Purchaser shall be obligated to make such Purchase pursuant to the terms
hereof. The making of a Purchase by an SPC hereunder shall be deemed to utilize the Commitments of all the Purchasers to the same extent, and as if, such Purchase were made by the Granting Purchaser. Each party hereto hereby agrees that no SPC

  

 71 

 shall be liable for any payment under this Agreement for which a Purchaser would otherwise be liable, for so long as, and
to the extent, the related Granting Purchaser makes such payment. In furtherance of the foregoing, each party hereto hereby agrees that, prior to the date that is one year and one day after the payment in full of all outstanding senior indebtedness
of any SPC, it will not institute against, or join any other Person in instituting against, such SPC any bankruptcy, reorganization, arrangement, insolvency or liquidation proceedings or similar proceedings under the laws of the United States of
America or any State thereof. In addition, notwithstanding anything to the contrary contained in this Section 9.1, any SPC may assign all or a portion of its interests in any Receivable Interests to its Granting Purchaser or to any financial
institutions providing liquidity and/or credit facilities to or for the account of such SPC to fund the Purchases made by such SPC or to support the securities (if any) issued by such SPC to fund such Purchases; provided, however, that
except in the case of an assignment to a Granting Purchaser or a financial institution that is either an Affiliate of such SPC or another Purchaser, the Agent and, unless an Event of Termination has occurred and is continuing, the Seller must
consent to such assignment in writing (which consent may not be unreasonably withheld). Each SPC shall execute an agreement whereby such SPC shall agree (subject to customary exceptions) to preserve the confidentiality of any confidential
information relating to the Transaction Parties and its Affiliates or Subsidiaries received from the Agent or Purchasers. 
  
 Section 9.2 The Register. 
  
 The Agent shall maintain at its office referred to in Section 11.3 a copy of each Assignment and Acceptance delivered to and accepted by it and a register
(the “Register”) for the recordation of the names and addresses of the Purchasers and the Commitment of, and each Receivable Interest owned by, each Purchaser from time to time, which Register shall be available for inspection by
the Seller at any reasonable time upon reasonable prior notice. The entries in the Register shall be conclusive and binding for all purposes, absent manifest error, and the parties hereto may treat each Person whose name is recorded in the Register
as a Purchaser hereunder for all purposes of this Agreement. No Receivable Interest, nor any Assignment and Acceptance, shall be effective unless it is entered in the Register in due course. 
  
 Section 9.3 Participations. 
  
 With the prior written consent of the Agent, each Purchaser may sell
participations to one or more Persons in or to all or a portion of its rights and obligations under the Transaction Documents (including all its rights and obligations with respect to Receivable Interests). The terms of such participation shall not,
in any event, require the participant’s consent to any amendments, waivers or other modifications of any provision of any Transaction Documents, the consent to any departure by any Transaction Party therefrom, or to the exercising or refraining
from exercising any powers or rights such Purchaser may have under or in respect of the Transaction Documents (including the right to enforce the obligations of any Transaction Party), except if any such amendment, waiver or other modification or
consent would reduce the amount, or postpone any date fixed for, any amount (whether of Capital, Yield or fees) payable to such participant under the Transaction Documents, to which such participant would otherwise be entitled under such
participation. In the event of the sale of any participation by any Purchaser, (w) such Purchaser’s obligations under the Transaction Documents shall remain unchanged, (x) such Purchaser shall remain solely responsible to the other parties for
the performance of such obligations, (y) such Purchaser shall remain the holder of such Capital for all purposes of this Agreement and (z) the Seller, the Agent and the other Purchasers shall continue to deal solely and directly with such Purchaser
in connection with such Purchaser’s rights and obligations under this Agreement. Each participant shall be entitled to the benefits of Sections 2.12(a), 2.13 and 2.14 as if it were a Purchaser; provided, however, that anything
herein to the contrary notwithstanding, the Seller shall not, at any time, be obligated to make under Section 2.12(a), 2.13 or 2.14 to the participants in the rights and obligations of 
  

 72 

 any Purchaser (together with such Purchaser) any payment in excess of the amount the Seller would have been obligated to
pay to such Purchaser in respect of such interest had such participation not been sold. Any Purchaser may, in connection with any participation or proposed participation pursuant to Section 9.3, disclose to the participant or proposed participant
any information relating to any Transaction Party or any Affiliate or Subsidiary of Lyondell furnished to the Purchasers by or on behalf of such Transaction Party or such Affiliate or Subsidiary, as applicable; provided that, prior to any
such disclosure, each such participant or proposed participant shall execute an agreement whereby such participant or proposed participant shall agree (subject to customary exceptions) to preserve the confidentiality of any confidential information
relating to the Transaction Parties and any Affiliate or Subsidiary of Lyondell received from the Agent or the Purchasers. 
  
 ARTICLE X 
  
 INDEMNIFICATION 
  
 Section 10.1 Indemnities. 
  
 Without limiting any other rights that any Indemnified Party may have hereunder or under applicable law, and whether or not any of the transactions contemplated hereby are consummated, (A) the Seller hereby agrees to
indemnify each Indemnified Party from and against, and hold each thereof harmless from, any and all claims, losses, liabilities, costs and expenses of any kind whatsoever (including, without limitation, reasonable attorneys’ fees and expenses)
(all of the foregoing being collectively referred to as “Indemnified Amounts”) arising out of, or resulting from, in whole or in part, one or more of the following: (a) this Agreement or any other Transaction Document (other than
the Lyondell Undertaking or the Servicer’s activities as Servicer) to which it is a party; (b) the use of proceeds of any Purchase or reinvestment; (c) the interest of any Purchaser in any Receivable, any Contract or any Related Security; or
(d) any transaction contemplated by this Agreement or any other Transaction Document (other than the Lyondell Undertaking) to which it is a party; and (B) the Servicer hereby agrees to indemnify each Indemnified Party for Indemnified Amounts arising
out of or resulting from the Lyondell Undertaking or the Servicer’s activities as Servicer or Buyer’s Servicer hereunder or under the other Transaction Documents; excluding, however, in all of the foregoing instances under clauses (A) and
(B) above, Indemnified Amounts (1) to the extent resulting from (x) the gross negligence or willful misconduct on the part of such Indemnified Party or, (y) the failure to collect amounts in respect of a Pool Receivable, to the extent such failure
results from a discharge of the Obligor with respect thereto in a proceeding in respect of such Obligor under applicable bankruptcy laws or otherwise results from the Obligor’s financial inability to pay such amounts or (2) that are subject to
the exclusions from reimbursement or payment therefor under Section 2.14. Without limiting or being limited by the foregoing and whether or not any of the transactions contemplated hereby are consummated, the applicable Seller Party shall pay within
five Business Days after demand to each Indemnified Party any and all amounts necessary to indemnify such Indemnified Party from and against any and all Indemnified Amounts which relate to or result from, or which would not have occurred but for,
one or more of the following: 
  
 (i) any
Receivable becoming a Pool Receivable which is stated to be, but is not, an Eligible Receivable; 
  
 (ii) any representation or warranty or statement made or deemed made by such Seller Party (or any of its officers) under or in connection
with this Agreement or any other Transaction Document or any Seller Report or other document delivered or to be delivered in connection herewith or with any other Transaction Document being incorrect in any material respect when made or deemed made
or delivered; 
  

 73 

 (iii) the failure by such Seller Party to comply with any applicable law, rule or
regulation with respect to any Pool Receivable or the related Contract or any Related Security with respect thereto; or the failure of any Pool Receivable or the related Contract or any Related Security with respect thereto to conform to any such
applicable law, rule or regulation; 
  
 (iv) the
failure to vest in the Purchaser of a Receivable Interest a first priority perfected undivided percentage ownership interest, to the extent of such Receivable Interest, in each Receivable in, or purported to be in, the Receivables Pool and the
Related Security and Collections in respect thereof, free and clear of any Lien (except for Liens created pursuant to the Transaction Documents); or the failure of the Seller to have obtained a first priority perfected ownership interest in the Pool
Receivables and the Related Security and Collections with respect thereto transferred or purported to be transferred to the Seller under the Receivables Sale Agreement, free and clear of any Lien (except for Liens created pursuant to the Transaction
Documents); 
  
 (v) the failure of such Seller
Party to have filed, or any delay by such Seller Party in filing, financing statements or other similar instruments or documents under the UCC of any applicable jurisdiction or other applicable laws with respect to any Receivable in, or purported to
be in, the Receivables Pool and the Related Security and Collections in respect thereof, whether at the time of any Purchase or reinvestment or at any subsequent time unless such failure results directly and solely from the Agent’s failure to
take appropriate action; 
  
 (vi) any dispute,
claim, offset or defense (other than discharge in bankruptcy of the Obligor) of any Obligor to the payment of any Receivable in, or purported to be in, the Receivables Pool (including, without limitation, any defense based on the fact or allegation
that such Receivable or the related Contract is not a legal, valid and binding obligation of such Obligor enforceable against it in accordance with its terms), or any other claim resulting from the sale of the goods or services related to such
Receivable or the furnishing or failure to furnish such goods or services; 
  
 (vii) any failure of such Seller Party to perform its duties or obligations in accordance with the provisions of this Agreement or any other Transaction Document or to perform its duties or obligations under any
Contract; 
  
 (viii) any product liability,
personal injury, copyright infringement, theft of services, property damage, or other breach of contract, antitrust, unfair trade practices or tortious claim arising out of or in connection with the subject matter of any Contract or out of or in
connection with any transaction contemplated by this Agreement, any other Transaction Document or any other instrument or document furnished pursuant hereto or such Contract; 
  
 (ix) the commingling by such Seller Party of Collections of Pool Receivables at any time with other funds;

  
 (x) any action or omission by such Seller
Party, reducing or impairing the rights of any Purchaser of a Receivable Interest under this Agreement, any other Transaction Document or any other instrument or document furnished pursuant hereto or thereto or with respect to any Pool Receivable;

  

 74 

 (xi) any cancellation or modification of a Pool Receivable, the related Contract or any
Related Security, whether by written agreement, verbal agreement, acquiescence or otherwise, unless such cancellation or modification was made by or with the express consent of the Agent or a Servicer that is not Lyondell or an Affiliate or
Subsidiary of Lyondell; provided that in no event shall Indemnified Amounts include any unpaid portion of a Pool Receivable effected by any such cancellation or modification; 
  
 (xii) any investigation, litigation or proceeding related to or arising from this Agreement, any other
Transaction Document or any other instrument or document furnished pursuant hereto or thereto, or any transaction contemplated by this Agreement or any Contract or the use of proceeds from any Purchase or reinvestment pursuant to this Agreement, or
the ownership of, or other interest in, any Receivable, the related Contract or Related Security; 
  
 (xiii) the existence of any Lien (except for Liens created pursuant to the Transaction Documents) against or with respect to any
Restricted Account or any Pool Receivable, the related Contract or the Related Security or Collections with respect thereto; 
  
 (xiv) any failure by such Seller Party to pay when due any taxes, including without limitation sales, excise or personal property taxes,
payable by such Seller Party in connection with any Receivable or the related Contract or any Related Security with respect thereto; 
  
 (xv) any claim brought by any Person other than an Indemnified Party arising from any activity of such Seller Party in servicing,
administering or collecting any Pool Receivable; or 
  
 (xvi) any failure by any Lock-Box Bank or other depository bank at which a Restricted Account is maintained to comply with the terms of the Transaction Document governing such Restricted Account to which it is a party. 
  
 ARTICLE XI 
  
 MISCELLANEOUS 
  
 Section 11.1 Amendments, Etc. 
  
 No amendment or waiver of any provision of this Agreement or the
Intercreditor Agreement, and no consent to any departure by the Seller or the Servicer therefrom, shall be effective unless in a writing signed by the Agent and the Required Purchasers and, in the case of any such amendment, the Seller and the
Servicer and then such amendment, waiver or consent shall be effective only in the specific instance and for the specific purpose for which given; provided, however, that no amendment, waiver or consent shall: 
  
 (a) without the prior written consent of each Purchaser, 
  
 (i) amend the definitions of “Eligible
Receivable”, “Net Receivables Pool Balance”, “Required Net Receivables Pool Balance” or “Super Majority Purchasers”, “Required Purchasers”; or 
  

 75 

 (ii) amend, modify or waive any provision of this Agreement in any way which would

  
 (A) reduce the amount of a Capital
Investment or Yield that is payable on account of any Receivable Interest or delay any scheduled date for payment thereof or reduce the Applicable Margin or change the order of application of Collections to the payment thereof, or 
  
 (B) impair any rights expressly granted to such Purchaser
under this Agreement, or 
  
 (C) reduce fees
payable by the Seller to or for the account of such Purchaser hereunder or delay the dates on which such fees are payable, or 
  
 (iii) amend or waive the Event of Termination contained in Section 7.1(f) relating to the bankruptcy of any Transaction Party, or amend or
waive the Event of Termination contained in Section 7.1(h) relating to the Net Receivables Pool Balance, or 
  
 (iv) change the percentage of Commitments, or the number of Purchasers or Purchasers, which shall be required for the Purchasers or any of
them to take any action hereunder, or 
  
 (v)
amend this Section 11.1, or 
  
 (vi) extend the
Commitment Termination Date, or 
  
 (vii)
increase the amount of the Total Commitment, or 
  
 (viii) reduce the Reserve Percentage, or amend the definition of “Reserve Percentage”, in each case such that the Reserve Percentage is reduced, below 15%; 
  
 (b) without the consent of the applicable Purchaser, increase the Commitment of such Purchaser, subject such Purchaser to
any additional obligations, or decrease the Receivable Interest of such Purchaser; and 
  
 (c) without the consent of the Super Majority Purchasers, amend the definitions of “Receivables Excess Availability” or “Total Excess Availability” amend, or waive any Event of
Termination or Potential Event of Termination arising under, Section 7.1(l) hereof; 
  
 provided, however, that the Agent shall not, without the prior written consent of the Required Purchasers, either agree to any amendment or waiver of any other provision of the Lyondell Undertaking or any provision of any
Intercreditor Agreement or other Transaction Document or consent to any departure from the Lyondell Undertaking or the Intercreditor Agreement or other Transaction Document by any party thereto, and provided further, that (x) no
amendment, waiver or consent shall, unless in writing and signed by the Agent in addition to the Purchasers required above to take such action, affect the rights or duties of the Agent under this Agreement or the other Transaction Documents, and (y)
no amendment, waiver or consent shall, unless in writing and signed by the Swing Purchaser in addition to the Purchasers required above to take such action, affect the rights or duties of the Swing Purchaser under this Agreement or the other
Transaction Documents. 
  

 76 

 If, in connection with any proposed amendment, modification, waiver or termination requiring the consent
of all affected Purchasers, the consent of the Required Purchasers is obtained but the consent of other Purchasers whose consent is required is not obtained (any such Purchaser whose consent is not obtained being referred to as a
“Non-Consenting Purchaser”), then, so long as the Purchaser that is the same entity as the Agent is not a Non-Consenting Purchaser, at the Seller’s request, the Agent or an Eligible Assignee acceptable to the Agent shall have
the right with the Agent’s consent and in the Agent’s sole discretion (but shall have no obligation) to purchase from such Non-Consenting Purchaser, and such Non-Consenting Purchaser agrees that it shall, upon the Agent’s request,
sell and assign to the Purchaser that is the same entity as the Agent or to such Eligible Assignee, all of the Commitment and Receivable Interest of such Non-Consenting Purchaser for an amount equal to the outstanding Capital represented by the
Receivable Interest of the Non-Consenting Purchaser plus all accrued Yield and fees with respect thereto through the date of sale less unamortized upfront fees, such purchase and sale to be consummated pursuant to an executed
Assignment and Acceptance. 
  
 No failure on the part of any
Purchaser or the Agent to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of
any other right. 
  
 Section 11.2 Right of
Set-off. 
  
 Each Purchaser is hereby authorized by the
Seller upon the occurrence and during the continuance of an Event of Termination, to the fullest extent permitted by law, to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other
Indebtedness at any time owing by such Purchaser to or for the credit or the account of the Seller against any and all of the obligations of the Seller now or hereafter existing under this Agreement to such Purchaser or, if such Purchaser is CUSA,
to the Agent or any Affiliate thereof, irrespective of whether or not any formal demand shall have been made under this Agreement and although such obligations may be unmatured. Each Purchaser agrees promptly to notify the Seller after any such
setoff and application; provided, however, that the failure to give such notice shall not affect the validity of such setoff and application. The rights of each Purchaser under this Section 11.2 are in addition to other rights and
remedies (including, without limitation, other rights of setoff) which such Purchaser may have. 
  
 Section 11.3 Notices, Etc. 
  
 All notices and other communications hereunder shall, unless otherwise stated herein, be given in writing or by any telecommunication device capable of
creating a written record (including, with respect to Approved Electronic Communications and other notices and communications described below, electronic mail), (i) to each of the Seller, the Servicer, the Agent and the Initial Purchasers, at its
address set forth under its name on the signature pages hereof, (ii) to each Purchaser other than the Initial Purchasers, at its address specified on the Assignment and Acceptance pursuant to which it became a Purchaser hereunder or (iii) to any
party hereto at such other address as shall be designated by such party in a notice to the other parties hereto given as provided herein. 
  
 All notices and other communications given to any party hereto in accordance with the provisions of this Agreement shall be deemed to have been given on
the date of receipt if delivered by hand or overnight courier service or sent by telecopy equipment of the sender, or on the date five Business Days after dispatch by certified or registered mail if mailed, in each case delivered, sent or mailed
(properly addressed) to such party as provided in this Section 11.3 or in accordance with the latest unrevoked direction from such party given in accordance with this Section 11.3. 
  

 77 

 Notices and other communications to the Purchasers hereunder not constituting Approved Electronic
Communications may be delivered or furnished by electronic communications pursuant to procedures approved by the Agent; provided that the foregoing shall not apply to notices pursuant to Article II or III unless otherwise agreed by the Agent
and the applicable Purchaser. Each of the Agent, the Seller and the Servicer may, in its discretion, agree to accept notices and other communications to it hereunder or under any other Transaction Document that do not constitute Approved Electronic
Communications, by electronic communications pursuant to procedures approved by it; provided that approval of such procedures may be limited to particular notices or communications. 
  
 Section 11.4 Binding Effect; Assignability.

  
 This Agreement shall be binding upon and inure to the
benefit of each party hereto and their respective successors and assigns, except that neither the Seller, any Originator, nor the Servicer shall have the right to assign its rights or obligations hereunder or any interest herein without the prior
written consent of all Purchasers. This Agreement shall create and constitute the continuing obligation of the parties hereto in accordance with its terms, and shall remain in full force and effect until such time, after the Termination Date, as no
Capital or any other obligation of the Seller, any Originator, or the Servicer under any Transaction Document shall be outstanding; provided, however, that rights and remedies with respect to the provisions of Sections 2.12, 2.13,
2.14, 10.1, 11.5, 11.6, and 11.8 shall be continuing and shall survive any termination of this Agreement. 
  
 Section 11.5 Costs and Expenses. 
  

The Seller shall pay (i) all reasonable out-of-pocket expenses incurred by the Agent, including the reasonable fees, charges and disbursements of Davis
Polk & Wardwell, special counsel for the Agent and any local counsel retained by them, in connection with the syndication of the receivables facilities provided for herein, the preparation and administration of the Transaction Documents or any
amendments, modifications or waivers of the provisions thereof (whether or not the transactions contemplated hereby or thereby shall be consummated) and (ii) all out-of-pocket expenses incurred by the Agent or any Purchaser, including the fees,
charges and disbursements of any counsel for the Agent or any Purchasers, in connection with the enforcement or protection of its rights in connection with any Transaction Document, including its rights under this Section, or in connection with the
Receivable Interests, including all such out-of-pocket expenses incurred during any workout or restructuring in respect of such Receivable Interests. It is understood that reimbursement of the Agent in respect of matters covered by Section 5.1(f) or
5.4(f) of this Agreement is subject to the applicable limitations specified herein. 
  
 Section 11.6 Confidentiality. 
  
 Each of the Agent, the Purchasers and the SPC’s (as defined in Section 9.1(e)) agrees to maintain the confidentiality of the Information (as defined
below), except that Information may be disclosed (a) to its and its Affiliates’ directors, officers, employees and agents, including accountants, legal counsel and other advisors (it being understood that the Persons to whom such disclosure is
made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent required or requested by any regulatory authority, (c) to the extent required by applicable laws or
regulations or by any subpoena or similar legal process, (d) to any other party to this Agreement, (e) in connection with the exercise of any remedies under any Transaction Document or any suit, action or proceeding relating to any Transaction
Document or the enforcement of rights thereunder, (f) subject to obtaining a written agreement containing provisions substantially the same as those of this Section from the intended recipient of such Information, to any assignee of or participant
in, or any prospective assignee of or participant in, any of its rights or obligations under this Agreement (including 
  

 78 

 any assignee or any prospective assignee of an SPC of the type described in the last sentence of Section 9.1(e)), (g)
with the consent of the Seller or any other Transaction Party, (h) for purposes of Section 9.1(e) only, to any rating agency, (i) to the extent such Information (x) becomes publicly available other than as a result of a breach of this Section or (y)
becomes available to the Agent or any Purchaser on a nonconfidential basis from a source other than the Transaction Parties or (j) to any direct or indirect contractual counterparty in any swap, hedge or similar agreement (or to such contractual
counterparty’s professional advisor) so long as the recipient of such Information agrees to be bound by the provisions of this Section. For the purposes of this Section, “Information” means all information received from the
Transaction Parties relating to the Transaction Parties and their Affiliates or Subsidiaries or their respective businesses, other than any such information that is available to the Agent or any Purchaser on a nonconfidential basis prior to
disclosure by any Transaction Party. Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of
care to maintain the confidentiality of such Information as such Person would accord to its own confidential information. 
  
 Notwithstanding any other provision herein, each Purchaser and the Agent (and each employee, representative or other agent of such party) may disclose to
any and all Persons, without limitation of any kind, any information with respect to the “tax treatment” and “tax structure” (in each case, within the meaning of Treasury Regulation Section 1.6011-4) of the transactions
contemplated by the Transaction Documents and all materials of any kind (including opinions or other tax analyses) that are provided to the Agent or such Purchaser relating to such tax treatment and tax structure. 
  
 Section 11.7 Governing Law. 
  
 This Agreement shall be governed by, and construed in accordance with, the
laws of the State of New York. 
  
 Section
11.8 Jurisdiction, Etc. 
  
 (a) Any legal action or
proceeding with respect to this Agreement or any other Transaction Document may be brought in the courts of the State of New York sitting in the Borough of Manhattan, the City of New York, or of the United States of America for the Southern District
of New York, and, by execution and delivery of this Agreement, each of the Seller and the Servicer hereby accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of the aforesaid courts. The parties hereto
hereby irrevocably waive any objection, including any objection to the laying of venue or based on the grounds of forum non conveniens, that any of them may now or hereafter have to the bringing of any such action or proceeding in such respective
jurisdictions. 
  
 (b) Each of the Seller and the Servicer hereby
irrevocably consents to the service of any and all legal process, summons, notices and documents in any suit, action or proceeding brought in the United States of America arising out of or in connection with this Agreement or any other Transaction
Document by the mailing (by registered or certified mail, postage prepaid) or delivering of a copy of such process to the Seller or Servicer, as the case may be, at its address specified in Section 11.3. Each of the Seller and Servicer agrees that a
final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. 
  
 (c) Nothing contained in this Section 11.8 shall affect the right of the Agent or any Purchaser to serve process in any
other manner permitted by law or commence legal proceedings or otherwise proceed against the Seller or Servicer or any other Transaction Party in any other jurisdiction. 
  

 79 

 Section 11.9 Execution in Counterparts. 
  
 This Agreement may be executed in any number of counterparts, each of which
when so executed shall be deemed to be an original and all of which when taken together shall constitute one and the same agreement. Delivery by telecopier of an executed counterpart of a signature page to this Agreement shall be effective as
delivery of an original executed counterpart of this Agreement. 
  
 Section 11.10 Intent of the Parties. 
  
 It is the intention of the parties hereto that each Purchase and reinvestment shall convey to each Purchaser, to the extent of its Receivable Interests, an undivided ownership interest in the Pool Receivables, and the
Related Security and Collections in respect thereof and that such transaction shall constitute a purchase and sale and not a secured loan for all purposes other than for federal income tax purposes. If, notwithstanding such intention, the conveyance
of the Receivable Interests from the Seller to any Purchaser shall ever be recharacterized as a secured loan and not a sale, it is the intention of the parties hereto that this Agreement shall constitute a security agreement under applicable law,
and the Seller hereby grants to the Agent for the benefit of itself and each such Purchaser a duly perfected first priority security interest in all of the Seller’s right, title and interest in, to and under the Pool Receivables and the Related
Security and Collections in respect thereof, the Restricted Accounts and all proceeds thereof, free and clear of Liens (except for Permitted Liens) and Seller also hereby grants to the Agent for the benefit of itself and each Purchaser a duly
perfected first priority security interest in all of the Seller’s right, title and interest in, to and under any Cash Assets and any cash collateral under this Agreement. 
  
 Section 11.11 Entire Agreement. 
  
 This Agreement and the other Transaction Documents contain a final and complete integration of all prior expressions by the
parties hereto with respect to the subject matter hereof and shall constitute the entire agreement and understanding among the parties hereto with respect to the subject matter hereof and supersede all prior agreements and understandings, written or
oral, relating to the subject matter hereof. 
  
 Section 11.12 Severability of Provisions. 
  
 Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions
hereof or affecting the validity or enforceability of such provision in any other jurisdiction. 
  
 Section 11.13 Waiver of Jury Trial. 
  
 Each of the parties hereto irrevocably waives all right to trial by jury in any action, proceeding or counterclaim (whether
based on contract, tort or otherwise) arising out of or relating to this Agreement or any of the other Transaction Documents, the Purchases or the actions of the Agent or any Indemnified Party in the negotiation, administration, performance or
enforcement hereof or thereof. 
  

 80 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their respective officers
thereunto duly authorized, as of the date above written. 
  

			
	LYONDELL FUNDING II, LLC, as Seller
		
	By:	 	 /s/ Charles L. Hall

	Name:	 	Charles L. Hall
	Title:	 	Vice President and Controller
		
	Address:	 	 One Houston Center
 1221 McKinney Street
 Houston, TX 77010
 Attention: Assistant Treasurer

	
	Telephone No.: 713/652-7200
	Telecopier No.: 713/652-4598
	
	LYONDELL CHEMICAL COMPANY, as Servicer
		
	By:	 	 /s/ Karen A. Twitchell

	Name:	 	Karen A. Twitchell
	Title:	 	Vice President and Treasurer
		
	Address:	 	 One Houston Center
 1221 McKinney Street
 Houston, TX 77010
 Attention: Assistant Treasurer

	
	Telephone No.: 713/652-7200
	Telecopier No.: 713/652-4598

  
 Receivables
Purchase Agreement 

			
	 AGENT

	
	 CITICORP USA, INC.,
as Asset Agent and Administrative Agent

		
	 By:
	 	 /s/ David Jaffe

	 Name:
	 	 David Jaffe

	 Title:
	 	 Vice President

		
	 Address:
	 	 388 Greenwich Street
 19th Floor
 New York, New York 10013

		
	 	 	 Attention: David Jaffe

	
	 Telephone No.: (212) 816-2329

	 Telecopier No.: (212) 816-2613

  

			
	 SOLE LEAD ARRANGER AND SOLE BOOKRUNNER

	
	 CITICORP GLOBAL MARKETS INC.,
as Sole Lead Arranger and Sole Bookrunner

		
	 By:
	 	 /s/ David Jaffe

	 Name:
	 	 David Jaffe

	 Title:
	 	 Authorized Signer

		
	 Address:
	 	 388 Greenwich Street
 19th Floor
 New York, New York 10013

		
	 	 	 Attention: David Jaffe

	
	 Telephone No.: (212) 816-2329

	 Telecopier No.: (212) 816-2613

	
	 Bank of America, N.A., as an Initial Purchaser

  
 Receivables
Purchase Agreement 

			
	 By:
	 	 /s/ Stephen King

	 Name:
	 	 Stephen King

	 Title:
	 	 Vice President

		
	 Address:
	 	 Bank of America, N.A.
 55 South Lake Avenue, Suite 900
 Pasadena, CA 91191

	
	 Telephone No.: (626) 397-1229

	 Telecopier No.: (626) 397-1275

	
	 CREDIT SUISSE FIRST BOSTON, ACTING THROUGH ITS CAYMAN ISLANDS BRANCH, as an Initial Purchaser

		
	 By:
	 	 /s/ S. William Fox

	 Name:
	 	 S. William Fox

	 Title:
	 	 Director

		
	 Address:
	 	 11 Madison Avenue
 New York, NY 10010

	
	 Telephone No.: 212-325-9923

	 Telecopier No.: 212-325-8615

		
	 By:
	 	 /s/ Denise L. Alvarez

	 Name:
	 	 Denise L. Alvarez

	 Title:
	 	 Associate

		
	 Address:
	 	 11 Madison Avenue

	 	 	 New York, NY 10010

	
	 Telephone No.: 212-538-0938

	 Telecopier No.: 646-935-7806

  
 Receivables
Purchase Agreement 

			
	 WELLS FARGO FOOTHILL, LLC, as an Initial Purchaser

		
	 By:
	 	 /s/ Sanat S. Amladi

	 Name:
	 	 Sanat S. Amladi

	 Title:
	 	 Vice President

		
	 Address:
	 	 2450 Colorado Avenue, Suite 3000 West
 Santa Monica, CA 90404

	
	 Telephone No.: (310) 453-7394

	 Telecopier No.: (310) 453-7447

	
	 Bank One, NA, as an Initial Purchaser

		
	 By:
	 	 /s/ J. Devin Mock

	 Name:
	 	 J. Devin Mock

	 Title:
	 	 Director

		
	 Address:
	 	 1717 Main Street, LL1
 Dallas, TX 75201

	
	 Telephone No.: 214 290-2596

	 Telecopier No.: 214 290-5382

	
	 National City Commercial Finance, Inc., as an Initial Purchaser

		
	 By:
	 	 /s/ James C. Ritchie

	 Name:
	 	 James C. Ritchie

	 Title:
	 	 Vice President

		
	 Address:
	 	 1965 East 6th Street, Suite 400
 Locator 01-3049
 Cleveland, OH 44114

	
	 Telephone No.: (216) 222-9918

	 Telecopier No.: (216) 222-9555

  
 Receivables
Purchase Agreement 

			
	 The Bank of New York, as an Initial Purchaser

		
	 By:
	 	 /s/ Raymond J. Palmer

	 Name:
	 	 Raymond J. Palmer

	 Title:
	 	 Vice President

		
	 Address:
	 	 The Bank of New York
 Attn: Lisa Williams
 One Wall Street, 19th Floor
 New York, NY 10286

	
	 Telephone No.: 212-635-7834

	 Telecopier No.: 212-635-7923

  
 Receivables
Purchase Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}]]